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Bioinorganic chemistry strives to understand the roles of metals in biological sys-
tems, whether in the form of naturally occurring or addition of non-essential metals to
natural systems. Metal ions play vital roles in many cellular functions such as gene expres-
sion/regulation and DNA transcription and repair. The study of metal-protein-DNA/RNA
interactions has been relatively unexplored. It is important to understand the role of met-
alloprotein interactions with DNA/RNA as this enhanced knowledge may lead to better
understanding of diseases and therefore more effective treatments.
A major milestone in the development of this field was the discovery of the cyto-
toxic properties of cisplatin in 1965 and its FDA approval in 1978. Since then, two other
chemotherapeutic drugs containing platinum, carboplatin and oxaliplatin, have been used in
the clinic. These three compounds are all bifunctional with the ligands surrounding platinum
in the cis conformation and rearrangement of the ligands to the trans orientation results in
a loss of cytotoxic properties due to rapid deactivation through binding to S-containing pro-
teins. This enhanced reactivity yields new opportunities to study the reactions between
proteins and DNA.
One of the first crosslinking experiments used transplatin to crosslink NCp7 to viral
RNA in order to understand how/where the protein bound to RNA. We have studied the
interaction between cis and trans dinuclear platinum complexes and the C-terminal zinc
finger (ZF). The trans complex reacts at a faster rate than the cis isomer and causes N-
terminal specific cleavage of the ZF. The dinuclear structure plays a critical role in the
peptide cleavage as studies with transplatin (the mononuclear derivative) does not result in
cleavage.
Monofunctional trans platinum-nucleobase complexes (MPNs) serve as a model for
the binding of transplatin to DNA. This provides an interesting opportunity to study their
reactions with S-containing proteins, such as HIV1 NCp7. MPNs have been shown to bind to
the C-terminal ZF of HIV1 NCp7, resulting in zinc ejection. This occurs through a two-step
process where the nucleobase pi-stacks with Trp37 on the ZF, followed by covalent binding
at the labile Cl site to Cys. MPNs have also shown antiviral activity in vitro.
The labile Cl on MPNs reduces specificity of these compounds, as it leaves an available
coordination site on the platinum center for binding to other S-proteins or DNA. Therefore,
we have moved to an inert PtN4 coordination sphere, [Pt(dien)L]2+ (dien= diethylenetri-
amine). Due to the strong bond between platinum and nitrogen, covalent reactions are
highly unlikely to occur at rapid rates. The strength of the pi-stacking interaction between
nucleobases (free and platinated) and the aromatic amino acid, tryptophan (Trp), showed
an enhanced binding constant for platinated nucleobases. This was confirmed by density
functional theory (DFT) calculations as the difference in energy between the HOMO of Trp
and the LUMO of the nucleobase was smaller for the platinum complex. The studies were
extended to the Trp-containing C-terminal ZF of HIV1 NCp7 and an increase in association
constant was seen compared to free Trp.
Reaction of PtN4 nucleobases compounds with a short amino acid sequence con-
taining either Ala (no pi-stacking capabilities) or Trp (pi-stacking interactions) revealed an
enhanced rate of reactivity for the Trp-containing peptide. This result supports the theory of
a two-step reaction mechanism where the platinum-nucleobase complex recognizes the pep-
tide through a pi-stacking interaction with Trp followed by covalent binding to the platinum
center.
The [Pt(dien)L]2+ motif allows for systematic modification of the structural elements
surrounding platinum in a search for the most effective compound. Methylation of the
dien ligand should, in theory, increase lipophilicity of the compounds, however, due to 2+
charge of the compounds, this simple association does not hold true. Analysis of the cellular
accumulation profiles showed little change in the uptake with the addition of methyl groups
to the dien ligand, in agreement with the non-linear change in lipophilicity.
Modification of L using different nucleobases allows for the tuning of the strength of
the pi-stacking interaction between Trp and the platinum complex. The addition of inosine
(which lacks a H-bonding donor/acceptor at the C2 position) resulted in a lower association
constant with both N-AcTrp and the C-terminal zinc finger of HIV1 NCp7. Interestingly, the
addition of xanthosine resulted in an ehanced pi-stacking interaction with the C-terminal zinc
finger of HIV1 NCp7; likely as a results of the addition of a H-bonding donor (double-bonded
O) at the C2 position.
The ability of PtN4 nucleobase complexes to inhibit formation of the NCp7 complexa-
tion with viral RNA was studied by mass spectrometry and gel electrophoresis. Dissociation
of the NCp7-RNA complex was seen upon addition of PtN4 compounds. These compounds
were also able to retard formation of the NCp7-RNA complex when pre-incubated with
the protein. These results have important implications as inhibition of complex formation
between NCp7 and viral RNA has negative implications for viral replication.
Despite the success of platinum-nucleobase compounds, it is important to evaluate
all potential pi-stacking ligands. A series of pyridine- and thiazole-based compounds were
evaluated for the strength of the pi-stacking interaction with N-AcTrp and the C-terminal
ZF of HIV1 NCp7. There was notable increase in association constant for the platinum-
DMAP (4-dimethylaminopyridine) complex compared to other ligands studied. This result
highlights the importance of exploring multiple avenues for the design of specifically targeted
inhibitors and further confirms the viability of the medicinal chemistry dual approach of
target recognition (non-covalent) followed by target fixation (covalent).
Chapter 1
Introduction
1.1 General Overview
Figure 1.1: Structures of traditional
platinum complexes used in the devel-
opment of anti-cancer agents.
Bioinorganic chemistry strives to under-
stand the roles of metals in biological systems,
whether in the form of naturally occurring or
non-essential metal addition to natural systems.
Metal ions play vital roles in many cellular func-
tions such as gene expression/regulation and DNA
transcription and repair1,2. The study of metal-
protein-DNA/RNA interactions has been relatively
unexplored3,4. It is important to understand the
role of metalloprotein interactions with DNA/RNA
as this enhanced knowledge may lead to better un-
derstanding of diseases and therefore more effective
treatments.
One of the major milestones in the devel-
opment of this field was the discovery of cisplatin.
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Cisplatin is a remarkable compound that has improved the odds of survival for nearly all
cancer patients that receive it as treatment. Since the discovery of its cytotoxic properties in
19655 and FDA approval in 1978, cisplatin has become a regular part of the chemotherapy
cocktail used to treat testicular, ovarian, head and neck, bladder and cervical cancer, among
others. In more recent years, carboplatin and oxaliplatin have been approved for use in the
clinic, Figure 1.1. Together, the three platinum compounds make up a multi-billion dollar
drug industry and have significantly improved survival rates for cancer patients6.
Figure 1.2: Cellular processing of cisplatin is a multistep process in which cisplatin enters
the cell, undergoes hydrolysis and binds to proteins (results in deactivation of compound)
and DNA (results in apoptosis).
Due to its success, there has been an extensive amount of research aimed at discov-
ering the mechanism of action for cisplatin in the hopes of improving upon the drug. While
all of the molecular details have not been obtained, it is clear that cisplatin, oxaliplatin
2
and carboplatin exert cytotoxicity through loss of the labile chloride (cisplatin) or oxygen
(oxaliplatin and carboplatin) ligands upon cell uptake and binding to the N7 of guanine in
DNA, causing a distortion in the DNA structure, Figures 1.2 and 1.36.
Figure 1.3: Left: structure of B-DNA, Center: DNA bend caused by a 1,2-intrastrand
crosslink by cisplatin, and Right: DNA Bend caused by a 1,2-interstrand crosslink by cis-
platin.
This distortion is recognized by high mobility group proteins (HMG) and TATA-binding
proteins, and eventually induces apoptosis unless the cells have developed resistance7,8. Cis-
platin resistant cell lines have been shown to recognize the cisplatin-DNA adduct, remove it
and repair the DNA using nuclear excision repair (NER). Two proteins involved in the re-
pair of cisplatin-DNA adducts are replication protein A (RPA) and xeroderma pigmentosum
group A (XPA) have been shown to have different affinities to cisplatin- and oxaliplatin-
DNA adducts, which may explain the lack of cross-resistance between the compounds9,10.
Resistance can also be enhanced through reduced cellular accumulation11,12 and rapid detox-
3
ification of the system (glutathione-binding)13−15.
Treatment with platinum chemotherapeutic agents also results in severe side effects
such as kidney and nervous system toxicity, nausea, vomiting, etc. This toxicity has been
accepted as a function of the non-specific reaction between cisplatin and S-containing residues
(Cys, Met) in proteins16. For reasons of resistance and non-specificity, it is important to
continue to probe the activity of cytotoxic platinum agents and develop new structurally
distinct compounds.
The cis orientation has proven to be crucial for the clinical success of platinum
agents. When oriented in trans geometry, the labile Cl ligands are aquated rapidly due
to the trans effect. This rapid aquation allows for reactions with proteins, such as human
serum albumin and glutathione, resulting in deactivation of the compounds and removal
from the system6. However, the addition of a planar amine (pyridine, quinoline, etc) ligand
in place of ammonia enhances cytotoxic properties in both cisplatin sensitive and resistant
cell lines17,18. Mechanistic studies on these compounds have shown that the additional steric
hindrance of the planar amine results in a somewhat slower rate of aquation, which leads to
long-lived mono-adducts on DNA. Compared to cisplatin, which is 70% bound to DNA in a
bifunctional intrastrand adduct (either G,G or A,G), trans-planar amine complexes (TPAs)
bind to DNA in a mixture of interstrand, intrastrand and monofunctional adducts19−21. The
planar amine in the cis position on TPA complexes has also been found to intercalate DNA,
creating a bend similar to cisplatin. Due to this similarity, monofunctional adducts of trans-
[PtCl2(NH3)(quin)] and trans-[PtCl2(NH3)(thiazole)] are recognized by HMG proteins and
repaired by NER, Table 1.121. This novel DNA-binding motif may help to explain the unique
cytotoxic properties of these compounds when compared to other platinum agents.
Trans-platinum complexes have also been used as probes for DNA-protein reactions.
One of the first experiments used transplatin as a crosslinking agent for NCp7 with HIV1
RNA. NCp7 was shown to catalyze the formation of the RNA dimer and a crosslinking ex-
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Table 1.1: Summary and comparison of basic characteristics of the monofunctional adduct
of trans-PtTz with 1,2-GG intrastrand crosslink (CL) of cisplatin and the monofunctional
adduct of [PtCl(dien)]Cl
monofunctional adduct 1,2-GG intrastrand monofunctional adduct
of trans-PtTz CL of cisplatin of [PtCl(dien)]
termination of yes yes noDNA synthesis
DNA bending 34o 32-34o no
KD(app) (HMGB1a 38.5 nM 30.8 nM norecognition)
KD(app) (HMGB1a 2.05 µM 1.85 µM norecognition)
NER by eukaryotic yes yes noexcinuclease
periment determined that the location of the Pt-RNA-NCp7 crosslink was between positions
315 and 324 of the RNA22. It has since been discovered that the binding of NCp7 occurs
at the Ψ-RNA site. This binding has been studied in depth, allowing for analysis of the
structure of the adduct. The binding affinities for different stem loop regions 1-4 of Ψ-RNA
have been determined and it was found that the NCp7 binds the tightest to SL2 and SL323,24.
1.2 Zinc Finger Proteins
Zinc finger proteins constitute 2-3% of the human genome and play a diverse role
in many cell processes, such as transcription, DNA repair, cellular signaling and apoptosis.
The role of zinc in zinc finger proteins is a structural one and zinc fingers play an important
role in the three-dimensional folding of the protein of which it is a part25. Loss of zinc from
ZF proteins causes a loss of structure and often this leads to loss of the protein’s function26.
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Figure 1.4: Structural zinc is coordinated to
four amino acids in a tetrahedral arrangement.
Zinc fingers (ZFs) are classified by the
number and type of amino acids that make
up the Zn(II) coordination sphere, Figure
1.5. Zinc is an intermediate hard/soft acid
and is most commonly coordinated to histi-
dine and cysteine residues in a tetrahedral
geometry when in a strucutral role, Figure
1.4. Therefore, the classifications of zinc fin-
gers include C2H2, C3H, and C4. Of the
three types of zinc fingers, C2H2 fingers are
the most common and are present in many
human transcription factors27. The different
types of zinc fingers often have different functions and the examples shown in Figure 1.5 will
be discussed briefly.
Figure 1.5: Examples of the three zinc coordination spheres found in zinc finger proteins.
C2H2 zinc finger proteins are commonly part of transcription factors. One example
of a C2H2 zinc finger is the human transcription factor Sp1, which contains three C2H2
zinc finger domains. Sp1 functions by recognizing DNA through hydrogen bonding with
nucleotides in the major groove and by interaction of amino acids with the DNA nucleotides.
Because this protein does not use the symmetry of DNA to recognize it, a series of zinc fingers
is linked together in order to be specific to a long sequence26.
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C4 zinc finger proteins are common in DNA repair enzymes and nuclear localized
systems, e.g. XPA. As discussed earlier, XPA plays a critical role in the recognition of
damaged DNA and signaling for other proteins the NER complex, such as RPA28.
C3H ZF proteins are much less common than C2H2 and C4 and are involved in the
binding of RNA and ss or dsDNA through the interaction of aromatic amino acids with
nucleotides. They are found in nearly all retroviruses. One example of a C3H ZF is the
HIV-1 NCp7, which interacts with ssRNA through the pi-stacking interaction of Phe/Trp
and G/C. This protein is critically involved in the HIV viral life cycle by playing roles in
RNA packaging, reverse transcription and integration26.
1.3 HIV1 NCp7
NCp7 is a basic 55-amino acid protein containing two C3H zinc fingers. The basicity
of this protein is highlighted by the presence of 15 Lys and Arg residues, Figure 1.6. NCp7
binds Zn with very high affinity, with Ka values between 1012-1014 M−1 29. The C-terminal,
Figure 1.6: Top- Sequence of HIV1 NCp7 and Bottom- NMR strucutre of the three-dimension
folding of the peptide.
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N-terminal and zinc finger linker sequences provide no secondary structure; therefore, the
zinc fingers are the most important structural elements. It has also been found that the
C-terminal zinc finger is more reactive than the N-terminal zinc finger30−32, with Cys49
being the most reactive site on NCp733. As part of the viral packaging process, NCp7 binds
to Ψ-RNA through pi-stacking interactions of the aromatic amino acid residues, Phe and
Trp, with nucleotides on the RNA (Cyt, Gua)23,24,34. This pi-stacking recognition element is
unique to NCp7 when compared to cellular C2H2 and C4 zinc fingers and provides a starting
point for the development of specific inhibitors35.
Figure 1.7: HIV life cycle highlighted by the various steps in which current HIV therapies
interrupt.
HIV1 NCp7 has become an attractive drug target in recent years for several reasons.
Current therapies include a combination of drugs that inhibit reverse transcriptase and
protease, Figure 1.7. While this approach has been successful in reducing the viral loads
of many patients, there are problems of resistance, drug toxicity and latent viral reservoirs
that are contained in long-lived cell populations. The development of resistance is enhanced
by the ability of the viral enzymes to efficiently carry out their functions despite mutations.
This ability to easily mutate while retaining viral function is a major limiting factor of drug
regimens. NCp7 is an attractive target because it is highly conserved in all viral strains and
mutations in the zinc-binding sequence have been shown to render the virus non-infectious36.
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Figure 1.8: The various roles of NCp7 in the HIV life cycle are highlighted. NCp7 participates
in nearly all steps of the life cycle, with the exception of cell entry.
NCp7 is cleaved from the parent GAG protein which encodes for proteins that play a
role in compartmentalization of viral components and maintenance of the structural integrity
of the virus. The roles of NCp7 are complex and numerous; this protein plays a role in reverse
transcription, integration of viral components into the host cell, and viral packaging, Figure
1.836,37. A major difficulty in targeting NCp7, as with any target, is specificity. The use
of zinc fingers in normal cellular functions means that the drugs have to be able to only
react with the NCp7 and not just the zinc finger motif. The C3H motif of NCp7 provides a
starting point due to the rarity of such zinc finger coordination spheres.
According to previous studies, C4 should be more reactive than C3H, which should
be more reactive than C2H2. The inherent difference in reactivity is due to an increase in the
number of nucleophilic cysteine residues and may provide a starting point for the rational
design of inhibitory agents. To date, many types of inhibitors have been tested with NCp7
and few have yielded the specificity needed to successfully inhibit HIV without affecting
9
cellular functions26,36.
A successful approach to targeting NCp7 and inhibiting viral activity is through
modification of the Cys residues coordinating zinc. While zinc fingers contain redox inert
d10 structural Zn(II) ions, the coordinated Cys residues are highly nucleophilic and are
susceptible to electrophilic attack by small molecules. The first inhibitor of NCp7 was 3-
nitrosobenzamide (NOBA)(Figure 1.9), which ejected zinc from the protein and inhibited
its function. The compound was highly reactive and its toxic properties stalled further
development38.
Figure 1.9: Structures of well-studied com-
pounds designed to target NCp7.
Compounds have since been devel-
oped that can selectively target HIV NCp7
through electrophilic attack with lower toxi-
city profiles39. The effectiveness and mecha-
nism of action of the disulfide drugs pictured
in Figure 1.9 were evaluated through a num-
ber of biochemical techniques. A dose and
time dependent increase in the fluorescence
of the Zn-(TSQ)2 (TSQ= N-(6-methoxy-
8-quinolyl)-p-toluenesulfonamide) complex
was seen upon incubation of NOBA, DIBA-
1, ADA and dithiane was seen, with DIBA-1
causing the most rapid zinc ejection. Capil-
lary zone electrophoresis showed that upon
incubation with the electrophilic agents the
peak for NCp7 shifted, broadened and formed multiple peaks indicating reaction of the
compounds with the protein. Gel electrophoretic studies showed that incubation of these
four compounds with NCp7 at 1 µM for 2-3 hours completely inhibited binding with DNA.
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When these compounds were tested with Sp1 (C2H2) and GATA (C4), only NOBA showed
inhibition of the binding properties with DNA. These data suggest that ADA, dithiane and
DIBA-1 are selective inhibitors for NCp7 interactions with DNA. The idea of specificity for
these compounds is also supported by the fact that they do not inhibit the spumavirus, which
does not have a zinc finger protein, but do inhibit all other retroviruses tested39. The pro-
posed mechanism for the disulfide compounds, DIBA-1 and dithiane, can be found in Figure
1.10, where binding of the compound induces cleavage of the disulfide bond which is followed
by subsequent binding to another zinc finger, creating inactive ZF protein polymers40.
DIBA-1 is part of a family of DIBA compounds that contain various changes on the
disulfide-linked aromatic structure. These compounds were found to inactivate cell-free
virions, inhibit acute and chronic infections, exhibiting broad antiviral activity. They were
also found to be synergistic with current HIV therapies and no resistance was detected41.
This class of compounds is not without problems, as the disulfide bond can be easily reduced,
limiting the effective half-life of the compound32.
The success of this class of compounds is illustrated by the clinical trial of ADA
in advanced AIDS patients with resistant strains. The trial found that 27% of patients
Figure 1.10: Mechanism of action for disulfide complexes designed to target NCp7.
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had a reduction in viral load when treated with ADA in conjunction with other approved
treatments and 45% showed a recovery in CD4 cells. No evidence of resistance to ADA was
seen. The apparently disappointing results
Figure 1.11: A- Structural motif of
compounds found to inhibit function of
NCp7 from a high throughput screen
of 4800 compounds and B- Fluoroscein-
based structure of compound identified as
inhibitors of NCp7.
of a low rate of decrease in viral load may
not be a good indicator of the compound’s suc-
cess because of the way in which it targets HIV.
By inhibiting NCp7, the virus is rendered non-
infectious, but may still be present in the body.
While the study had a small sample size (n=11),
it showed the relevance of NCp7 and these elec-
trophilic compounds as a strategy to combat
HIV42.
Other strategies have been used to tar-
get and inactivate NCp7, such as peptidomimet-
ics, nucleomimetics, use of actinomycin D to pre-
vent RNA synthesis, and vaccinations40, as well
as a different class of compounds called SAMTs
(S-acyl-2-mercaptobenzamide thioester)43 which
modify the NCp7 portion of the GAG pre-
cursor protein thereby blocking GAG process-
ing. A library of approximately 2,000 small
molecules from the NCI Diversity Set suggested
a good correlation between trytpophan quench-
ing and inhbition of NCp7-nucleic acid binding
for fluorescein-based compounds44. A second high-throughput screening revealed 5 hits out
of 4800 compounds. The ability of these compouds to inhibit the NCp7-mediated destabi-
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lization of cTAR DNA was correlated with their ability to compete with nucleic acid binding
to NCp745, Figure 1.11.
1.4 Use of Platinum Complexes to Target NCp7
1.4.1 Interactions of monofunctional Pt complexes with S-donors
While bifunctional platinum compounds are known to exhibit cytotoxic properties,
monofunctional complexes, such as [PtCl(dien)]Cl (dien=diethylenetriamine) do not have the
same cellular effects46. In order to study the effect of the “carrier” dien ligand, [PtCl(terpy)]Cl
(terpy= 2,2’;6’,2”-terpyridine) was also studied, Figure 1.12. [PtCl(terpy)]+ also provides the
possibility of pi-stacking interactions with aromatic amino acids and has, in fact, been shown
to exhibit some selectivity towards amino acids; specifically the SH in cysteine and N in
histidine and arginine47.
The reaction of [PtCl(dien)]+ with the C-terminal zinc finger of HIV1 NCp7 by
ESI-MS yielded three main adducts immediately upon incubation; {ZF/[Pt(dien)]}+, {ZF/
[PtCl(dien)]}+, and {ZF/[Pt(dien)]/Na}+. Further incubation (up to 48 hrs) did not result
in any additional adducts. The adducts seen by MS display displacement of Cl by S, most
likely from Cys49 as it has been shown to be the most nucleophilic site on the C-terminal
ZF48,49. Of special interest is the peak corresponding to {ZF/[PtCl(dien)]}+. Redox reactions
Figure 1.12: Left- Structure of [PtCl(dien)]+, Center- Structure of [PtCl(terpy)]+ and Right-
Sequence of NCp7 C-terminal zinc finger.
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are unlikely for platinum and it is likely that 4-coordinate square planar coordination will
remain intact. Therefore, it is possible that the Cl is displaced from platinum by a Cys S
and the zinc coordination sphere is expanded to 5-coordinate (Figure 1.13B).
The rigid aromatic chelating ring of terpy and electron-withdrawing effect through
pi-backbonding to Pt suggest that [PtCl(terpy)]+ will be more reactive than [PtCl(dien)]+.
Immediately upon addition of [PtCl(terpy)]+ to the C-terminal ZF of HIV1 NCp7, four new
peaks were seen in the mass spectrum. No simple stoichiometry could account for the new
species, but it is likely that extensive platination of the peptide is seen. Deconvolution of
the spectrum supports this as [Pt(terpy)]3/peptide is seen. MS2 of this peak shows loss of
[Pt(terpy)] indicating that at least one [Pt(terpy)] species remains intact upon binding to
the ZF. Interestingly, [ZnCl(terpy)]+ is seen suggesting “metal scrambling” between the two
species. No such event is seen for [PtCl(dien)]+.
The circular dichroism (CD) spectrum of the C-terminal ZF of HIV1 NCp7 is charac-
Figure 1.13: CD spectra for the reaction between the (A) [MCl(terpy)]+ (M = Pt(II), Pd(II),
Au(III)) complexes and (B) [MCl(dien)]+ (M = Pt(II) or Pd(II), Au(III)) with the C-terminal
ZF of HIV1 NCp7 after 15 min of incubation. (C) Proposed structure of 5-coordinate zinc.
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terized by a slightly positive maximum centered at 210 nm and a stronger negative minimum
centered between 190-200 nm. Loss of zinc from the ZF results in a decrease in the positive
band and a significant increase in the intensity of the negative band as well as a slight red
shift. These changes are indicative of a random coil49. Incubation of [PtCl(dien)]+ and
[PtCl(terpy)]+ contrasts the reactivity of the species. There is very little change in the spec-
trum for [PtCl(dien)]+ after 15 minutes of incubation, while [PtCl(terpy)]+ induces are large
conformational change, Fig 1.13.
Figure 1.14: Structure of trans-
platinum mononucleobase com-
plexes.
Another class of monofunctional platinum com-
pounds are of the structure [PtCl(L)(L’)(nucleobase)]+
where L, L’ are nitrogen donors, Figure 1.14. The
competitive reactions of SP-4-2-[PtCl(9-EtGua)(NH3)-
(quinoline)]+ and trans-[PtCl(9-EtGua)(pyridine)2]+ with
5’-guanosine mono-phosphate (5’-GMP) and N-Acetyl-
methionine (N-AcMet) were studied by 1H NMR Spec-
troscopy. The estimated half-times for reaction with 5’-
GMP and N-AcMet were, respectively, 7.4 and 2.3 h for
SP-4-2-[PtCl(9-EtGua)(NH3)(quinoline)]+ and 4.90 and
<0.75 h for trans-[PtCl(9-EtGua)(pyridine)2]+. This con-
firms the previous observation of faster reaction kinetics
with S vs N ligands. The difference in rate between the
two species also highlights the ability to tune sulfur reac-
tivity through modification of the planar amine ligand50.
Based on this ability to control reactivity, a se-
ries of compounds following the same structural motif,
[PtCl(L)(L’)(nucleobase)]+ using 9-EtGua and 1MeCyt as
the nucleobase, were studied. As seen in Table 1.2, com-
15
Table 1.2: In vitro cytotoxicities and antiviral infectivity results for [SP-4-2]-
[PtCl(nucleobase)(L)(L’)](NO3) bFor details see www.niaid.nih.gov/dmid/apdsame.htm.
cThe parent dichloride compound trans-Pt-Cl2(NH3)(quinoline). EC50 is dose to inhibit
viral infectivity while CC50 is cytotoxic dose in cell carriers. HCMV, human cytomegalo
virus; VCV, varicella virus; HIV-1, human immunodeficiency virus type 1; HSV-1, herpes
simplex virus-1; HSV-2, herpes simplex virus-2; EPV, Epstein-Barr virus.
In Vitro data
Cpd Nucleobase L L’ Virusb EC50 CC50 SI
(µg/mL) (µg/mL) (CC50/IC50)
1 9-EtGua NH3 NH3 HCMV >20 73 <3.7
3 9-EtGua NH3 Quinoline VCV 51 >100 >1.9
HIV-1 41.9 >200 >47.5
4 1-MeCyt NH3 Quinoline VCV >20 94.4 <4.7
5 9-EtGua NH3 Isoquinoline HSV-1 >20 81.8 <4.1
HSV-2 >20 81.8 <4.1
6 1-MeCyt NH3 Isoquinoline EBV 25.1 >50 >2
VCV >20 82.2 >4.1
7 9-EtG NH3 Thiazole VCV >20 94.8 >4.7
10 9-EtGua 4-Mepy 4-Mepy EBV 42 >50 >1.2
Ic NH3 Quinoline 2.98
pounds of this structure show some antiviral activity in vitro. These platinum agents react
through displacement of the labile chloride leaving group and an important factor is the
change from two chlorides (cytotoxic agents) to one chloride (antiviral agents). Thus, struc-
tural features enhancing antiviral selectivity are recognizable51.
It is plausible that the antiviral activity of these compounds may be a result of
zinc ejection from zinc finger proteins. When the C-terminal ZF of HIV1 NCp7 was incu-
bated with SP-4-2-[PtCl(nucleobase)(NH3)(L)]+ in the presence of 4-(2-pyridylazo)resorcinol
(PAR) the absorbance at 500 nm attributed to Zn(PAR)2 increases while that of free PAR
at 420 nm decreases. This ZF binding is supported by the kinetic preference for N-AcMet
over 5’-GMP for SP-4-2-[PtCl(9-EtGua)(NH3)(L)]+ compounds51.
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Of a similar structure, [PtCl(9-EtGua)(pyr)2]+ shows nearly identical reactivity with
the C-terminal ZF of HIV1 NCp7 as SP-4-2-[PtCl(9-EtGua)(NH3)(quinoline)]+ by mass
spectrometry. In both cases, intact compound, free 9-EtGua and 9-EtGua associated with
the ZF are seen in the mass spectrum. There are also a number of platinum adducts such
as, ZF + [Pt(pyr)2] and apo-ZF + 2[Pt(pyr)2]. Study of the reaction by circular dichroism
show a decrease in ordered structure, indicative of zinc ejection. Therefore, the proposed
mechanism of action for these compounds is two steps- first, the compounds pi-stack with
Trp37, which brings the platinum center close to S-containing amino acids, such as Cys, after
which covalent binding occurs. Finally, trans-labilization of 9-EtGua creates a secondary
binding site on Pt and Zn is released from the peptide, Scheme 1.149.
Scheme 1.1: A proposed chemical mechanism for zinc ejection from the C-terminal ZF of
HIV1 NCp7 using platinum-nucleobase electrophiles. The specific nature of the coordination
site for the [Pt(py)2] unit remains to be determined.
1.5 Reactions with Zn Model Chelates
Zinc model chelates have been used as a examples for reactions of Zn-containing
proteins upon methylation52. Therefore, the reactions between three platinum complexes;
[Pt(pyridine)2(9-EtGua)Cl]+; [PtCl(dien)]+; and [PtCl(terpy)]+; and [Zn(bme-dach)]2 have
been studied to model the interaction between platinum complexes and the C-terminal ZF
of HIV1-NCp753,54. For the reaction of [Zn(bme-dach)]2 and [Pt(pyridine)2(9-EtGua)Cl] (1:1
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ratio) an intermediate Pt-Zn species is seen in the mass spectrum corresponding to [Zn(bme-
dach){Pt(pyr)2(9-EtGua)}]. This is supported by splitting of the H8 signal of 9-EtGua in 1H
NMR, indicating a sterically hindered species. One product species is [{Zn(bme-dach)}{Pt(9-
EtGua)}], which upon subsequent MS, yields a final product of [Pt(bme-dach)]. The same
result is achieved upon MS3 of [Zn(bme-dach)-PtCl]. This indicates that platinum binding
induces zinc ejection after which, platinum can be incorporated into the macrocycle53.
The same zinc model was used to study the reactions of [PtCl(dien)]+ and [PtCl-
(terpy)]+, Figure 1.15. For the reaction of [PtCl(dien)]+ with the model chelate, mass spec-
trometry shows the formation of two major peaks ([Zn(bme-dach)(Pt(dien))]2+ and [Zn(bme-
dach)Cl-(Pt(dien))]+) and two minor peaks ([(Zn(bme-dach)2)Pt(dien)] and [(Zn(bme-dach)3)Pt-
Figure 1.15: Reaction pathways of the reaction of [Zn(bme-dach)]2 with [PtCl(dien)]Cl and
[PtCl(terpy)]Cl showing the formation of thiolate-bridged, metal-exchanged, and multimetal-
lic aggregate species.
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(dien)]); the products do not change with time. MS2 of [Zn(bme-dach)Cl(Pt(dien))]+ shows
loss of Cl and MS3 yields [PtCl(dien)]+ and [[Zn(bme-dach))Pt]+. 195Pt NMR of the reaction
shows the reaction from PtN3S to PtS4 over time and a yellow precipitate was isolated and
identified by crystallography as [Zn(bme-dach)]2Pt. The opening of the dien chelate ring
displays the strong trans influence of the cysteinate54.
The reaction of [PtCl(terpy)]+ with [Zn(bme-dach)]2 was studied at a ratio of 1:1
(Zn:Pt) and 2:1 (Zn:Pt). At a 1:1 ratio, the mass spectrum showed a series of ligand-
scrambled species at 5 minutes. Peaks were seen for [ZnCl(terpy)]+, [Pt(bme-dach)]+, and
{[Zn- (bme-dach)]2PtCl]}+. The major peak for 1:2 ratio corresponds to [(Zn(bme-dach)-
Pt(terpy)]+ and minor peaks are seen for [Zn3(bme-dach)2(terpy)Cl3], [Zn(bme-dach)]3PtCl]+,
and [Zn(bme-dach)]4PtCl]+ 54.
The model chelate studies correlate well with experimental data, as ligand scrambling
was also seen for the reaction of [PtCl(terpy)]+ with the C-terminal ZF of HIV1 NCp7. These
studies further exemplified the ability to change the reactivity profile of platinum complexes
with Zn-containing nucleophiles.
1.6 Non-covalently-interacting PtN4 complexes as selec-
tive agents for targeting NCp7
While the monofunctional platinum complexes exhibit some antiviral activity, the
labile chloro group allows for non-specific reactions between the platinum center and sulfur-
containing proteins, such as human serum albumin (HSA) or glutathione. Therefore, we have
moved to a non-covalent approach, in which platinum is bound to four substitution inert N-
containing ligands. Compounds of the structure [Pt(dien)(L)]n+ where L is a nucleobase have
been evaluated for their pi-stacking interactions with Trp and the C-terminal ZF of HIV1
NCp7, Figure 1.16. We have used the analogy of a “weak electrophile” for these substitution-
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inert complexes compared to other organic weak electrophiles that have been used to target
NCp7.
Figure 1.16: Structure of
[Pt(dien)L]n+ complexes with
the platinum binding site
highlighted in red.
The pi-stacking interaction between aromatic
amino acids, such as Trp, and a nucleobase is a defining
characteristic of protein/DNA recognition. It has been
shown that N-quaternization of nucleobases enhances the
stacking interaction by lowering the energy of the LUMO
of the nucleobase, making it closer in energy to the HOMO
of Trp. The change in the energy of the LUMOmay be due
to the removal of the lone pair of electrons on the nitrogen
of the nucleobase55. Another way to remove the lone pair
is through coordination to a metal. In this way, metalation
and alkylation can be directly compared as a way to mod-
ify nucleobases to increase the stacking interaction with
aromatic amino acids. Assessment of the HOMO/LUMO
energies can be a simple way to compare alkylation and metallation and predict their effects
on pi-stacking with Trp. DFT calculations have shown that coordination of the nucleobase
derivatives 1MeCyt and 9-EtGua to Pt or Pd results in a lowering of the HOMO and LUMO,
similar to that seen upon protonation and methylation56. The energy of the LUMO of the
Pt complexes are closer to the HOMO of Trp than for Pd, which is in agreement with higher
Ka values that have been published for Pt57,58.
Fluorescence quenching of Trp is measured in the presence of a nucleobase or platinum-
nucleobase complex in order to calculate an association constant. Due to an electron transfer
from the Trp indole ring to the nucleobase in the excited state, a quenching of Trp fluorescence
is seen and can therefore be considered a good indicator of the strength of the interaction55.
Our group has published studies of platinum and palladium nucleobase/nucleotide complexes
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with N-AcTrp compared to free nucleobase/nucleotide. On average, free 9-EtGua, GMP, and
CMP have Ka values of 3x103 M−1 while platination increases the Ka for all nucleobases to
6.8, 6.9, and 7.0 x103 M−1, respectively. 1MeCyt has a Ka value higher than the other free
nucleobases/nucleotide at 6.0x103 M−1 and upon platination sees a slightly smaller increase
to 8.8x103 M−1. This increase is associated with the above-mentioned lowering of the LUMO
of the nucleobase57. These studies show that platinum nucleobase complexes have the po-
tential to be used as probes for protein/DNA interaction through their ability to pi-stack
with Trp.
Figure 1.17: (A) Fluorescence quenching of L-Trp in the presence of [Pt(dien)L]2+ (B) Cal-
culated Ka values for free and [Pt(dien)L]2+ nucleobases with L-Trp and the C-terminal ZF
of HIV1 NCp7.
The studies to determine the Ka of platinum complexes with Trp in solution can be
extended to short peptide sequences. Electrophilic compounds that modify the Cys residues
and subsequently eject zinc have been identified (8). Our group has extended the concept
of electrophilic attack to PtN4 species. The Trp stacking interaction with the C-terminal
ZF of HIV1 NCp7 for [Pt(dien)(9-EtGua)]2+ and [Pt(dien)(GMP)] was studied and the Ka
values were found to be 7.5 and 12.4 x103 M−1, respectively (Figure 1.17)49. While the
phosphate group of the GMP does not have a strong effect on the stacking interaction with
free Trp, it enhances the stacking with ZF. This may be due to an extra recognition feature
(Lys-phosphate) that has been previously reported for NCp7 with dACGCC49,59. The CD
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spectrum of the ZF does not change in the presence of [Pt(dien)(9-EtGua)]2+ which suggests
that the stacking interaction does not disrupt the three-dimensional structure. Analysis by
ESI-MS shows an adduct corresponding to [Pt(dien)(9-EtGua)]/ZF and upon MS2 of the
parent ion, peaks corresponding to [Pt(dien)(9-EtGua)], ZF, [Pt(dien)(9-EtGua)]/ZF, and
[Pt(dien)]/ZF were seen indicating that non-covalent and covalent complexes form between
ZF and [Pt(dien)(9-EtGua)]2+ 49.
1.7 Interaction of Platinated DNA with the C-terminal
ZF of HIV1 NCp7
Figure 1.18: Structure of
[Pt(dien)6-mer].
The interaction of Pt(dien)(6-mer) (6-mer = d’(5’-
TACGCC-3’) with the C-terminal finger of the HIV NCp7
zinc finger was studied by NMR Spectroscopy, Figure
1.18. Upon coordination to platinum, significant struc-
tural changes were seen compared to the uncoordinated 6-
mer, Figure 1.19. The tryptophan resonances were shifted
upfield and broadened, while the H8 of Gua4 remained
downfield, confirming platination. Both cytosines re-
mained in the same environment upon platination. Other
major shifts were seen for Gln45, Met46, Lys47, and
Glu50. The Zn-Cys/His chemical shifts show only minor
changes60.
The solution structures of the ZF, 6-mer/ZF, and Pt(dien)6mer/ZF adducts were
calculated from NOESY-derived distance constraints. An interaction between Trp37 and
the ribose protons of Gua4 of the hexanucleotide was observed. Metallation of Gua4 results
in a change of orientation of the aromatic ring of tryptophan (Figure 1.19B), a result of which
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Figure 1.19: (A) Superposition of the minimized structures of the 6-mer/F2 adduct (green)
and the Pt(dien)(6-mer)/F2 adduct (orange). (B) Change in conformation of Trp37 upon
platination of Gua4. (C) Stabilizing interactions of Cyt6 with the protein residues, Cys49
and Thr50, in the Pt(dien)(6-mer)/F2 adduct (hydrogen bonding highlighted in red box).
is a conformational change in the overall DNA structure. This is reflected in the weaken-
ing of the Trp37-Gua4 contact for Pt(dien)(6-mer) when compared with unbound 6-mer.
These conformational changes can be attributed to the steric effects caused by platination
of Gua460.
Molecular dynamics calculations of the DNA-protein interactions showed that the
pi-stacking between Trp37 and Gua4 as well as the hydrogen bonding between the ribose and
phosphate oxygen(s) of Cyt5 and Gua4 help stabilize the interactions between the 6-mer and
ZF. Once platinum is bound, the 6-mer is less flexible and stays in one stable conformation on
the surface of the zinc finger. The Gua4-Trp37 interaction is disrupted, resulting in hydrogen
bonding interactions between Cyt6 and Cys49 and Thr50. Additionally, the backbone CH
group is close to N3 of Cyt6. With the addition of this third hydrogen bond, the bonding
mode imitates the three intermolecular Cyt-Gua base pair hydrongen bonds (Figure 1.19C)60.
These results are the first example of structural characterization of platinated single-
stranded DNA interacting with a zinc finger protein, resulting in conformational change of
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the peptide. The studies performed show the feasibility of using DNA-tethered coordination
compounds to target zinc finger proteins60.
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Dissertation Outline
The work presented in this dissertation is a continuation of the previously published
work designing platinum agents selective for HIV1 NCp7. Targeting of NCp7 is of particular
interest due to its intolerance to mutation and importance in the viral life cycle. The success
of our work to develop anti-HIV platinum complexes is highlighted by the fact that some of
the previous [PtCl(L)(L’)(nucleobase)]+ compounds show anti-viral activity in vitro. It is
important to understand how platinum complexes interact with proteins and what enhances
these reactions. The effect of the presence of a tryptophan residue in a short peptide sequence
on the reactivity of the platinum-nucleobase compound [Pt(dien)(9-EtGua)]2+ was evaluated
using 195Pt, 1H NMR and mass spectrometry in Appendix A.
Previous studies have used the C-terminal ZF of HIV1 NCp7 as a model for the full
two-zinc finger peptide, NCp7. NCp7 plays a critical role in nearly all steps of the HIV1
viral life cycle. Therefore, the ability of [Pt(dien)(9-EtGua)]2+ to interrupt the binding of
NCp7 and viral RNA was evaluated using mass spectrometry and gel electrophoresis. These
results are reported in Chapter 2. Chapters 3 and 4 explore modulation of the interaction
of PtN4 complexes with N-AcTrp and the C-terminal ZF of HIV1 NCp7. It is important
to optimize this interaction as it may have important implications for the efficacy of the
platinum drug in a larger biological role (interruption of the HIV life cycle).
Chapter 5 and Appendix B evaluate the use of covalently-binding platinum drugs
to target NCp7. Other unpublished work related to the development of antiviral platinum
agents is discussed in Chapter 6. A review of the importance of metal compounds in the
study of the interactions of proteins and DNA/RNA can be found in Appendix C.
Published work will be included in a format as close as possible to that in which it
was published.
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Chapter 2
A new class of HIV nucleocapsid protein (NCp7)-nucleic acid
antagonists
Sarah R. Spella, Samantha D. Tsotsorosa, John B. Mangrumb, Erica J.
Petersona, Daniele Fabrisb, and Nicholas P. Farrella∗
aDepartment of Chemistry, Virginia Commonwealth University, 1001 W. Main Street,
Richmond, VA 23284-2006 USA
bThe RNA Institute, University at Albany, State University of New York, 1400 Washington
Avenue, Albany NY 12222, USA In preparation for submission to J. Inorg. Biochem.
2.1 Contribution
S.D.T.’s contributions include synthesis of [Pt(dien)(9-EtGua)]2+ following literature
methods, fluorescence studies, circular dichroism studies and mass spectrometry studies for
the platinum complex. S.R.S. contribrutions include synthesis of [Au(dien)(9-EtGua)]3+,
circular dichroism and mass spectrometry studies for the gold complex. S.D.T. and S.R.S.
were responsible for preparation of the figures. J.B.M.’s contribution inlcudes assistance
with mass spectrometry experiments. S.R.S. also contributed to the preparation of the
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manuscript.
2.2 Introduction
Assessment of protein packing, steric accessibility and electrostatic screening of zinc
finger cores has recognized the enhanced reactivity of Zn-Cys3His coordination spheres over
their Cys2His2 counterparts1,2. Selectivity for the former, and the ability to distinguish be-
tween different zinc finger-coordination spheres, can be found in nucleophilic discrimination
through reaction of weak “organic” electrophiles with the highly nucleophilic zinc-cysteine
residues1,2. In coordination chemistry the equivalent of weak “inorganic” electrophiles has
been suggested by us to be formally substitution-inert MN4 compounds with four strong
M-N bonds typical of the quintessential soft electrophiles Pt(II) and Au(III)3. Compounds
containing a Pt(Au)-Cl bond are likely to be far too reactive for protein selectivity - exem-
plified by the often quoted statement that < 5% of the administered dose of the anticancer
drug cisplatin, cis-[PtCl2(NH3)2], is considered to get to its cellular target DNA.
A significant source of selectivity for HIV-1 inhibition lies in identification of nucleo-
capsid NC-nucleic acid antagonists4−6. Agents which interrupt the interaction with “natural”
substrate combined with either electrophilic attack or covalent modification may be classed
as a discrete approach to zinc finger inhibition. The aromatic amino acids tryptophan (Trp)
and phenylalanine (Phe) are critical for the NC-nucleic acid molecular recognition. The
mutation of even one of these residues significantly decreases NC’s nucleic acid chaperone
activity, and correlates with inhibition of viral replication7. Trp interacts with nucleobases
through both H-bonding and pi-stacking with the indole ring of the W37 residue inserted
between adjacent C and G bases and stacked on the latter8−11. Metallation of nucleobases, as
with protonation and alkylation, enhances pi-pi stacking interactions with tryptophan, in part
due to lowering of the HOMO-LUMO gap12. Using the C-terminal finger of the HIVNCp7
(F2, residues 34-52) we have demonstrated the targeting of the critical tryptophan residue
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with metallated nucleobases13,14.
Figure 2.1: Structures of A)
[M(dien)(9-EtGua)]n+ (M=Au, n=
3, I ; Pt, n=2, II), B) SL2 RNA
(SL2) and C) HIVNCp7 (NC).
We have now extended these studies to the
“full” two-zinc finger NC and its complex with SL2
RNA (SL2). In the presence of the metallated nucle-
obases [M(dien)(9-EtGua)]n+ (M=Au, n=3, I; M=Pt,
n=2, II); 9-EtGua = 9-ethylguanine) the NC-SL2 in-
teraction is inhibited in an antagonist fashion and ex-
pands the chemistry of this important HIV target in
hitherto unrecognized directions. Incorporation of a
functionalized nucleobase within the MN4 structure
as in [M(dien)(Nucleobase)]n+ gives agents capable in
principle of (i) molecular recognition through the non-
covalent tryptophan-nucleobase interaction and (ii)
subsequent peptide covalent bond formation through
manipulation of the reactivity of the coordination
sphere. The contrast in substitution kinetics between the isoelectronic and isostructural
Au(III) and Pt(II) compounds provides valuable insights into the antagonist mechanism,
allowing for further systematic enhancement of this new biological role for platinum metal
complexes. The proposed chemistry represents the first class of inorganic molecules capable
of systematic study on the HIV zinc finger with the potential for intrinsic selectivity. The
structures of the complexes and biomolecules are shown in Figure 2.1.
2.3 Results and Discussion
Incubation of [Au(dien)(9-EtGua)]3+ (I) with intact NC resulted in the detection
of species produced by ejection of both Zn2+ ions and incorporation of up to 3 Au ions -
AuF, Au2F and Au3F, Figure 2.2. There was no evidence for intermediate Au-ligand-peptide
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Figure 2.2: ESI-FTICRMS spectra (positive ion mode) of a 1:1 reaction of NC:[Au(dien)(9-
EtGua)]3+.
species, in contrast to the reaction of the C-terminal finger of NC with [Au(I)(PPh3)(L)]+15.
The CD spectrum of NC is characterized by a positive maximum observed at 215 nm.
The Au compound caused a decrease in intensity of this band and a significant increase in
the negative ellipticity with a slight blue shift of the 195-200 nm band, which are indicative
of conformational changes from ordered structure to random coil, Figure 2.3A16,17. The
pronounced changes are consistent with a loss of structural integrity in NC upon treatment
with I.
The effects of these conformational changes on the NC-SL2 interaction were investi-
gated by FT-ICRMS by adding SL2 to an NC sample that was pre-incubated with I for 30
min, or by adding I to preformed NC-SL2 complex. In the former case, only free unbound
SL2 was observed, thus indicating that the major structural changes induced by Zn2+-Au3+
replacement abrogated the binding capabilities of NC (Figure 2.4). In the latter case, a direct
comparison of data obtained from NC-SL2 in the presence/absence of I showed a significant
increase of free SL2 in solution (Figure 2.5 and Figure 2.6), thus suggesting that the gold com-
pound is capable of inducing dissociation of the peptide from its cognate RNA. In addition,
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Figure 2.3: A. CD spectra of the reaction of NC and [M(dien)(9-EtGua)]n+ at 15 minutes
incubation. B. NC Fluorescence quenching upon addition of [Pt(dien)(9-EtGua)]2+ from
10-100 molar ratios (Pt:Trp).
minor signals corresponding to [(Au,ZnNC)-SL2] and [(Au2NC)-SL2] were detected, which
are consistent with direct displacement of Zn2+ from the intact NC-SL2complex (Figure 2.7).
An advantage of the [M(dien)(9-EtGua)]n+ system is that both isostructural and
isoelectronic systems can be studied. The CD spectrum in the presence of [Pt(dien)(9-
EtGua)]2+ (II) case shows that there is little disruption of the 3D structure in the presence
of the Pt(II) complex, as evidenced by the maintenance of the positive ellipticity, (Figure
2.3A). Incubation of the intact NC with II results in a concentration-dependent decrease
in fluorescence from which an association constant (Ka) of 2.0 x 104 M−1 was calculated,
compared to 7.5 x 103 M−1 for the C-terminal finger alone, [24], Figure 2.3B.
In the case of the Pt complex, analysis under identical experimental conditions as the
Au(III) case revealed only weak association between II and NC. Nevertheless, pre-incubation
significantly retarded the kinetics of formation of the NC-SL2 complex. Furthermore, ad-
dition of II to preformed NC-SL2 complex induced the release of free SL2, similar to the
observations afforded by the gold compound, Figure 2.8. In this case, the release of nucleic
acid was also accompanied by the detection of a relatively abundant species corresponding
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Figure 2.4: FT-ICRMS spectrum (negative ion mode) of 1:1 [Au(dien)(9-EtGua)]3+/NC
(incubated for 30 minutes) followed by addition of SL2 RNA.
Figure 2.5: FT-ICRMS spectra (negative ion mode) of 2:1 NC-SL2 complex upon addition
of 1 eq. [Au(dien)(9-EtGua)]3+ (top t=0, run immediately; bottom after 15 mins reaction)
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Figure 2.6: FT-ICRMS spectrum (negative ion mode) of NC:SL2 RNA complex in a 2:1
ratio. Note that under these MS conditions, the complex remains intact. These conditions
were used before addition of any metallated nucleobase.
Figure 2.7: Expanded region of 2:1 NC/RNA complex reacted with 1 eq. [Au(dien)(9-
EtGua)]3+ showing presence of possible RNA-Au-NC crosslinking.
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to a [Pt(dien)(9-EtGua)]2+-SL2 adduct. Biophysical studies on the interaction of II with
Calf Thymus DNA indicated little or no reaction [15], but the tertiary structure of RNA
may enhance association.
Figure 2.8: ESI-MS Spectrum (negative ion mode) of NC-SL2 (2:1) in presence of 2.5 eq.
of [Pt(dien)(9-EtGua)]2+ showing liberation of SL2 with decrease in intensity of NC-SL2
species and observation of SL2-[Pt(dien)(9-EtGua)] species.
Electrophoretic mobility shift assays (EMSA) confirm the general trend of these re-
sults, Figure 2.9. Increasing concentrations of [Pt(dien)(9-EtGua)]2+ results in a decrease
in intensity of the NC-SL2 band. Concomitantly, the free SL2 band changes to an upward
smear, which again may indicate interaction of the compound itself with the RNA. In con-
trast, there is no diminution of the NC-SL2 band in the presence of the Au compound,
which could be explained by the absence of any interaction, in contradiction to the MS and
CD results. An alternative explanation is the possible cross-linking of the two biomolecules
by the gold compound, or metabolite or substitution product thereof. In this case, EMSA
analysis may be precluded from properly resolving the cross-linked adduct by the large size
of the NC-SL2 complex
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The cross-linking hypothesis was further investigated by fluorescence polarization ex-
periments using labelled SL2-[Flc]. A control sample consisting of NC and SL2-[Flc] afforded
results consistent with formation of the NC-SL2 complex, Table 2.1. Upon incubation of NC
for 1 h with increasing concentrations of [Au(dien)(9-EtGua)]3+ addition of SL2-RNA-[Flc]
gave polarization values that were higher than those obtained from the control sample. Al-
though it would be tempting to explain the strengthening of the RNA-protein interaction
with the formation of a stable [NC-Au-SL2] species, the fluorescent anisotropy experiments
cannot per se provide direct proof of its formation. Nevertheless, the minor products observed
in the MS spectra, Figure 2.7, are consistent with such a hypothesis. The gold compound
does not interact with RNA itself, as indicated by the values of polarization afforded by
this control, Table 2.1. In agreement, no [Au(dien)(9-EtGua)]-SL2 adducts were observed
from the MS analysis of Figure 2.5. The “parent” [AuCl(dien)]2+ also has only weak affin-
ity for DNA18. These results can be rationalized by considering that upon NC interaction,
Figure 2.9: Effect of Metal-Nucleobase Compounds on SL2 RNA -NCp7 protein interaction.
A: Control Experiment. 32P end-labeled SL2 RNA (2nM) incubated with varying concen-
trations of NCp7 in binding buffer. Lane 1 contains SL2; Lanes 2-8 1µM, 500, 250, 125,
62.5, 31.3, and 15.6 nM NCp7 respectively. B: Incubation of NC (250nM) with [Pt(dien)(9-
EtGua)]2+ for 1hr followed by addition of SL2 (2nM) in binding buffer and further incubation
for 1 h. Lane 1 contains SL2 only, Lane 2 SL2 and NCp7 only; Lanes 3-9 contain NC, SL2 and
500, 250, 125, 62.5, 31.3, 15.6, and 7.8 µM of I respectively. C: Identical to B in all respects
but Lanes 3-9 contain 7.8, 15.6, 31.3, 62.5, 125, 250, and 500 µM [Au(dien)(9-EtGua)]3+
respectively.
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the Au ligands are lost (confirmed by MS and CD studies, Figures 2.2 and 2.3A) and it is
possible that coordinatively unsaturated Au-S or Au-OH(H2O) species could then bind to
nucleotides. Of relevance, trans-[PtCl2(NH3)2] (tDDP) produces cross-links between NC and
HIV-1 RNA19, presumably by taking advantage of the long-lived nature of monofunctional
tDDP-biomolecule adducts20.
Table 2.1: Fluorescence Polarization (mP) of NC (100 nM) incubated with indicated concen-
trations of [Au(dien)(9-EtGua)]3+ (I) followed by addition of SL2-[Flc] (10nM). See Materials
and Methods.
SL2 SL2 SL2+NC SL2+NC SL2+NC SL2+NC SL2+NC
(-)I (+I)I (-1)I (+)0.01µM I (+)0.08µM I (+)1.25µM I (+)10µM I
106 101 173.5 169 175 191.5 203
In summary, the results are consistent with the ability of the chemotype [M(dien)(9-
EtGua)]n+ to act as antagonist of the NC-SL2 interaction, with significant potential for
optimization as a structurally discrete new class of agents capable of disrupting the chap-
erone activity of NC, Scheme 2.1. The differences in profile between the two metallated
nucleobases reflect the different substitution kinetics of the central metal ions. Thus, we
see immediate displacement of Zn2+ by Au3+ (MS, CD) whereas with the kinetically inert
Pt2+ an association constant can be measured and there is no evidence of Zn2+ dislocation
from the NC under these conditions - the stacking reaction is observed by fluorescence and
CD. In this case, purely “non-covalent” approaches appear to allow physical blocking of the
interaction. It is reasonable to expect the Au compound to react in the same way - the
subsequent loss of ligands upon covalent reaction with peptide is just too fast. Model stud-
ies with N-AcTrp confirm the greater stacking of the Au(III) species relative to Pt(II)21.
Thus, a classical “two-step” approach of molecular recognition followed by target fixation
(electrophilic attack on the zinc finger core) is suggested13. The greater reactivity of the
Au(III) species is also reflected in the possible formation of the higher-order aggregates.
Both components of the NC-nucleic acid chaperone activity have been targeted22−26.
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Scheme 2.1: HIV Nucleocapsid-Nucleic Acid Antagonism based on metallated nucleobases.
A study of approximately 2,000 small molecules from the NCI Diversity Set suggested a pos-
sible fluoroscein-based pharmacore with a good correlation between tryptophan quenching
and inhibition of NC-nucleic acid binding22. A second high-throughput screening of small
molecules for inhibition of NC-mediated destabilization of the stem-loop structure of cTAR
DNA (a sequence complementary to the transactivation response element) produced five se-
lected hits from a total of 4800 compounds23. The inhibitory activity of 4 of the 5 correlated
with their ability to compete with the nucleic acid for binding to NC13. Along with platinum
compounds1,13, gold drug binding to single zinc fingers has been reported by a number of
authors15,27−28, but this report is the first of coordination compounds reacting on a “multi-
ple (>1)” zinc finger peptide. The chemotype has the potential for intrinsic selectivity for
this important target over other zinc fingers - the formally substitution-inert species are the
equivalent of “weak” electrophiles proposed as one approach to selectivity3,4.
2.4 Materials and Methods
2.4.1 Synthesis and Biomolecule Preparation
The Pt and Au compounds were prepared as described previously3,11. For the MS studies
the NC was prepared in the Fabris lab. Briefly, Nucleocapsid (NC) protein of HIV-1 was
obtained by in vitro expression in E. coli, subsequently purified under non-denaturing con-
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ditions to preserve the coordination of Zn2+ by its characteristic zinc-finger domains. For
the gel shift and biophysical studies, the NC (identical sequence) was a generous gift of Dr.
R.J. Gorelick, NIH. RNA oligonucleotides corresponding to the SL2 stem loop domain of
the HIV-1 genome packaging signal (Ψ-RNA) were purchased from IDT (Coralville, IA) and
desalted using ultrafiltration against 150 mM ammonium acetate.
2.4.2 Mass Spectrometry
Experiments were conducted on a modified Bruker Daltonics (Billerica, MA) SolariX FTICR-
MS equipped with a 12T superconducting magnet. Analyses were carried out by direct
infusion using tapered quartz nanospray emitters loaded with 5-10 µL of sample with a
spray voltage between 800-1100 V relative to the capillary inlet supplied by an inserted
stainless steel wire.
Solutions were prepared as follows:
A. 1:1 reaction of NC with [Au(dien)(9-EtGua)]3+
A solution of [Au(dien)(9-EtGua)]3+ (7.5 µM in 1 µL H2O) was added to a solution of NC
(7.5 µM in 1 µL H2O) and volume was brought up to 10 µL with 7µL 150 µM ammonium
acetate and 1 µL isopropyl alcohol. The solution was analyzed immediately in positive ion
mode.
B. 1:1:1 reaction of NCp7/[Au(dien)(9-EtGua)]3+ with SL2-RNA, Figure S1.
A solution of NC (7.5 µM in 1 µL H2O) and [Au(dien)(9-EtGua)]3+ (7.5 µM in 1 µL) was
incubated for 30 minutes at room temperature. SL2-RNA (7.5 µM in 1 µL), 6 µL 150 mM
ammonium acetate, and 1 µL isopropyl alcohol were added and the mixture was analyzed
immediately in negative ion mode.
C. Control experiment showing formation of NC/SL2 (2:1) complex, Figure S2
A solution of NC (7.5 µM in 4 µL H2O) was added to a solution of SL2 (7.5 µM in 2 µL
H2O) and volume was brought up to 10 µL with 3 µL 150 mM ammonium acetate, and 1
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µL isopropyl alcohol. The solution was analyzed immediately. No significant incubation was
necessary.
D. 2:1:1 reaction of NC/RNA complex with [Au(dien)(9-EtGua)]3+
A solution of NC (7.5 µM in 4 µL H2O) was added to a solution of SL2 (7.5 µM in 2 µL
H2O) to form the 2:1 NC/RNA complex. The complex formed immediately; no significant
incubation was necessary. A solution of [Au(dien)(9-EtGua)]3+ (7.5 µM in 2 µL) was added
and volume was brought up to 10 µL with 1 µL 150 mM ammonium acetate and 1 µL
isopropyl alcohol. The mixture was analyzed in negative ion mode immediately (time = 0)
and after 15 minutes incubation.
E. 2:1:2.5 reaction of NCp7/RNA complex with [Pt(dien)(9-EtGua)]2+, Figure S4.
A solution of NC (7.5 µM in 4 µL H2O) was added to a solution of SL2 (7.5 µM in 2 µL H2O)
to form the 2:1 NC/RNA complex. Complex formed immediately; no significant incubation
was necessary. A solution of [Pt(dien)(9-EtGua)]2+ (37.5 µM in 1 µL) was added and volume
was brought up to 10 µL with 2 µL 150 mM ammonium acetate and 1 µL isopropyl alcohol.
The mixture was analyzed immediately in negative ion mode.
2.4.3 Circular Dichroism
Methods were adapted from those previously published3,18.
2.4.4 Fluorescence Spectroscopy
Methods were adapted from those previously published3. A 3 mL solution of NC (5 µM) in
water was titrated with aliquots of the corresponding quenching compound (7.5 mM) in the
range [quencher]/[N-AcTrp]) 10-100.
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2.4.5 Gel Shift Assays
As a control experiment, 32P end-labeled SL2 RNA (2 nM) was incubated with varying
concentrations of NC in binding buffer (50 mM Tris-HCl, 40 mM MgCl2, 200 mM NaCl, 0.1
mM ZnCl2, 5% glycerol, and 1% BME) for 1 hr at 30oC. In all subsequent reactions, 250 nM
NC was incubated with increasing concentrations of [Au(dien)(9-EtGua)]3+ or [Pt(dien)(9-
EtGua)]2+ for 1 hr in binding buffer. Subsequently, 2 nM SL2 was added to the buffer and
the mixture incubated for an additional hour.
2.4.6 Fluorescence Polarization
In 250 µL total volume, increasing concentrations of NC were incubated with 10 nM fluorescein-
labeled SL2 RNA for 4 hrs in minimal buffer (25 µM phosphate buffer, pH 7.2 and 225 mM
NaCl) at room temperature to afford control values. In all subsequent experiments, in 250
µL total volume, 100 nM of NC was incubated in minimal Buffer (25 µM phosphate buffer,
pH 7.2 and 225 mM NaCl) with varying concentration of drug before addition of 10 nM
SL2-RNA[Flc]. The reactions were incubated 4hrs at room temperature and analyzed on a
SynergyTM NEO HTS multi-mode microplate reader system.
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Modification of the [Pt(dien)L]2+ coordination sphere to develop
inhibitors of HIV1 NCp7
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3.1 Contribution
This chapter is solely the work of S.D.T. with the exception of the EMSA experi-
ments, which were designed by E.J.P..
3.2 Introduction
The [M(dien)(nucleobase]n+ coordination sphere allows for modification in several
ways to enhance the pi-stacking interaction with Trp, as well as the cellular properties, such
as cellular accumulation and cytotoxicity. Here, we evaluate the effect of methylation of
the dien ligand as well as various nucleobase-derivatives as the pi-stacking ligand. Results
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suggest that addition of methyl groups to the dien ligand does not significantly impact
cellular accumulation or cytotoxity, but the addition of xanthosine (Xan) results in a very
strong pi-stacking interaction when compared to the 9-ethylguanine compound.
3.3 Results and Discussion
3.3.1 Chemistry
The structures of the compounds reported in this paper can be found in Figure 3.1.
Two main modifications were made on the [Pt(dien)L]2+ structure; methylation of the dien
and change in pi-stacking ligand. Methylation of the dien may provide increased lipophilicity
which may have implications for cellular accumulation, while the change in L affects the
strength of the pi-stacking interaction.
Figure 3.1: General structure for [Pt(dien)L]2+ compounds, where the dien can be methy-
lated (NMe, N,N’-dimethyl or N,N’-N,N’-tetramethyl) and L is a nucleobase.
The addition of methyl groups, besides adding lipophilic groups, also adds consider-
able steric hindrance about the platinum-nucleobase bond. This can be seen in the 1H NMR
of 1c and 1d. The H8 signal of the 9-EtGua splits into two singlets due to this restricted
rotation. Temperature dependence studies of the H8 signal reveal a significant difference
between the Me2dien compound and the Me4dien compound, Figure 3.2. The coalescence
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temperature for the Me2dien compound is 35oC, whereas the H8 signal for the Me4dien com-
plex does not coalesce up to 70oC. The calculated energies of the rotation barrier, Ebarrier,
was calculated based on the coalescence temperature following literature methods1. There
is a >2 kcal/mol difference between Ebarrier for the two compounds, 15.90 for Me2dien and
>17.92 kcal/mol for Me4dien. This energy difference highlights the significant steric hin-
drance created by the methyl groups. This splitting is also seen in the 195Pt NMR, Figure
3.3
Figure 3.2: Temperature dependence of the 1H NMR splitting of the H8 signal for A-
[Pt(Me4dien)(9-EtGua)]2+ and B- [Pt(Me2dien)(9-EtGua)]2+.
As seen in Table 3.1, Ka values are reported for the platinum-nucleobase complexes
with N-AcTrp and the C-terminal ZF of HIV1 NCp7. The addition of the sugar moiety on
guanosine (Gua) and Xan enhances the interaction with tryptophan slightly over the parent
9-EtGua compound. This may be due to addition H-bond contributions from the sugar.
The most significant increase in association constant is between the Xan compounds (3a, 3b,
3c, 3d) and the C-terminal ZF of HIV1 NCp7; the additional double-bonded oxygen on the
pyrimidine ring, a H-bond acceptor, may explain this trend. The C-terminal ZF contains
several Lys residues in addition to an Arg, which are H-bond donors. Due to the lack of
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Figure 3.3: Temperature dependence of the 195Pt NMR splitting of the signal for A-
[Pt(Me4dien)(9-EtGua)]2+ and B- [Pt(Me2dien)(9-EtGua)]2+.
a large increase in Trp stacking, it is reasonable to assume these additional H-bonds may
contribute to the strong interaction between the Xan compounds and the ZF.
Table 3.1: Association constants for PtN4 complexes with N-AcTrp. Values in parentheses
are Ka values for the C-terminal ZF of HIV1 NCp7.
Ka (x103) M−1
L [Pt(dien)L]2+ [Pt(NMedien)L]2+ [Pt(Me2dien)L]2+ [Pt(Me4dien)L]2+
7MeG 9.01 ± 0.09 — — —(10.42 ± 0.29) — — —
Ino 5.63 ± 0.3 — — —(3.20 ± 0.29) — — —
9-EtGua 6.88 ± 0.36 13.52 ± 0.48 7.40 ± 0.93 11.78 ± 1.02(13.10 ± 0.94) (14.70 ± 1.60) (12.02 ± 0.37) (18.30 ± 0.34)
Gua 13.10 ± 1.29 12.78 ± 0.22 6.84 ± 0.67 15.19 ± 1.21(15.80 ± 2.83) (12.11 ± 1.13) (11.37 ± 2.01) (9.16 ± 1.46)
Xan 16.13 ± 1.10 11.56 ± 0.33 11.74 ± 0.53 11.30 ± 0.36)(46.64 ± 0.28) (60.22 ± 2.18) (35.80 ± 0.76) (48.67 ± 0.29)
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3.3.2 Biology
It is important to understand the biological properties of the platinum-nucleobases
reported here, therefore we have evaluated the cellular accumulation, cytotoxicity and inhi-
bition of the complex formation between NCp7 and SL2. SL2 is one of the four stem loops
that comprises Ψ RNA, a component of the HIV genome.
Our initial hypothesis was that the addition of methyl groups to the dien ligand
would increase lipophilicity, in turn increasing the cellular accumulation. To evaluate this
hypothesis, we tested CCRF-CEM and Jurkat cell lines. Both cell lines are CD4+ and
HIV susceptible. As shown in Figure 3.4, the methylation of the dien did not result in a
significant difference in the cellular accumulation for platinum complexes containing 9-EtGua
(1a-d), Gua (2a-d) or Xan (a-d). Three compounds show greater accumulation compared
to all others: 1a, 1b, and 2a. From 3 to 6 hours, a negligible increase in accumulation is
seen for most compounds, with the exception of the three compounds that see the highest
concentration of platinum per cell. The cell uptake trends are similar for the CCRF-CEM
and Jurkat cells, which may be indicative of a similar uptake mechanism.
To rationalize the lack of trend upon dien methylation, the octanol-water coefficents
(log Poct/water) for compounds 1a-1d were calculated, Table 3.2. There does not appear to
be a trend in the number of methyl groups and log Poct/water or cellular accumulation. This
lack of correlation may be due to the charge on the compounds (2+).
Table 3.2: Association constants for PtN4 complexes with N-AcTrp. Values in parentheses
are Ka values for the C-terminal ZF of HIV1 NCp7.
Compound LogPoct/water
1a -1.59 ± 0.28
1b -0.36 ± 0.06
1c 0.22 ± 0.09
1d -0.36 ± 0.04
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Figure 3.4: Cellular accumulation of platinum-nucleobase compounds in (A) Jurkat and (B)
CCRF-CEM cells.
Table 3.3: IC50 values for compounds 1a, 1b, 2a and 3a as determined by WST Assay.
IC50
Compound CCRF-CEM Jurkat
1a >100 >100
1b >100 >100
2a >100 >100
3a >100 >100
Based on the cellular accumulation profile, cytotoxicity studies were performed for
compounds 1a, 1b and 2a as well as compound 3a (to test the cytotoxicity of Xan). The use
of WST over MTT was necessary as CCRF-CEM and Jurkat cells are suspension cells and
do not attach to the 96-well plate. None of the compounds exhibited significant cytotoxic
properties as all of IC50 values are over 100 µM, Table 3.3. This is a desirable property, as
the compounds are designed to inhibit HIV without affecting normal cellular function.
Finally, the ability of the compounds to inhibit or dissociate the complex between
NCp7 and SL2 was evaluated by EMSA gel shift assays. As part of the viral packaging
process, NCp7 binds to viral Ψ RNA, which is comprised of four stem loops (SL). SL2 and
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SL3 bind strongly to NCp7 and with similar affinity when compared to SL1 and SL42. For
this reason, we have selected the interaction between NCp7 and SL2 as a representative
system to evaluate the compounds ability to inhibit the protein-RNA interaction. Figure
3.5 shows the EMSA gels for the compounds 1a, 1b, 2a and 3a. The control experiment,
Figure 3.5A, shows the upward shift in the band associated with NCp7/SL2 complexation.
NCp7 was preincubated with platinum compound for 30 minutes followed by addition of SL2
and incubation for an additional 30 minutes. Compound 1a shows the greatest inhibition,
with nearly complete disappearance of the NCp7/SL2 band, while compound 1b shows very
little inhibition. Compounds 2a and 3a show some inhibition of the complex. Compound
3a, Figure 3.5D, results in a band corresponding to a larger, slow-moving species at the
top of the gel. A control experiment of SL2 and 3a was performed and the same aggregate
species were observed, Figure 3.6. This suggests the inhibition of the NCp7/SL2 complex is
a separate event from the formation of the large, slow-moving species.
The reverse reaction was performed where NCp7 was incubated with SL2 for 30 min-
utes, ensuring ample time for complexation, after which platinum was added and incubated
for 30 minutes. Similar results were seen where compound 1a exhibited the greatest inhibi-
tion, though interestingly aggregates are seen at the top of the gel. This is not seen for the
opposite reaction or compound 1b, Figure 3.7.
3.4 Conclusions
The work presented in this article highlights the various strategies we have employed
to understand the interaction between platinum-nucleobase compounds and Trp as well as
some of their basic biological properties. The stability of the PtN4 coordination sphere allows
for a targeted reaction with NCp7. In an effort to improve this specific reaction, we have
found that the addition of Xan increases the association constant with the C-terminal ZF
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Figure 3.5: (A) Control experiment showing the formation of the SL2-NCp7 complex. Lane
1: Marker, Lane 2: SL2, Lanes 3-10: SL2 + NCp7 (500, 250, 125, 62.5, 31.25, 15.63, 7.81,
3.91 nM). (B-E) Addition of SL2 to NCp7/Drug solution. Lane 1: Marker, Lane 2: SL2,
Lane 3: SL2 + NCp7, Lanes 3-10: NCp7/Drug + SL2 (1 mM, 500 µM, 250 µM, 125 µM,
62.5 µM, 31.25 µM, 15.63 µM).
greatly over the parent 9-EtGua compound. Addition of methyl groups to the dien did not
result in a clear relationship to the lipophilicity of the compounds or cellular accumulation.
The lack of cytotoxicity exhibited by the compounds reported here is favorable. While
there are no clear trends in cellular accumulation, the platinum-nucleobase compounds do
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Figure 3.6: Control experiment incubating [Pt(dien)L]2+ with SL2 or SL2/NCp7. Lane 1:
SL2, Lane 2: NC + SL2, Lane 3: NC/1mM 1a +SL2, Lane 4: 1mM 1a +SL2, Lane 5:
NC/1mM 3a +SL2, Lane 6: 1mM 3a +SL2.
Figure 3.7: (A-D) Addition of SL2 to NCp7/Drug solution. Lane 1: Marker, Lane 2: SL2,
Lane 3: SL2 + NCp7, Lanes 3-10: NCp7/Drug + SL2 (1 mM, 500 uM, 250 uM, 125 uM,
62.5 uM, 31.25 uM, 15.63 uM).
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enter the cell and for the compounds that see the highest concentration of platinuim per
cell, a clear increase between 3 and 6 hours of incubation was observed. Compound 1a was
able to strongly inhibit the interaction between NCp7 and SL2, while the others only weakly
interrupted this interaction. The IC50 values for compounds 1a and 2a are 250 µM and
1mM, respectively, when the platinum compound was pre-incubated with NCp7. For the
reverse reaction, only compound 1a showed enough inhibition to determine an IC50 (1mM).
These IC50 values are comparable to organic compounds reported in the literature3. It may
be tempting to assume greater inhibition should have been seen for compound 3a over 1a
due to the significantly higher association constant, but the addition of the sugar ring adds
considerable bulk to the compound. While the exact mechanism of inhibition is not clear,
it is reasonable to assume that the addition of the sugar on Xan and Gua would create
steric constraints affecting the inhibition of NCp7/SL2 complexation. Overall, the biological
properties displayed are favorable. The goal was to develop non-cytotoxic compounds that
are able to inhibit the function of NCp7.
It is important to improve the compounds designed to target NCp7 as it is a chal-
lenging target. Previous work has used weak organic electrophiles to modify the Cys residues
of the zinc finger but progress stalled due to a lack in selectivity and issues with toxicity4−6.
We compare our substitution-inert PtN4 compounds to these organic weak electrophiles and
suggest that they possess intrinsic selectivity for NCp7 based on the molecular recognition
of the stacking interaction between Trp and Gua/nucleobase7.
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3.5 Experimental
3.5.1 Synthesis
3.5.1.1 Materials and Reagents
The complexes [PtCl(dien)]Cl (dien = diethylenetriamine) and Me2dien were prepared
by literature methods8,9 purity was confirmed by 1H and 195Pt NMR Spectroscopy, and Ele-
mental Analysis (performed by QTI Laboratory, USA). Me4dien was purchased from Matrix
Scientific. All other reagents were purchased from Sigma Aldrich, USA and used without
further purification. The NCp7 C-terminal peptide sequence (KGCWKCGKQEHQMKDC-
TER) was purchased from GenScript Corporation.
3.5.1.2 Synthesis of PtN4 complexes
[Pt(dien)(9-EtGua)](NO3)2 - [PtCl(dien)]Cl was dissolved in H2O and 9-ethylguanine (1 mol
eq.) and AgNO3 (1.98 mol eq.) were added. The solution was heated at 50oC in the dark for
24 hours. The solution was cooled to room temperature and filtered through celite to remove
the precipitated AgCl. The solution was rotovapped to dryness and acetone was added to
precipitate the final product. The solid was dried in vacuo. Anal. Calcd for C11H22N10O7Pt:
C 21.97; H, 3.69; N, 23.20. Found: C, 20.19; H, 3.39; N, 22.86. 1H NMR (D2O): 1.44 (3H,
t), 3.00 (8H, m), 4.14 (2H, q), 8.19 (1H, s). 195Pt NMR: -2850.
[Pt(dien)(Gua)]NO3 Cl 0.8H2O- [Pt(dien)(Gua)]NO3 Cl was synthesized in a similar
manner as [Pt(dien)(9-EtGua)](NO3)2. Briefly, [PtCl(dien)]Cl was dissolved in H2O and
guanosine (1 mol eq.) and AgNO3 (0.98 mol eq.) were added. The solution was heated at
50oC in the dark for 24 hours. The solution was cooled to room temperature and filtered
through celite to remove the precipitated AgCl. The solution was rotovapped to dryness
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and acetone was added to precipitate the final product. The solid was dried in vacuo. Anal.
Calcd for C14H27.6N9ClO8.8Pt: C 24.25; H, 4.01; N, 18.18. Found: C, 24.62; H, 3.99; N,
17.80. 1H NMR (D2O): 3.00 (8H, m), 3.78 (2H, m), 4.26 (1H, t), 4.39 (2H, t), 5.95 (1H, d),
8.42 (1H, s). 195Pt NMR: -2857.
[Pt(dien)(Ino)](NO3)2 0.06C3H6O - [Pt(dien)(Ino)](NO3)2 was synthesized in a similar
manner as [Pt(dien)(9-EtGua)](NO3)2. Anal. Calcd for C14.18H25.36N9O11.06Pt: C 24.54; H,
3.68; N, 18.17. Found: C, 24.65; H, 3.47; N, 17.35. 1H NMR (D2O): 3.00 (8H, m), 3.90 (2H,
m), 4.41 (1H, t), 4.73 (2H, t), 6.14 (1H, s), 8.32 (1H, s), 8.81 (1H, s). 195Pt NMR: -2854.
[Pt(dien)(Xan)](NO3)2 2H2O- [Pt(dien)(Xan)](NO3)2 was synthesized in a similar man-
ner as [Pt(dien)(9-EtGua)](NO3)2. Anal. Calcd for C14H29N9O14Pt: C 22.65; H, 3.94; N,
16.98. Found: C, 22.35; H, 3.24; N, 16.73. 1H NMR (D2O): 3.00 (8H, m), 3.93 (2H, m), 4.37
(2H, m), 4.56 (2H, t), 5.93 (1H, s), 8.43 (1H, s). 195Pt NMR: -2849.
[Pt(dien)(7MeG)](NO3)2 - [Pt(dien)(7MeG)](NO3)2 was synthesized in a similar manner
as [Pt(dien)(9-EtGua)](NO3)2. Anal. Calcd for C14.18H25.36N9O11.06Pt: C 24.54; H, 3.68; N,
18.17. Found: C, 24.65; H, 3.47; N, 17.35. 1H NMR (D2O): 3.00 (8H, m), 3.99 (3H, s), 8.12
(1H, s). 195Pt NMR: -2890.
[PtCl(NMedien)]Cl 0.5H2O- [Pt(NMedien)Cl]Cl was prepared in the same manner as
[PtCl(dien)]Cl8. Anal. Calcd for C5H15N3Cl2Pt: C 15.31; H, 4.11; N, 10.71. Found: C,
15.49; H, 4.00; N, 10.19. 1H NMR (D2O): 3.03 (11H, m). 195Pt NMR: -2598.
[Pt(NMedien)(9-EtGua)](NO3)2 - [Pt(NMedien)(9-EtGua)](NO3)2 was synthesized in a
similar manner as [Pt(dien)(9-EtGua)](NO3)2. Anal. Calcd for C12H24N10O7Pt: C 23.42; H,
3.93; N, 22.76. Found: C, 23.16; H, 3.35; N, 22.20. 1H NMR (D2O): 1.44 (3H, t), 3.03 (11H,
m), 4.14 (2H, q), 8.18 (1H, s). 195Pt NMR: -2725.
[Pt(NMedien)(Gua)](NO3)2 0.75H2O- [Pt(NMedien)(Gua)](NO3)2 was synthesized in a
similar manner as [Pt(dien)(9-EtGua)](NO3)2. Anal. Calcd for C15H29.5N10O11.75Pt: C
24.58; H, 4.06; N, 19.11. Found: C, 24.11; H, 3.48; N, 19.04. 1H NMR (D2O): 3.03 (11H,
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m), 3.89 (2H, m), 4.26 (1H, t), 4.40 (2H, t), 4.72 (1H, t), 5.97 (1H, d), 8.42 (1H, s). 195Pt
NMR: -2729.
[Pt(NMedien)(Xan)](NO3)2 2.5H2O- [Pt(NMedien)(Xan)](NO3)2 was synthesized in a
similar manner as [Pt(dien)(9-EtGua)](NO3)2. Anal. Calcd for C15H32.05N9.05O14.65Pt: C
23.53; H, 4.21 N, 16.47. Found: C, 23.44; H, 4.20; N, 15.99. 1H NMR (D2O): 3.03 (11H, m),
3.93 (2H, m), 4.37 (2H, m), 4.56 (2H, t), 5.93 (1H, s), 8.43 (1H, s).
[PtCl(Me2dien)]Cl 0.5H2O- [Pt(Me2dien)Cl]Cl was prepared in the same manner as
[PtCl(dien)]Cl8. Anal. Calcd for C6H17N3Cl2Pt: C 18.14; H, 4.31; N, 10.58. Found: C,
18.33; H, 3.84; N, 10.41. 1H NMR (D2O): 2.88 (14H, m). 195Pt NMR: -2824.
[Pt(Me2dien)(9-EtGua)](NO3)2 2H2O - [Pt(Me2dien)(9-EtGua)](NO3)2 was synthesized
in a similar manner as [Pt(dien)(9-EtGua)](NO3)2. Anal. Calcd for C13H30N10O9Pt: C
23.46; H, 4.54; N, 21.05. Found: C, 23.07; H, 4.21; N, 20.73. 1H NMR (D2O): 1.50 (3H, t),
2.88 (14H, m), 4.21 (2H, q), 8.70 (1H, broad s). 195Pt NMR: -2876, -2907.
[Pt(Me2dien)(Gua)](NO3)2.5 2.5H2O- [Pt(Me2dien)(Gua)](NO3)2 was synthesized in a
similar manner as [Pt(dien)(9-EtGua)](NO3)2. Anal. Calcd for C16H35.5N10.5O15Pt: C 23.74;
H, 4.36; N, 18.17. Found: C, 23.27; H, 3.83; N, 17.71. 1H NMR (D2O): 2.88 (14H, m), 3.90
(2H, m), 4.28 (1H, t), 4.43 (2H, t), 6.00 (1H, d), 8.88 (1H, d). 195Pt NMR: -2880, -2912.
[Pt(Me2dien)(Xan)](NO3)2.25 2.5H2O- [Pt(Me2dien)(Xan)](NO3)2 was synthesized in a
similar manner as [Pt(dien)(9-EtGua)](NO3)2. Anal. Calcd for C16H34.25N9.25O15.25Pt: C
24.17; H, 4.31; N, 16.30. Found: C, 24.16; H, 3.77; N, 15.71. 1H NMR (D2O): 2.88 (14H,
m), 3.98 (2H, m), 4.43 (2H, m), 4.65 (2H, t), 6.02 (1H, s), 8.66 (1H, broad s).
[PtCl(Me4dien)]Cl - [Pt(Me4dien)Cl]Cl was prepared in the same manner as [PtCl(dien)]Cl8.
Briefly, [Pt(dmso)Cl2] was suspended in acetone, Me4dien (1 mol. eq.) was added and the
solution was refluxed for 3 hrs. The solution was cooled to room temperature and the solvent
was reduced to near dryness. Ether was added to precipitate the final product and the solid
was dried in vacuo. 1H NMR (D2O): 2.90 (20H, m). 195Pt NMR: -2704.
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[Pt(Me4dien)(9-EtGua)](NO3)2.4 3H2O- [Pt(Me4dien)(9-EtGua)](NO3)2 was synthesized
in a similar manner as [Pt(dien)(9-EtGua)](NO3)2. Anal. Calcd for C15H36N10.4O11.2Pt: C
24.47; H, 4.93; N, 19.78. Found: C, 24.12; H, 4.43; N, 19.12. 1H NMR (D2O): 1.51 (3H, t),
2.90 (20H, m), 4.22 (2H, q), 8.69 (1H, d). 195Pt NMR: -2758, -2773.
[Pt(Me4dien)(Gua)](NO3)2.4 3H2O- [Pt(Me4dien)(Gua)](NO3)2 was synthesized in a sim-
ilar manner as [Pt(dien)(9-EtGua)](NO3)2. Anal. Calcd for C18H40.4N10.4O15.2Pt: C 25.72;
H, 4.80; N, 17.33. Found: C, 25.44; H, 4.36; N, 16.83. 1H NMR (D2O): 2.90 (20H, m), 3.92
(2H, m), 4.31 (1H, t), 4.46 (2H, t), 6.03 (1H, d), 8.90 (1H, d). 195Pt NMR: -2763, -2778.
[Pt(Me4dien)(Xan)](NO3)2.4 3H2O- [Pt(Me4dien)(Xan)](NO3)2 was synthesized in a sim-
ilar manner as [Pt(dien)(9-EtGua)](NO3)2. Anal. Calcd for C16H34.2N9.25O15.25Pt: C 25.69;
H, 4.67; N, 15.65. Found: C, 25.19; H, 4.19; N, 15.11. 1H NMR (D2O): 2.90 (20H, m), 4.00
(2H, m), 4.45 (2H, m), 4.66 (2H, t), 6.03 (1H, s), 9.00 (1H, s).
3.5.2 Preparation of the Zinc Finger
The peptide was dissolved in deionized water at a concentration of 2mM. The pH was
adjusted to 7.2 using NH4OH and zinc acetate (1.3 molar eq.) was added to the solution. For
fluorescence experiments, a 5 µM solution of ZF was prepared by diluting the concentrated
stock solution.
3.5.3 Nuclear Magnetic Resonance Spectroscopy
All samples were prepared in D2O at a concentration of ∼4mg/mL for 1H NMR and
∼15mg/mL for 195Pt NMR. For 1H NMR, the solvent peak (D2O) was referenced to 4.80ppm.
195Pt NMR samples were measured using Na2PtCl6 as an external reference. For temperature
dependence studies, ∼4mg/mL solutions of 1c and 1d were heated in 5oC increments and a
spectrum was recorded. The spectra of 1c and 1d were recorded from 5-65oC and 24-70oC,
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respectively. The Ebarrier of rotation was calculated using the equation: Ebarrier (in kcal/mol)
= 4.575x10−3 * Tc * (9.972 + log(Tc/∆ν)1. Where Tc is the coalescence temperature and
∆ν is the spacing between the H8 signals.
3.5.4 Fluorescence Experiments
Fluorescence studies were recorded on a Varian Cary Eclipse fluorometer with a single-
cell Peltier accessory. Samples were irradiated with 280 nm light and spectra were recorded
from 300 to 450 nm with a scan rate of 600 nm/min at 25oC. The experiments were carried
out in 20 mM Tris buffer with 50 mM NaCl at pH 7.4. 5 µM N-acetyl tryptophan or zinc
finger was titrated with [M(dien)L]n+ at molar ratios of drug from 10 to 100 for all complexes.
The absorbance for all compounds at 100 molar equivalents was <0.05; therefore, the inner
filter effect was disregarded10. The emission maximum (362 nm) was measured after each
titration. The Ka was determined from Eadie Hofstee plots from an average of 3 trials using
the equation: ∆F = (Ka)−1 * ∆F/[quencher] + ∆Fc
3.5.5 Cellular Accumulation
Four million cells were incubated in 10 mL of RMPI media (10% FBS, 1%Pen-Strep)
with 50 µM drug for 3 or 6 hours. The solutions were centrifuged at 1500 rpm at 4oC for 5
minutes, the media was removed and the cell pellet was washed with 2x10mL cold PBS. To
digest samples for ICP-MS analysis, 1 mL of conc. HNO3 was added to the pellet and left
to digest for 72 hours. Two mL of water were added, the solutions were filtered through a
0.45 µM GHP filter, and run on the ICP-MS to determine the concentration of platinum in
each sample.
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3.5.6 Gel Shift Assay
As a control experiment, 32P end-labeled SL2 RNA (2 nM) was incubated with varying
concentrations of NC in binding buffer (50 mM Tris-HCl, 40 mM MgCl2, 200 mM NaCl, 0.1
mM ZnCl2, 5% glycerol, and 1% BME) for 1 hr at 30oC. In all subsequent reactions, 250
nM NC was incubated with increasing concentrations of platinum complex for 30 min in
binding buffer. Subsequently, 2 nM SL2 was added to the buffer and the mixture incubated
for an additional 30 minutes. For the reverse reaction, NCp7 was incubated with SL2 for 30
minutes, followed by incubation with increasing concentrations of platinum complex for 30
minutes.
3.5.7 Cytotoxicity
CCRF-CEM or Jurkat cells were seeded at a concentration of 2.5x104 cells/100 µL.
Drugs 1a, 1b, 2a, and 3a were added at varying concentrations (100, 50, 25, 12.5, 6.25,
3.125, 1.6125 µM) and the cells were incubated at 37oC for 72 hours. WST-1 (10 µL of
commerical solution) was added and incubated for 4 hours. The absorbance at 405 nm was
recorded and the IC50 was determined.
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Modulation of the stacking interaction of MN4 (M=Pt, Pd, Au)
complexes with tryptophan through N-heterocyclic ligands
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4.1 Contribution
S.D.T.’s contribution is comprised of synthesis of [Pt(dien)(DMAP)](NO3)2, [Pd-
(dien)(DMAP)]Cl2, assistanted M.G.D. with synthesis of [Pt(dien)(bztz)](NO3)2, [Pt(dien)(4-
pic)](NO3)2, fluorescence experiments for [Pt(dien)(DMAP)](NO3)2, [Pd(dien)(DMAP)]Cl2
with N-AcTrp and ZF, 195Pt NMR for [Pt(dien)(DMAP)](NO3)2, 1HNMR for [Pt(dien)(DMAP)]-
(NO3)2 and [Pd(dien)(DMAP)]Cl2, reaction of [Pd(dien)(DMAP)]2+ with N-AcTrp by 1H
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NMR and preparation of the figures and written manuscript. A.B.B.’s contribution was
synthesis of the platinum pyridine, MeOpyr, quin, and tz complexes and the corresponding
fluorescence experiments. S.R.S.’s contribution was synthesis of [Au(dien)(DMAP)]3+ and
corresponding fluorescence experiments.
4.2 Introduction
N-quaternization of nucleobases enhances the stacking interaction, in part by low-
ering the energy of the lowest unoccupied molecular orbital (LUMO) of the nucleobase,
making it closer in energy to the highest occupied molecular orbital (HOMO) of the Trp1,2.
N-quaternization may be achieved by protonation, alkylation or metallation and it is pos-
sible that the lowering of the energy of the LUMO may be due in part to the removal of
the lone pair of electrons on the nitrogen of the nucleobase1,2. We have been systematically
examining the coordination chemistry of NCp7 with platinum-metal compounds based on
the [M(dien)(nucleobase)]n+ (MN4) motif (dien = diethylenetriamine). On average, free 9-
ethylguanine (9EtG), 5’-guanosine monophosphate (GMP), and 5’-cytosine monophospate
(CMP) have Ka values for association with tryptophan of 3 x 103 M−1 whereas platina-
tion increases the Ka for the three species to 6.8, 6.9, and 7.0 x 103 M−1, respectively2−5.
Extension to the Trp-containing C-terminal finger of NCp7 with [Pt(dien)(9EtG)]2+ and
[Pt(dien)(GMP)] gave Ka values of 7.5 and 12.4 x 103 M−1, respectively6.
4.3 Experimental
4.3.1 Materials and Reagents
The complexes [MCl(dien)]Cl (M = Pt, Pd, Au; dien = diethylenetriamine) were pre-
pared by literature methods5,8,9; purity was confirmed by 1H and 195Pt NMR Spectroscopy,
and Elemental Analysis (performed by QTI Laboratory, USA). All reagents were purchased
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Figure 4.1: Structures of the metal (M = Pt, Pd, Au) N-heterocycle complexes studied.
from Sigma Aldrich, USA and used without further purification. The NCp7 C-terminal
peptide sequence (KGCWKCGKQEHQMKDCTER) was purchased from GenScript Corpo-
ration.
4.3.1.1 Synthesis of N-heterocycle platinum complexes
[Pt(dien)(quin)](NO3)2: [PtCl(dien]Cl was stirred overnight in DMF with 1.98 equivalents
of AgNO3 in the dark. The solution was filtered through celite to remove the precipitated
AgCl. Quinoline (3 eq.) was added to the filtrate and the solution was stirred overnight.
The volume was reduced by rotary evaporation to near dryness, methanol and ether were
added. The final product was obtained upon centrifugation and dried in vacuo (50% yield).
Anal. Calcd for C13H20N6O6Pt: C, 28.32; H, 3.66; N, 15.24. Found: C, 27.76; H, 3.45; N,
14.88. 1H NMR (D2O): 3.00 (8H, m), 7.60 (1H, m), 7.90 (1H, m), 8.10 (2H, m), 8.50 (1H,
m), 9.50 (2H, m). 195Pt NMR: -2837.
[Pt(dien)(bztz)](NO3)2 0.75H2O: [Pt(dien)(bztz)](NO3)2 was synthesized in a similar
manner as [Pt(dien)(quin)](NO3)2 using benzothiazole as the planar amine ligand and water
as the solvent (29% yield). Anal. Cald for C11H19.5N6O6.75Pt: C, 23.14; H, 3.44; N, 14.72.
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Found: C, 23.14; H, 3.29; N, 14.26. 1H NMR (D2O): 3.00 (8H, m), 7.70 (1H, m), 7.80 (1H,
m), 8.10 (1H, m), 8.80 (1H, m), 9.70 (1H, s). 195Pt NMR: -2861.
[Pt(dien)(pyr)](NO3)2: [Pt(dien)(pyr)](NO3)2 was synthesized in a similar manner as
[Pt(dien)(bztz)](NO3)2 using pyridine as the planar amine ligand (62% yield). Anal. Cald
for C9.75H19.5N6O6.75Pt: C, 20.99; H, 3.82; N, 16.32. Found: C, 21.28; H, 3.34; N, 15.86. 1H
NMR (D2O): 3.00 (8H, m), 7.50 (2H, m), 8.00 (1H, m), 8.70 (2H, m). 195Pt NMR: -2833.
[Pt(dien)(MeOpyr)](NO3)2 H2O: [Pt(dien)(4-mopyr)](NO3)2 was synthesized in a sim-
ilar manner as [Pt(dien)(bztz)](NO3)2 using 4-methoxypyridine as the planar amine ligand
(24% yield). Anal. Cald for C11H22N6O8Pt: C, 21.86; H, 4.04; N, 15.30. Found: C, 21.31;
H, 3.91; N, 15.41. 1H NMR (D2O): 3.00 (8H, m), 3.90 (3H, s), 7.10 (2H, d), 8.40 (2H, d).
195Pt NMR: -2824.
[Pt(dien)(4-pic)](NO3)2 0.75H2O: [Pt(dien)(4-pic)](NO3)2 was synthesized in a similar
manner as [Pt(dien)(bztz)](NO3)2 using picoline as the planar amine ligand (48% yield).
Anal. Cald for C10.75H21.5N6O7.5Pt: C, 22.71; H, 4.10; N, 15.89. Found: C, 22.82; H, 3.69;
N, 15.39. 1H NMR (D2O): 2.4 ppm (3H, s), 3.00 (8H, m), 7.40 (2H, d), 8.50 (2H, m). 195Pt
NMR: -2835.
[Pt(dien)(tz)](NO3)2: [Pt(dien)(tz)](NO3)2 was synthesized in a similar manner as [Pt-
(dien)(bztz)](NO3)2 using thiazole as the planar amine ligand (39% yield). Anal. Cald for
C7H16N6O8SPt: C, 16.57; H, 3.18; N, 16.56. Found: C, 16.74; H, 2.67; N, 16.07. 1H NMR
(D2O): 3.00 (8H, m), 7.75 (1H, d), 7.94 (1H, d), 9.20 (1H, s). 195Pt NMR: -2820.
[Pt(dien)(CNpyr)](NO3)2: [Pt(dien)(CNpyr)](NO3)2 was synthesized in a similar manner
as [Pt(dien)(bztz)](NO3)2 using 4-cyanopyridine as the planar amine ligand (23% yield).
Anal. Cald for C7H16N6O8SPt: C, 22.25; H, 3.45; N, 18.16. Found: C, 21.93; H, 3.19; N,
18.11. 1H NMR (D2O): 3.00 (8H, m), 7.94 (1H, d), 9.00 (1H, d). 195Pt NMR: -2839.
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4.3.2 Techniques
4.3.2.1 Nuclear Magnetic Resonance Spectroscopy
All samples were prepared in D2O at a concentration of ∼ 4 mg/mL for 1H NMR and
∼ 15 mg/mL for 195Pt NMR. For 1H NMR, the solvent peak (D2O) was referenced to 4.80
ppm. 195Pt NMR samples were measured using Na2PtCl6 as an external reference.
4.3.2.2 Fluorescence Spectroscopy
Fluorescence studies were recorded on a Varian Cary Eclipse fluorometer with a single-
cell Peltier accessory. Samples were irradiated with 280 nm light and spectra were recorded
from 300 to 450 nm with a scan rate of 600 nm/min at 25oC. The experiments were carried
out in 20 mM Tris buffer with 50 mM NaCl at pH 7.4. 5 µM N-acetyl tryptophan or
zinc finger was titrated with [M(dien)L]n+ at molar ratios of drug from 1 to 10 for DMAP
complexes and 10 to 100 for all other complexes. The absorbance for the DMAP compounds
at 362 nm at 10 molar equivalents and all other compounds at 100 molar equivalents was
below 0.05; therefore, the inner filter effect was disregarded [17]. The emission maximum
(362 nm) was measured after each titration. The Ka was determined from EadieâĂŞHofstee
plots from an average of 3 trials using the equation: ∆F = (Ka) - 1 ∆F / [quencher] + ∆Fc.
4.4 Results and Discussion
To examine the pi-stacking potential of platinated N-heterocycle ligands an initial sys-
tematic survey was performed; Fig. 4.1 shows the structures of the synthesized complexes
and pyridine was used as the comparison point when referring to the effects of electron
donating or withdrawing groups.
Fig. 4.2 shows the % quenching of tryptophan fluorescence by the various
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Table 4.1: Association constants for metal-N-heterocycle complexes with N-acetyltryptophan
and the C-terminal zinc finger of HIVNCp7. Published values for the 9-ethylguanine complex
were taken from a- Ref. [3] and b- Ref. [6] and for [Au(dien)(DMAP)]3+ was taken from c-
Ref. [15].
Compound Ka (x10
−3) M−1
NAcTrp ZF
[Pt(dien)(9EtG)]2+ 6.88 ± 0.3a 7.5b
[Pt(dien)(bztz)]2+ 3.32 ± 0.36 3.20 ± 0.39
[Pt(dien)(CNpyr)]2+ 6.73 ± 0.26 7.72 ± 0.79
[Pt(dien)(DMAP)]2+ 25.0 ± 0.90 28.1 ± 1.76
[Pd(dien)(DMAP)]2+ 23.2 ± 0.31 —
[Au(dien)(DMAP)]2+ 25.5 ± 0.30c —
platinum compounds. The previously reported [Pt(dien)(9EtG)]2+ displayed a fluorescence
quenching of 94.34%. The pyr, MeOpyr, and 4-pic and thiazole complexes gave less than
10% fluorescence quenching.
Three complexes displaying high quenching - containing bztz, CNpyr and DMAP ligands
- were evaluated to determine an association constant, Table 4.1. While the bztz and CNpyr
compounds showed significant decrease in fluorescence intensity, the calculated Kas, 3.32 and
6.73 x 103 M−1 respectively, are similar to that of the 9EtG complex (6.88 x 103 M−1 [9]). In
contrast, the presence of the DMAP ligand results in a compound with a significant increase
in Ka (25.0 x 103 M−1) over that of 9EtG.
There is no clear trend in this series with respect to the simple quenching except that all
ligands represent potentially delocalized systems. This trend is reinforced by the observation
that the addition of a delocalized pi system in quinoline increased the fluorescence quenching
over pyridine, albeit not to as significant an extent as that of DMAP and benzothiazole, and
no Ka was measureable. The pKa for the platinated nitrogen may also give an indication
of the strength of the stacking interaction between platinum complexes and Trp. The pKas
under similar conditions for 9EtG, CNpyr, bztz and DMAP are 1.211, 1.912, 3.112, and 9.613,
respectively. Clearly the strong donor DMAP has the most profound effect, even though the
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Figure 4.2: Percent fluorescence quenching of N-acetyltryptophan by platinum-N-hetero-
cycle, [Pt(dien)L]2+, complexes. ** The percent fluorescence quenching for [Pt(dien)-
(DMAP)]2+ refers to the quenching at 10 molar equivalents. The values for all other com-
pounds refer to the percent fluorescence quenching at 100 molar equivalents.
platinated compound is actually slightly lower than free ligand, in contrast to the situation
for free 9EtG. Basicity considerations and use of electron-donating substituents would seem
important for identification of a wider group of improved N-heterocycle ligands.
Figure 4.3: The association constants for
[M(dien)L]n+ complexes with N-acetyltryp-
tophan as determined by fluorescence spec-
troscopy.
The [M(dien)] structure allows for sys-
tematic study of electronic and steric effects
(substitution on the dien ligand) and sub-
stitution effects where the isoelectronic M =
Pt(II), Pd(II) and Au(III) compounds can
be studied for effects of substitution labil-
ity of the central metal ion. We have con-
trasted the reaction products of C-terminal
HIV NCp7 with [MCl(dien)]n+ where M =
Pt, Pd and Au [21]. It was therefore of
interest to extend the DMAP findings to
Pd(II) and Au(III) because of the strong
stacking interaction the Pt-DMAP complex
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displays. In both cases, the calculated association constants confirmed the utility of the
DMAP ligand, being 25.5 x 103 M−1 for [Au(dien)(DMAP)]3+ 15, and 23.2 x 103 M−1 for
[Pd(dien)(DMAP)]2+, Fig. 4.3.
Again, both values are significantly higher than the corresponding 9-EtG complexes3,15.
No reaction was seen between [Pd(dien)(DMAP)]2+ with N-AcTrp at pH* 7.52 when followed
by 1H NMR over 2.5 h (data not shown). This implies improved complex stability over
[Pd(dien)(9EtG)]2+ which has been shown to react with N-AcTrp through displacement of
the 9EtG ligand at increasing pH4. Interestingly, the changes in the chemical shifts for
the DMAP protons are largest for Au(III) over that of the Pd(II) and Pt(II) complexes,
Table 4.2. This may reflect the short central M\N bond observed in [AuCl(dien)]2+ and the
demonstrated acidity of the dien ligand when bound to Au(III)15.
These results were then extended to the C-terminal ZF of NCp7, which contains a single
tryptophan in its sequence, Fig. 4.4. Generally, the association constants for the nucleobase
complexes increase for the ZF of NCp7 when compared to N-AcTrp2. This trend is not
followed for all N-heterocycles. The Kas for [Pt(dien)(bztz)]2+ and [Pt(dien)(CNpyr)]2+ are
approximately the same for the ZF when compared to N-AcTrp and the Ka for [Pt(dien)-
(DMAP)]2+ increases slightly. The interaction of the Au(III) and Pd(II) compounds with
HIV NCp7 resulted in rapid displacement of the central Zn2+ ion and no association constant
could be measured [Spell and Farrell, unpublished results].
Table 4.2: Major NMR ligand chemical shifts for [M(dien)(DMAP)]n+ complexes. Values in
parentheses are the difference in chemical shift (ppm) from free ligand followed by the 3JHH
coupling constants (Hz).
1H(∆δ1H) ppm, 3JHHHz
Compound H2/H6 H3/H4 NâĂŞMe2 δ195Pt(ppm)
[Pt(dien)(DMAP)]2+ 6.64 (0.15), 5 8.02 (-0.20), 7.5 3.06 (0.06) -2816
[Pd(dien)(DMAP)]2+ 6.66 (0.17), 7.5 7.92 (-0.31), 5 3.04 (0.04) –
[Au(dien)(DMAP)]2+ 6.90 (0.41), 5 8.02 (-0.21), 5 3.22 (0.22) –
The results here show that a limited number of N-heterocycle ligands, when metallated,
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also effectively engage in pi-stacking interactions with tryptophan and tryptophan-containing
peptides. These findings further expand the structural variation of the MN4 chemotype
where we have suggested that use of a substitution-inert ligand such as an N-heterocycle
group instead of the substitution-labile Cl, in for example [PtN3X, X = leaving group), is an
approach to selectivity for specific peptide-substitution reactions and templates for design of
specific protein inhibitors7. The DMAP complexes all bind very strongly with Trp and the
C-terminal ZF of NCp7, suggesting that they are suitable for further study with zinc finger
proteins complementary to our studies with metallated natural nucleobases.
Figure 4.4: Figure 4: A- Structure of the
HIV NCp7 zinc finger peptide and B- A
model of the pi-stacking interaction between
[Pt(dien)(9EtG)]2+ and N-acetyltryptophan.
With respect to zinc proteins in general,
target selectivity is a major issue for specific
inhibition using small molecules. In the case
of zinc fingers, the results here extend the
concept of “weak electrophiles” from organic
chemistry to substitution-inert MN4 plat-
inum compounds in attempts to gain selec-
tivity and distinguish between the cysteine
nucleophilicity of the various coordination
spheres Cys2His2, Cys3His, and Cys416−18.
The notable increase in association constant
of [M(dien)(DMAP)]n+ on the zinc finger through the “non-covalent” pi-pi stacking interac-
tion allows further avenues for design of specifically targeted inhibitors and further confirms
the viability of the medicinal chemistry dual approach of target recognition (non-covalent)
followed by target fixation (covalent)7.
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5.1 Contribution
This chapter is the work of solely S.D.T.
5.2 Introduction
Our work has focused on the development of platinum complexes designed to target
NCp7. By changing ligands on compounds with structure [Pt(L)(L’)(nucleobase)Cl]+, the
preference for S binding over N binding can be controlled1. In fact, the complex trans-
[PtCl(py)2(9-EtGua)] has been shown to have some antiviral activity in vitro2. Furthermore,
the move to a more substitution-inert PtN4 coordination sphere correlates to a shift towards
82
more selective compounds. The addition of [Pt(dien)(9-EtGua)]2+ to the C-terminal ZF of
HIV1 NCp7 results in a concentration-dependent decrease in the fluorescence of Trp37 from
which a Ka of 6.88 x 103 M−1 can be calculated3.
More recently, we have shown the N-terminal selective cleavage of the C-terminal ZF
of NCp7 by a trans-dinuclear platinum complex, 1,1-t,t. Immediately upon mixing, a peak
corresponding to the adduct of 1,1-t,t(-2Cl) and ZF (-KG) can be seen. Over time, there
is an appearance of a sister peak which corresponds to zinc ejection. No peptide cleavage
was seen for the cis-dinuclear complex, 1,1-c,c. This cleavage was the first reported peptide
cleavage by a platinum complex at neutral pH4. It is therefore of interest to look at possible
mechanisms for this peptide cleavage and to determine the mitigating factors. Here, we
investigate the reactions between cDDP and tDDP with the C-terminal zinc finger of HIV1
NCp7 to understand if a dinuclear structure is necessary for peptide cleavage.
Figure 5.1: A- Structure of cisplatin (left) and transplatin (right), B- Structure of HIV1
NCp7. The C-terminal ZF used is highlighted by dashed red box.
5.3 Experimental
5.3.1 Materials and Reagents
The complexes cisplatin and transplatin were prepared by literature methods; purity was
confirmed by 1H and 195Pt NMR Spectroscopy, and Elemental Analysis (performed by QTI
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Laboratory, USA). All reagents were purchased from Sigma Aldrich, USA and used without
further purification. The NCp7 C-terminal peptide sequence (KGCWKCGKQEHQMKDC-
TER) was purchased from GenScript Corporation.
5.3.2 Preparation of the Zinc Finger
The peptide was dissolved in deionized water at a concentration of 2mM. The pH was
adjusted to 7.2 using NH4OH and zinc acetate (1.3 molar eq.) was added to the solution. For
fluorescence experiments, a 5 µM solution of ZF was prepared by diluting the concentrated
stock solution.
5.3.3 Techniques
5.3.3.1 Fluorescence Spectroscopy
Fluorescence studies were recorded on a Varian Cary Eclipse fluorometer with a single-cell
Peltier accessory. Samples were irradiated with 280 nm light and spectra were recorded from
300 to 450 nm with a scan rate of 600 nm/min at 37oC. A solution of 1:1 tDDP or cDDP
and zinc finger was incubated at 37oC for up to 72 hours. Spectra were recorded every 5
minutes from t=0 to 60 minutes, every 30 minutes from t= 60 mins to 4 hours and every 2
hours from 4 hours to 72 hours.
5.3.3.2 Mass Spectrometry
For mass spectrometry experiments, initial 1mM reaction mixtures were made in water
at 24oC and pH 7.2 (adjusted using ammonium hydroxide). The reaction solutions were
incubated at 37oC and were sprayed using a final concentration of 10 µM. Experiments were
carried out on an Orbitrap Velos from Thermo Electron Corporation operated in positive
mode. Samples (20 µL) were diluted with methanol (200 µL) and directly infused at a flow
rate of 0.7 µL/min using a source voltage of 2.30 kV. The source temperature was maintained
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at 230C throughout.
5.3.3.3 {1H, 15N} HSQC
NMR experiments also followed published procedure and were conducted at 1 mM concen-
tration (1:1) in 5% D2O/95% H2O (13). For HSQC 1H,15N NMR Spectroscopy the spectra
were recorded at 37oC on a Bruker AVANCE III 600 MHz spectrometer (1H, 600.1 MHz; 15N,
60.8 MHz ) fitted with a pulsed field gradient module and 5mm inverse quadruple resonance
(QXI) probe. The 1H NMR chemical shifts were internally referenced to trimethylsilyl pro-
pionate, the 15N chemical shifts externally referenced to 15NH4NO3. The two-dimensional
{1H,15N} HSQC spectra were recorded in phase sensitive mode using Echo/Antiecho-TPPI
gradient selection. A total of 1024 points were acquired in the 1H dimension and 96 complex
points in the 15N dimension with 128 transients. 1 mM platinum complex was allowed to
react with 1 equiv. of ZF in 5% D2O / 95% H2O, and the reaction was followed by HSQC
spectroscopy.
5.4 Results
The interaction of cDDP and tDDP with the C-terminal ZF of NCp7 was investigated
by fluorescence, mass spectrometry, and {1H, 15N} HSQC. Tryptophan fluorescence is often
used to detect protein conformation. For a Trp containing protein, a decrease in fluorescence
is indicative of Trp folded into a hydrophobic pocket (14). Here, the fluorescence of Trp37
in the C-terminal ZF of HIV1 NCp7 was monitored over time in the presence of 1 equivalent
of either cDDP or tDDP. The results indicate a significantly slower reaction rate for cDDP.
The reaction of tDDP with ZF results in 50% quenching of the Trp37 fluorescence over the
course of 24 hours, while cDDP causes only a ∼10% decrease. After 72 hours of reaction,
cDDP induces a similar amount of quenching (33%) as the trans isomer, Figure 5.2. The
quenching of the Trp fluorescence here may be indicative of Zn ejection and peptide folding
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Figure 5.2: Fluorescence spectra of the 1:1 reaction of A) tDDP and B) cDDP with the
C-terminal ZF of HIV1 NCp7.
as a result of the binding of platinum complex.
The reaction was also followed by ESI-MS. In the case of tDDP, both time points yield
the same products, however, the intensity of the product peaks relative to free zinc finger
increases over time with a concomitant decrease in the peaks seen for peptide (apo-C-terminal
ZF). At both time points, the most dominant peak corresponds to intact zinc finger.
In the 30 minute spectrum, major product peaks for Pt(NH3)2/peptide (817.33 m/z,
3+ and 1225.49 m/z, 2+) and 2Pt(NH3)2/peptide (1340.00 m/z, 2+) can be seen, Figure
5.3A. MS2 of these peaks reveals loss of NH3 from the platinum moiety (Figure 5.4). Minor
peaks corresponding to Pt(NH3)2Cl/peptide (1244.48 m/z, 2+) and Pt2/ZF (893.67 m/z,
3+) are also present. MS2 of these peaks causes loss of Cl or NH3 from the platinum,
leaving the adduct with peptide intact and fragmentation of the protein for Pt2/ZF. The
isotopic distributions for all peaks match, as modeled by Isopro.
At 1 hour, smaller peaks corresponding to free peptide and larger product peaks relative
to the intensity of the peaks corresponding to free ZF are seen, Figure 5.3B. The main
products peaks are the same and MS2 yields the same daughter ions as seen at 30 minutes,
Figure 5.5. Interestingly, there is a minor product peak for intact tDDP/peptide (1261.41
m/z, 2+), Figure 5.3. The isotopic distribution appears to match but the peak is in very
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Figure 5.3: Mass spectra for the 1:1 reaction of tDDP with the C-terminal ZF of HIV1 NCp7
at A) 30 minutes and B) 60 minutes.
Figure 5.4: MS2 of the 1225.49 and 817.33 m/z peak corresponding to the 2+ and 3+ adducts
of [Pt(NH3)2]/peptide. The major product peak is the 2+ species Pt/peptide at 1208.98 m/z
(t= 30 minutes).
close proximity to another peak making identification slightly less clear. This peak is not
seen in the 30 min spectrum. It is unlikely that the adduct is a noncovalent interaction
between the platinum compound and peptide given the rapid rate of reaction for trans-
platinum complexes and the most likely explanation is the formation of “5-coordinate zinc”.
Previously, we have seen a similar 5-coordinate Zn species when [M(dien)Cl]n+ was reacted
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Figure 5.5: MS2 of the 1244.40 and 829.90 m/z peak corresponding to the 2+ and 3+
adducts of [Pt(NH3)2Cl]/peptide. The major product peaks are the 2+ and 3+ species of
[Pt(NH3)2]/peptide at 1225.49 and 816.63 m/z and the 2+ species of [Pt(NH3)]/peptide at
1218.43 m/z (t= 60 minutes).
with the C-terminal ZF of HIV NCp7 as well as with the Zn model chelate [Zn(bme-dach)2]
(15) (16).
Figure 5.6: Mass spectra for the 1:1 reaction of cDDP with the C-terminal ZF of HIV1 NCp7
at A) 30 minutes and B) 60 minutes.
The reaction of cDDP and ZF confirms the slower rate of reaction for compounds in
a cis-orientation rather than trans, where rapid trans-labilization of the Cl by a S-bound
species allows for very fast reactions. The only species seen at 30 and 60 minutes are intact
ZF, Figure 5.6. It is not until 4 hours that a platinum adduct is detectable, Figure 5.7. The
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single platinum adduct observed is [Pt(NH3)]/ZF].
Figure 5.7: The 1:1 reaction of cDDP with C-terminal ZF of HIV1 NCp7 at 4
No peptide cleavage was observed for either cDDP or tDDP, illustrating the need for a
dinuclear structure. Table 5.1 lists the expected and observed m/z ratios for the platinum-ZF
adducts. The slow reaction rate for cDDP is consistent with studies conducted using cDDP
to probe the reactivity of a C4 ZF protein. Only upon binding of two platinum moieties
was zinc release observed (17). Our work with trans-[PtCl(py)2(9-EtGua)] revealed similar
results as zinc loss was observed upon binding of two [Pt(py)2] units (13).
Finally, {1H, 15N} HSQC of 15N-labeled tDDP or cDDP with zinc finger can be seen in
Figure 5. The parent peak for tDDP is seen at {3.61, -64.7}ppm with platinum coupling
peaks at {3.57, -62.4} ppm and {3.65, -67.0}ppm. The hydrolysis of tDDP occurs at a must
faster rate than cDDP as seen by the immediately present hydrolysis peak for the trans-
isomer at {3.81, -63.2} ppm. A similar hydrolysis peak is seen for cDDP after approx. 1
hour.
The reaction of tDDP is complete within 27 minutes and after 24 hours, no changes
are seen in the spectrum (Figure 6). Three new products peaks are found at {3.85, -59.1},
{3.77, -58.5}, and {3.57, -59.3} all of which are consistent with S-binding. Given that there
are multiple Cys residues in the sequence of the C-terminal ZF, it is plausible that one or
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Table 5.1: Major NMR ligand chemical shifts for [M(dien)(DMAP)]n+ complexes. Values in
parentheses are the difference in chemical shift (ppm) from free ligand followed by the 3JHH
coupling constants (Hz).
Species Charge State Observed m/ Calculated m/z
Pt(NH3)2 + peptide 3+ 817.33 818.33
Pt(NH3)2 + peptide 2+
1225.49 1227.001225.50
Pt(NH3)2Cl + peptide 2+
1244.48 1244.481242.44
Pt(NH3)2Cl + peptide 3+ 829.90 829.99
2Pt(NH3)2 + peptide 2+ 1340.00 1341.51
Pt(NH3)2Cl2 + peptide 2+ 1261.41 1261.97
Pt(NH3)2Cl + ZF 2+ 1276.40 1276.78
Pt(NH3)2Cl + ZF 3+ 849.90 851.52
Pt(NH3)2 + ZF 3+ 838.60 839.64
Pt2 + ZF 3+ 893.67 893.27
Pt(NH3)2 + ZF 2+
1257.90 1258.961257.46
Pt(NH3)/ZF 3+ 833.63 833.97
more of these peaks may correspond to a bridged S-Pt-S species (18). The spectra for the
reaction of cDDP with ZF again displays a much slower rate of reaction. Two 15N upfield
shifted peaks at {3.61, -41.6} and {3.79, -40.6} ppm are seen after 1 hour of reaction. The
upfield shift on the nitrogen scale of the new peaks is consistent with the binding of S to the
Pt center. The reaction was followed from 27 mins to 24 hours, with spectra taken every
30 minutes and spectra taken every few days up to one week. After one week, the peak
corresponding to free 15N-cDDP was still present, illustrating the slower reaction rate of the
cis isomer.
5.5 Discussion
The reaction of tDDP and cDDP with the C-terminal ZF of HIV1 NCp7 was followed
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Figure 5.8: HSQC spectra of A) 15N-tDDP, B) 1:1 reaction of 15N-tDDP with C-terminal
ZF of HIV1 NCp7 at blue- 27 minutes and red- 24 hours, C) 15N-cDDP and D) 1:1 reaction
of 15N-cDDP with C-terminal ZF of HIV1 NCp7 at 24 hours.
using several different techniques. The results all show a significantly faster rate of reaction
for the trans isomer when compared to the cis. This is consistent with known biological
activity of trans-platinum complexes. The difference in reaction observed here is also consis-
tent with studies on Sp1, a human transcription factor comprised of three C2H2 zinc fingers.
A significantly faster rate of reaction was observed for tDDP when compared with cDDP
and trans-planar amine platinum complexes (19). The rate reactivity of cDDP towards Sp1
increased upon incubation with the reducing agent, tris-(2-carboxyethyl)phosphine. This
can be explained by the strong trans effect of the cDDP-bound reducing agents (20). Other
studies have yielded similar results and the reaction of cDDP with other zinc finger proteins
has been characterized (17, 21, 22).
Our results combined with those of others confirm the ability of bioinorganic chemistry
to serve as a tool that can be used to study and tune the reactivity of metal complexes,
specifically for metal-protein interactions. While it appears a dinuclear structure is neces-
sary to induce peptide cleavage at neutral pH, the isomeric conformation of the platinum
complexes leaves room for manipulation. This combined with the observed effects of various
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ligands in trans-[PtCl(L)(L’)(nucleobase)]+ complexes opens the door to further development
of platinum complexes designed to target ZF proteins.
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Samantha D. Tsotsoros and Nicholas P. Farrell
Department of Chemistry, Virginia Commonwealth University, 1001 W. Main Street,
Richmond, VA 23284-2006 USA
6.1 Introduction
The work that comprises this chapter is part of the larger goal of this dissertation to develop
compounds designed to target HIV1 NCp7. The compounds synthesized below were designed
to target HIV1 NCp7 as structural modifications of the PtN4 coordination sphere.
6.2 Experimental
6.2.1 Synthesis
K[PtCl3NH3] Cisplatin (6.96 mmol) was dissolved in 40 mL of water and 20 mL of HCl
and the solution was heated to reflux for 7 hours. The volume was reduced and the solution
cooled to 4oC overnight. Any precipitated cisplatin was filtered off and the volume was
reduced to 1/2V and the solution was cooled to 4oC overnight. Cisplatin was filtered and
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the solution was reduced to 2/3V and cooled to 4oC. Any precipitated cisplatin was filtered
off and the volume was doubled. The dilute solution was run down a DOWEX 50W8X-200
cation exchange column equilibrated with 2M KCl. The eluent was placed in the fridge over
the weekend and red solid was collected. The crude solid was recrystallized by dissolving in
water, filtering off any cisplatin and lyophilizing.
[PtCl2(en)] (1) K2PtCl4 (0.892 mmol) was dissolved in 4.5 mL of water and 228 µL of
ethylenediamine was added dropwise. The solution was stirred at room temperature for 1
hour. The yellow solid was collected and washed with ethanol and ether. 89% yield. 1H
NMR: 3.50 (4H, s). Anal. Calcd: C 7.37, H 2.47, N 8.59, Found: C 7.45, H 2.29, N 8.51.
[PtCl(en)(Gua)]NO3 [PtCl2(en)] (0.5107 g, 1.56 mmol) was suspended in 575 mL of DMF.
A solution of AgNO3 (0.258 g, 1.51 mmol) in 200 mL of DMF was added to the platinum
solution dropwise over 5 hours. The solution was stirred at room temperature overnight
in the dark. The AgCl precipitate was removed by filtration through celite and guanosine
(0.4436 g, 1.56 mmol) was added to the filtrate. The filtrate was stirred at room temperature
overnight and rotovapped to 50 mL. Acetone was added to precipitate the final product.
The product was filtered and washed with acetone and the filtrate was reduced in volume
and placed in the freezer. The first product was labeled Crop 1. Upon cooling, solid pre-
cipitated in the filtrate. The solution was filtered to isolate the precipitated product âĂŞ
this solid was labeled Crop 2. Once again, the filtrate was placed in the freezer and again
precipitation was seen. The solution was filtered and this product was labeled Crop 3. The
filtrate was placed in the freezer, but no further precipitation was observed.
The initial 1H NMR for Crop 1 showed mono-Gua product (H8 integrated at 1H) and free
Gua (H8 integrated at 1.20H). In order to remove the free Gua, the solid was stirred in MeOH
and filtered to remove any undissolved particles. After filtration, the volume was reduced
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and acetone was used to precipitate the product. NMR of Crop 1-A showed mono-Gua prod-
uct (H8 integrated at 1H), bis-Gua (H8 integrated at 0.35) and free Gua (H8 integrated at
0.22H). NMR for Crop 2 initially showed only the mono product with a small amount of free
Gua. The solid was stirred in methanol to remove the free guanosine and the resulting solid
was lableled Crop 2-A. The NMR for Crop2-A showed mono product, bis product and free
guanosine. The NMR for Crop 3 showed mono product, a small amount of bis product and
free guanosine. Separating of the mono and bis products is very difficult through solubility,
and use of a column or possibly HPLC may be necessary to achieve complete separation.
[PtCl(en)(NH3)]Cl
Method 1 (2)
K[PtCl3(NH3)] (110 mg, 0.31 mmol) was suspended in 15 mL of MeOH and heated. To
ensure complete dissolution, 10 mL of water was added. Ethylenediamine (0.30 mmol) was
added and the solution was heated at reflux for 3 hours. The solution was cooled to room
temperature and rotovapped to 5 mL. A large excess of acetone was added and a very white
product precipitated. The solid was filtered and washed with acetone and ether and placed
in the desiccator to dry. Elemental analysis was indicative of the formation of [Pt(en)2].
Anal. Calcd: 12.44, 4.18, 14.51, Found: 12.15, 4.03, 14.11.
Method 2 (1)
K[Pt(NHCl33)] (111 mg, 0.315 mmol) was dissolved in 4 mL of water. Ethylenediamine (80
uL, 1.19 mmol) was added dropwise, very slowly. A salmon colored precipitate formed im-
mediately. The reaction was stirred at room temperature for 1 hour. The solid was filtered
and washed with ethanol and ether and placed in the desiccator to dry. 57 mg of solid was
recovered. Product is precipitation of [PtCl3(NH3)][PtCl(en)(NH3)]. Anal. Calcd: C 3.84;
H 2.25; N, 8.95; Found: C 4.03; H 2.05; N, 8.82.
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[PtCl2(COD)] (2)(3) K2PtCl4 (1.62 mmol) was dissolved in 10 mL of water and filtered to
remove impurities. Glacial acetic acid (16 mL) was added followed by cyclooctadiene (674
µL). The reaction was heated to 90oC with rapid stirring for 30 minutes. The solution was
cooled to room temperature and the volume was reduced to <5 mL. The product precipi-
tated and was filtered and washed with water, ethanol and ether. 78% yield. 1H NMR: 1.53
(1H, s), 2.23 (5H, m), 2.67 (4H, m), 5.59 (4H, s).
[PtCl(terpy)]Cl (2)(3) [PtCl2(COD)] (0.42 mmol) was suspended in 17 mL of H2O and
2,2’,6’,2”-terpyridine (0.42 mmol) was added. The reaction was stirred at 40oC for 40 min-
utes. The solution was rotovapped to dryness and ether was added. Sonication was used to
remove the red residue from the glass and the solid was filtered and washed with ether. 1H
NMR: 7.4-8.2 (11H m).
[Pt(terpy)(9EtG)](NO3)2 [PtCl(terpy)]Cl (0.1 mmol) was dissolved in 20 mL of water,
1.98 eq. of AgNO3 was added and the reaction was stirred at room temperature overnight.
The precipitated AgCl was removed by filtration through a celite pad and 9-ethylguanine (1
eq.) was added to the filtrate. The reaction was stirred at 50oC for 72 hours and cooled to
room temperature. The solvent was reduced to 1/3V and acetone was added to precipitate
the product. 40% yield. 1H NMR: 1.58 (3H, t) 4.35 (2H, q), 7.2-8.5 (11H, m), 8.90 (1H, s).
[Pt(dien)(CMP)] [Pt(dien)Cl]Cl (0.42 mmol) was activated with 1.98 eq. of AgNO3
overnight. The AgCl precipitate was filtered off and CMP (0.42 mmol) was added to the
filtrate. The reaction was stirred at 50oC overnight. The solution was cooled to room tem-
perature and lyophilized. 52.4% yield. 1H NMR: 8.23 (1H, d), 6.21 (1H, d), 6.01 (1H, d),
4.35 (2H, m), 4.28 (2H, m), 3.99 (3H, m), 3.03 (8H, m).
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N-N’-dimethylethylenetriamine
Synthesis of Ts3dien (4) p-toluenesulfonylchloride (67.3067 g, 0.353 mol) was stirred in 176
mL of pyridine and heated to 40oC until all solid dissolved. Diethylenetriamine (12.6 mL,
0.102 mol) in 17.6 mL of pyridine was added slowly to maintain a reaction temperature of
50-60oC. The solution was stirred for 30 minutes and cooled to room temperature. 150 mL
of water was added to the orange/brown solution and the solution was stirred overnight.
The resulting solid was filtered and washed with ice-cold ethanol and dried at 60oC for 2
days. Recovered: 42.656 g, 65% yield.
Synthesis of Me2Ts3dien (5) Ts3dien (42.6557 g, 0.754 mol) was dissolved in 271 mL of
DMF and the solution was cooled on ice. NaH (11.02 g, 0.459 mol) was added and the
solution was stirred until gas evolution subsided. Dimethyl sulfate (25.3 mL, 0.267 mol) was
added dropwise. The solution was stirred for 1 hour at room temperature and 2 hours at
70oC. The solution was cooled to room temperature and NaOAc (9.0372 g, 0.117 mol) was
added and the reaction mixture was stirred for 45 minutes. The solid was filtered and the
filtrate rotovapped to dryness. The resulting solid was filtered and along with the first solid,
washed with MeOH, H2O, MeOH, and ether. Methylene chloride (180 mL) was added to
dissolve the solid. Any remaining solid was filtered and the filtrate was reduced to 1/2V. A
large excess of MeOH was added and the cream-colored precipitate was filtered and washed
with MeOH and ether. Recovered: 43.040g, 95% yield.
Synthesis of Me2dien (5) Acetic anhydride (107 mL) was cooled on ice and HBr (192 mL)
was added dropwise. The solution was stirred on ice for 20 minutes and at room temperature
for 12 hours. Ts3me2dien (43.0405 g, 0.2136 mol) was added to the acid solution and the
reaction mixture was heated at reflux for 10 hours. The solution was cooled to room tem-
perature, rotovapped to 1/2V, and extracted with 2x105 mL portions of ether. The aqueous
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layer was rotovapped to 1/2V and ethanol was added to induce crystallization. The solution
was cooled on ice and ether was added. The resulting solid was filtered and washed with
2:1 ethanol:ether and ether. The solid was mixed with NaOH (21.36 g, 0.534 mol) and was
stirred until smoking subsided. The resulting slurry was extracted with methylene chloride
and any remaining solid was filtered and washed with methylene chloride. The filtrate was
rotovapped to remove the methylene chloride. Recovered: 5.0295 g, 53% yield.
[Pt(dien)(Xnt)](NO3)2 [PtCl(dien)]Cl (0.47 mmol) was dissolved in 10 mL of water, 1.98
eq. of AgNO3 and 1 eq. of xanthine were added and the reaction was stirred overnight at
50oC. The solution was filtered through a celite pad to remove the precipitated AgCl and
the filtrate was rotovapped to 1/3V. A large excess of acetone was added to precipitate the
product and the solid was filtered and washed with acetone and ether. 70% yield. 1H NMR:
2.15 (1H, s), 3.00 (8H, m), 8.68 (0.3H, s), 7.95 (0.2H, s), 8.10 (0.1H, s), 8.25 (0.2H, s). The
appearance of multiple H8 peaks is indicative of platinum binding to multiple sites on the
Xnt. Therefore, the reaction should be carried out at an appropriate pH so that only the
H8 is deprotonated.
[Pt(me4dien)(Cl)]PF6 (2) Pt(dmso)2Cl2 (1g, 2.36mmol) was suspended in 200 mL of
methanol and placed at 50oC with stirring. Me4dien (440 µL, 2.36 mmol) in 40 mL of
MeOH was added to the Pt solution and heated at reflux for 2.5 hours. The solution was
cooled to room temperature and a small amount of white solid precipitated. The solvent
was reduced to 1/3V and NH4PF6 (2.36 mmol) was added. The solution was placed in the
freezer overnight. 337mg of large yellow crystalline solid was collected. 1H NMR: 3.00 (20H,
m) Anal. Calcd: C, 17.97; 3.96; N, 7.86 Found: C, 17.71; H, 3.79; N, 7.41.
[Pt(me4dien)(GMP)]PF6- [Pt(me4dien)Cl]PF6 (0.167 mmol) was dissolved in 8.6 mL of
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water. AgNO3 (1 eq) was added and the reaction was left in the dark at 37oC overnight.
The AgCl precipitate was filtered off and 5’GMP (1 eq.) disodium salt was added. The
reaction was placed at 50oC for 24 hours. The volume was reduced to dryness, 2 mL of ether
was added and the solid was scraped from round-bottom flask. The solid was placed in the
dessicator to dry overnight. 80.2% yield.
[Pt(me4dien)(9EtG)]PF6- [Pt(me4dien)Cl]PF6 (0.20 mmol) was dissolved in 14 mL of
H2O and heated to 37oC with intermittent sonication to dissolve. AgNO3 (0.196 mmol) was
added to solution and the reaction was placed in the dark at 37oC for two days. The AgCl
precipitate was filtered using celite. 9-ethylguanine (0.20 mmol) was added to the filtrate
and the reaction was placed at 50oC with stirring for five days. The solution was cooled to
room temperature and filtered to remove any precipitate. The solution was rotovapped to
dryness, leaving a white solid. 78.6% yield. 1H NMR in D2O: 8.7 ppm (0.76H, d), 8.3 ppm
(0.34H, s), 4.2 ppm (2.15H, m), 2.9 ppm (8H, m), and 1.5 ppm (3H, m).
6.2.2 Techniques
Circular Dichroism
CD spectra were recorded on a Jasco J-600 Spectropolarimeter (Jasco, Corp., Tokyo, Japan).
Each spectrum was recorded from 190 nm to 250 nm in a 0.1 cm cuvette path length at room
temperature under N2. Spectra were baseline corrected using the Jasco software and noise-
reduced using Origin. Pt compounds were added to the peptides at a ratio of 1:1 and
incubated at 37oC for 15 minutes, 1 hour, 3 hours, 5 hours or 24 hours accordingly. The pH
of the solutions was adjusted to 7.2-7.4 with NH4OH.
Fluorescence Spectroscopy
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A. Association Constant Determination: Fluorescence spectra were recorded on a Varian
Cary Eclipse Fluorescence Spectrometer with a single-cell Peltier accessory. Fluorescence
spectra were recorded from 300 nm to 450 nm with a scan rate of 120 nm/min. Measure-
ments were recorded at 20oC. The maximum intensity of the spectrum was measured and
the association constants for each drug were calculated from the Eadie-Hofstee plots. The
data presented is an average of 3 trials.
B. TSQ Assay: 2µM zinc finger was prepared in water with 50 µM TSQ (with or without
1 eq. of platinum complex) at a final volume of 3 mL. The sample was excited at 344 nm
and emission was monitored at 365 nm. To prepare a standard curve, Zn was added from
0.5-3.0 µM.
Reaction of [Pt(dien(L)](NO3)2 with N-AcCys by 1H NMR
[Pt(dien)(L)](NO3)2and N-AcCys were dissolved in 500 µL of D2O at a 1:1 ratio and the 1H
NMR was monitored on a 300 MHz Varian NMR Spectrometer once an hour for 15 hours
and once a day for 7 days.
DNA Melting Point
DNA melting studies were recorded on a JASCO V-550 UV/Vis spectrometer. Studies were
performed with drug to nucleotide ratios (ri) of 0.01, 0.03, 0.05, 0.075, and 0.1 in 10 mM
NaClO4 at pH 6.10. The concentration of Calf Thymus DNA was 100 µM for each experi-
ment. The results were determined from an average of 2 trials.
Cellular Accumulation
CCRF-CEM and Jurkat cells were seeded at 2 million cells per plate. 20 µM cDDP and
AH78 was added and the cells were incubated for 3 and 6 hours. The media was removed
and the cells were washed twice with 10 mL of cold PBS. The pellets were stored in the
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freezer. To digest samples for ICP-MS analysis, 1 mL of conc. HCl was added to the cell
pellets and left to digest for 2 hours. Water (1 mL) was added to dilute the solution and the
samples were run.
Cytotoxicity Assay
Cell viability of HCT116, A2780, MCF7, and MDA-MB-231 cells was studied by MTT
assay. 5000 cells/well were plated on a 96-well plate and incubated in quadruplet with
[Pt(dien)L]n+ for 72 hours at various drug concentrations (HCT116, A2780: 200, 100, 50,
25, 12.5, 6.25, and 3.125 µM or MCF7, MDA-MB-231: 50, 25, 12.5, 6.25, 3.125, 1.5625,
0.78125 µM). The drug solution was removed and 100 µL of 0.5 mg/mL MTT solution was
added and incubated for 4 hours. The MTT solution was removed and 100 µL of DMSO
was added to solubilize the formazan crystals. The absorbance at 570 nm was determined
on a µQuant Microplate Spectrophotometer from Bio-Tek instruments.
Fourier Transform Ion Cyclotron Resonance Mass Spectrometry
Experiments were conducted on a modified Bruker Daltonics (Billerica, MA) SolariX FTICR-
MS equipped with a 12T superconducting magnet. Analyses were carried out by direct in-
fusion using tapered quartz nanospray emitters loaded with 5-10 µL of sample with a spray
voltage between 800-1100 V relative to the capillary inlet supplied by an inserted stainless
steel wire. Solutions were prepared as follows:
A. Control experiment was performed as discussed in Chapter 4.
B. 1:1 reaction of NCp7 with [Pt(dien)(Gua)]2+
A solution of NC (7.5 µM in 1 µL H2O) was added to a solution of [Pt(dien)(Gua)]2+ (7.5
µM in 1 µL) and the volume was brought up to 10 µL with 7 µL 150 mM ammonium acetate
and 1 µL isopropyl alcohol. The mixture was analyzed immediately in negative ion mode.
C. 5:1 reaction of NCp7 with [Pt(dien)(Gua)]2+
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A solution of NC (7.5 µM in 1 µL H2O) was added to a solution of [Pt(dien)(Gua)]2+ (37.5
µM in 1 µL) and the volume was brought up to 10 µL with 7 µL 150 mM ammonium acetate
and 1 µL isopropyl alcohol. The mixture was analyzed immediately in negative ion mode.
D. A solution of NC (7.5 µM in 1 µL H2O) and [Pt(dien)(Gua)]2+ (7.5 µM in 1 µL) was
incubated for 30 minutes at room temperature. SL2-RNA (7.5 µM in 1 µL), 6 µL 150 mM
ammonium acetate, and 1 µL isopropyl alcohol were added and the mixture was analyzed
immediately in negative ion mode.
E. A solution of NC (7.5 µM in 4 µL H2O) was added to a solution of SL2 (7.5 µM in 2 µL
H2O) to form the 2:1 NC/RNA complex. The complex formed immediately; no significant
incubation was necessary. A solution of [Pt(dien)(Gua)]2+ (7.5 µM in 2 µL) was added and
volume was brought up to 10 µL with 1 µL 150 mM ammonium acetate and 1 µL isopropyl
alcohol. The mixture was analyzed in negative ion mode immediately.
6.3 Results and Discussion
6.3.1 1H NMR Spectroscopy
It is important to understand the reactions between platinum complexes and S-containing
amino acids, such as Cys, due to the high concentrations of proteins like human serum
albumin (HSA) and glutathione. These proteins are responsible for binding to platinum,
essentially deactivating the drugs leading to removal from the system. Reactions with sulfur
proteins have been found to be the main source of toxic side effects caused by cisplatin(6).
The compounds [Pt(dien)(9EtG)]2+, [Pt(dien)(1-MeCyt)]2+ and [Pt(Me4dien)(9EtG)]2+ are
designed to have very slow or non-existent reactions with S-containing species. The 1:1
overnight reaction of [Pt(dien)(9EtG)]2+ (Figure 6.1); [Pt(dien)(1MeCyt)]2+ (Figure 6.2);
and [Pt(Me4dien)(9EtG)]2+, Figure 6.3 with N-AcCys was monitored by 1H NMR. No major
changes were seen in the spectrum indicating the inertness of the PtN4 coordination sphere.
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In the presence of more than one equivalent of a Cys-containing species at 37oC, displacement
of the 9EtG has been seen to some extent (7).
Figure 6.1: 1H NMR of a 1:1 reaction (D2O) of [Pt(dien)(9EtG)]2+ with N-AcCys
Figure 6.2: 1H NMR of a 1:1 reaction (D2O) of [Pt(dien)(1MeCyt)]2+ with N-AcCys.
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Figure 6.3: 1H NMR of a 1:1 reaction (D2O) of [Pt(Me4dien)(9EtG)]2+ with N-AcCys.
6.3.2 Temperature Dependence of the H8 Signal Splitting in
[Pt(me4dien)GMP]
As seen in Chapter 5, addition of a nucleobase to [Pt(Me4dien)] results in a very sterically
hindered complex. The 1H NMR of [Pt(Me4dien)GMP] shows the sample splitting of the
H8 of Gua as [Pt(dien)(9EtG)]2+ due to the hindered rotation of the nucleobase about the
Pt-N bond. A temperature-dependant NMR experiment was performed from 24oC to 65oC.
The increase in temperature caused a slight decrease in the spacing and broadening of the
two H8 peaks, indicating that the methyl groups on the dien provide a significant amount of
steric hinderance, Figure 6.4. If the temperature had continued to be raised, it is reasonable
to assume that the two signals would have coalesced.
6.3.3 UV-Vis of PtN4 compounds
The UV absorption for the compounds studied in Chapter 5 was obtained. The maximum
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Figure 6.4: Temperature-dependent 1H NMR spectrum of [Pt(me4dien)(5’-GMP)].
absorbances and extinction coefficients can be found in Table 6.1.
6.3.4 Circular Dichroism studies with zinc finger peptides
Circular dichroism gives information about the secondary structure of proteins. Therefore, it
is a useful tool in studying the reaction between compounds and peptide sequences. Here, we
studied the interaction of an inert PtN4 coordination sphere compared to the more reactive
PClN3 compounds. The basis for these studies is targeting the C-terminal ZF of HIV1 NCp7.
It is important to understand how the zinc coordination sphere affects the reactivity of the
zinc finger and therefore several sequences were used: the C-terminal ZF of NCp7, mutant
peptides based on the C-terminal knuckle of NCp7 with the Met residue removed, and F3
of Sp1 (Figure 6.5 (C2H2).
6.3.4.1 Circular Dichroism of Apo-Peptide vs. Zinc Finger
Incubation of the free peptides with 1.3 equivalents of ZnOAc in water at pH 7.2-7.4 results
in a decrease in the negative intensity of the peak at 197 nm with a red shift to 200 nm and
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Table 6.1: UV-Vis of all compounds synthesized and reported in Chapter 5. Values in
parenthesis are the extinction coefficient,  in L mol−1 cm−1.
Compound λmax (nm)
[Pt(dien)(7MeG)]2+ 280 (6087) 256 (5716) 208 (26135)
[Pt(dien)(Ino)]2+ — 257 (9293) 208 (26684)
[Pt(dien)(9EtG)]2+ 281 (6152) 256 (8511) 206 (26246)
[Pt(NMedien)(9EtG)]2+ 275 (5627) 255 (7361) 207 (24836)
[Pt(me2dien)(9EtG)]2+ 281 (6152) 256 (7641) 206 (26508)
[Pt(me4dien)(9EtG)]2+ 282 (4203) 258 (6298) 208 (25787)
[Pt(dien)(Gua)]2+ 280 (6632) 260 (9026) 205 (21798)
[Pt(NMedien)(Gua)]2+ 277 (6818) 258 (8906) 207 (26513)
[Pt(me2dien)(Gua)]2+ 279 (6039) 259 (8559) 208 (27132)
[Pt(me4dien)(Gua)]2+ 283 (4704) 258 (7768) 209 (27021)
[Pt(dien)(Xan)]2+ 281 (7557) 255 (7333) 208 (26048)
[Pt(NMedien)(Xan)]2+ 280 (6087) 256 (5716) 208 (26135)
[Pt(me2dien)(Xan)]2+ 279 (6327) 256 (6522) 208 (26906)
[Pt(me4dien)(Xan)]2+ 280 (5554) 257 (5929) 208 (27566)
Figure 6.5: Structures of the zinc fingers studied. A- C-terminal ZF of HIV1 NCp7, B-
Mutant peptides, X= Cys or His and C- SP1 F3.
an increase in positive ellipticity from 210-230 nm, indicative of the formation of zinc finger.
6.3.4.2 Circular Dichroism of the C-terminal ZF of HIV1 NCp7
The reaction of the C-terminal zinc finger of HIV1 NCp7 with [PtCl(dien)]+, [Pt(dien)-
(1MeCyt)]2+ and [Pt(dien)(9EtG)]2+ was monitored over 24 hours. As seen in Figure 6.6, 24
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hours of incubation with [PtCl(dien)]+ resulted in a decrease in the positive ellipticity at 220
nm and an increase in the negative band at 200 nm; both changes are indicative of zinc ejec-
tion. In contrast, both PtN4 species showed no change to the CD spectra. This result high-
lights the inertness of [Pt(dien)(nucleobase)]2+ complexes when reacted with S-containing
species, especially compared to the more reactive parent compound, [PtCl(dien)]+.
6.3.4.3 Circular Dichroism of the C-terminal ZF of C3H Mutant Peptide
Upon incubation of the zinc finger with [Pt(dien)Cl]+, structural perturbation was seen as
indicated by the large increase in negative intensity and small shift towards 197 nm, Figure
6.7. The reaction of this drug with the mutant zinc finger was greater than that with the
NCp7 C-terminal sequence. This may be attributed to the strain in the zinc finger caused
by a smaller zinc coordination sphere. The N4 analog, [Pt(dien)(9EtG)]2+, did not induce
Figure 6.6: Circular dichroism of the C-terminal ZF of HIV1 NCp7 with A- [PtCl(dien)]+,
B- [Pt(dien)(9EtG)]2+, and C- [Pt(dien)(1MeCyt)]2+.
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structural changes. This result is expected, as the N4 analogs are inert species that should
not covalently interact with the zinc peptides.
6.3.4.4 Circular Dichroism of the Full NCp7
The CD spectra of the full NCp7 protein showed changes over time, Figure 6.8. This may
be due to the flexibility in the protein. Due to the changes seen for NCp7 alone, study
of the reaction with compounds does not lead to any clear results. Therefore, another
technique would be more suitable to study this reaction or the CD can be taken at very low
temperatures to slow the motion of the protein.
6.3.4.5 Circular Dichroism of SP1 F3 C2H2 Zinc Finger
The incubation of this zinc finger at 37oC with no drug showed structural changes, however
to account for this a spectrum was run at each incubation time point to allow for direct
comparison when the zinc finger was incubated with drug. Incubation of the Sp1 F3 C2H2
zinc finger with [Pt(dien)Cl]+ over 24 hours did not result in any structural changes to
the peptide. This result suggests a slower reaction rate for the drug with the C2H2 zinc
finger than the C3H NCp7 and mutant zinc fingers, Figure 6.9. This is expected due to the
Figure 6.7: Circular dichroism of the C-terminal ZF of HIV1 NCp7 with A- [PtCl(dien)]+,
and B- [Pt(dien)(9EtG)]2+.
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Figure 6.8: Circular dichroism spectra for the full NCp7 over a span of 24 hours.
decrease in the number of cysteine residues, which are reactive towards Pt. Incubation with
[Pt(dien)(9EtG)]2+ also did not induce any structural changes to the zinc finger.
Figure 6.9: Circular dichroism of SP1 F3 with A- [PtCl(dien)]+, and B- [Pt(dien)(9EtG)]2+.
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6.3.5 Fluorescence Spectroscopy
6.3.5.1 Determination of Association Constant
Fluorescence spectroscopy has been used to determine the association constant for platinum
compounds with N-AcTrp and the C-terminal ZF of HIV1 NCp7 ( 8, 9, 10). Here, we
determined the association constant for the C3H and C2H2 mutant peptides to determine if
the change in coordination sphere affects pi-stacking interactions with [Pt(dien)(9EtG)]2+.
The association constants are all very close in value and can be considered the same within
the error calculated. This indicates that the constricted coordination sphere (C3H) mutant
and change in the number of cysteines (C2H2) do not affect the strength of the pi-stacking
interaction, Table 6.2.
Table 6.2: The association constant calculated for [Pt(dien)(9EtG)]2+ with different peptide
sequences.
Compound Ka (x10−3) M−1
NCp7 C-Terminal C3H 13.10 ± 0.94
C3H Mutant 12.17 ± 0.07
C2H2 Mutant 13.93 ± 1.71
6.3.5.2 TSQ Assay
N-(6-Methoxy-8-quinolyl)-p-toluenesulfonamide (TSQ) is used as a probe for the presence
of zinc. Upon addition of zinc, a complex of TSQ2Zn is formed and fluoresces at 365 nm,
compared to 385 nm for TSQ without zinc. This fluorescence can be used to quantitate
the release of zinc from zinc finger proteins. Here, the C-terminal ZF of HIV1 NCp7 and
Sp1F3 were analyzed for release of zinc, Figure 6.10. The addition of TSQ to a solution of
the C-terminal ZF of NCp7 resulted in immediate release and chelation of zinc from the ZF;
therefore, this assay is unsuitable for use to monitor the reaction of platinum complexes with
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the ZF. The incubation of Sp1 F3 with TSQ resulted in a significantly slower time-dependent
release of Zn but the chelation of Zn by TSQ makes this assay unsuitable to study the rate
of Zn release caused by a platinum compound.
Figure 6.10: A- Standard curve for addition of Zn2+ to a 50µMTSQ solution, B- Fluorescence
of the C-terminal ZF of HIV1 NCp7 immediately upon addition of TSQ, and C- Time-
dependent release of Zn2+ from Sp1 F3 upon incubation with TSQ.
6.3.6 DNA Melting Point Studies
Cytotoxic platinum agents, such as cisplatin, exert their toxic effects through binding to
DNA leading to apoptosis. The compounds developed in this dissertation should not exhibit
such binding, as PtN4 coordination spheres are relatively stable and should react slowly.
The melting point of Calf Thymus DNA was determined by UV-Vis spectroscopy after 24
112
hour incubation with platinum complex. As seen in Table 6.3, addition of platinum drug
to DNA had little to no effect on the melting point, indicating a lack of reactivity. This is
complementary to the work already published (7).
Table 6.3: The melting point of calf thymus DNA after incubation with platinum-nucleobase
compound as determined by UV-Vis spectroscopy.
Dilution (Ri)
Compound 0 0.01 0.03 0.05 0.075 0.1
[PtCl(dien)]+ 68.5 69.5 68 67.3 66.5 65
[Pt(dien)(9EtG)]2+ 68.5 67.85 68.2 68.45 69.75 68.05
[Pt(dien)(GMP)] 69 67.3 68.8 69.7 69.3 68.7
[Pt(dien)(7MeG)]2+ 68.5 68.7 70.2 71.75 71.2 72.5
[Pt(dien)(Gua)]2+ 68.5 68.3 68.9 69.2 68.2 68.4
[Pt(me4dien)Cl]2+ 68.5 67.5 66.7 68.4 65.5 66.2
6.3.7 Cytotoxicity Assays
Ideally, the platinum compounds developed within this dissertation are selective for HIV1
NCp7 and therefore should not affect normal cellular functions. As part of this specificity,
the compounds should not be cytotoxic. The in vitro activity of certain [Pt(dien)L]n+ com-
plexes has not yet been studied. Therefore, MTT assays to determine cytotoxicity for the
complexes [Pt(dien)Cl]+, [Pt(dien)(9EtG)]2+, [Pt(dien)(GMP)], and [Pt(dien)(1MeCyt)]2+
were performed in HTC116, human colon carcinoma; A2780, human ovarian carcinoma;
MCF7, human breast carcinoma; and MDA-MB-231, human breast carcinoma. As shown
in Table 6.4, the compounds can generally be considered non-cytotoxic with the exception
of [Pt(dien)(GMP)] in A2780 cells. The enhanced cytotoxicity of the GMP compound in
A2780s is not entirely surprising as these cells are known to be very sensitive to platinum
agents. Overall, the cytotoxicity results displayed below support the idea of specificity, in
that the compounds are not toxic to non-HIV cells.
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Table 6.4: In vitro cytotoxicity of [PtCl(dien)]+ and platinum-nucleobase complexes in
HCT116, A2780, MCF7 and MDA-MB-231 cell lines as determined by MTT assay.
IC50 (µM)
Compound HCT116 A2780 MCF7 MDA-MB-231
[PtCl(dien)]+ >200 >200 — —
[Pt(dien)(9EtG)]2+ 100 140.5 >50 >50
[Pt(dien)(GMP)] 73.9 2.5 >50 >50
[Pt(dien)(1MeCyt)]2+ >200 126.5 — —
6.3.8 Cellular Accumulation Studies
As evidenced in Chapter 5, cellular accumulation studies are another important tool to
determine the activity profile of platinum drugs. As a control experiment, the cellular
accumulation of cisplatin and AH78 was studied using CCRF-CEM and Jurkat cell lines.
These cell lines are both CD4+ and therefore HIV-susceptible. Figure 16.11 shows the uptake
profile for both compounds. As expected, AH78 enters the cells at a much faster rate than
cisplatin. The cellular accumulation of both compounds varied between cell lines, but an
increase in the amount of drug between 3 and 6 hours is indicative of active cell uptake. The
mechanism of this uptake remains to be investigated.
6.3.9 FTICR-MS of NCp7 with SL2 in the presence of
[Pt(dien)(Gua)]2+
It is important to evaluate the platinum compounds studied in this dissertation for more
than their basic properties, such as association with Trp. In order to evaluate the efficacy
of these compounds, it is important to study their ability to interrupt the NCp7/RNA in-
teraction. Interruption of this interaction may inhibit the virus from successful replicating.
Figure 11 shows the interaction of NCp7 with [Pt(dien)(Gua)]2+ in a 1:1 ratio. Small peaks
corresponding to the 1:1 adduct can be seen and when the ratio of drug:NCp7 is increase
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Figure 6.11: Cellular accumulation of AH78 (left) and cisplatin (right) in CCRF-CEM and
Jurkat cell lines.
to 5:1, these peaks become higher in intensity. The incubation of drug with NCp7 followed
by addition of SL2 RNA resulted in retardation of the formation of the NCp7/SL2 complex
as evidenced by the peak for free SL2, Figure 12. Formation of the NCp7/SL2 complex
followed by addition of the platinum drug was performed, but degradation of the SL2 so-
lution convoluted the results and no conclusions can be made. It is reasonable to assume,
based on the previous study and the study of [Pt(dien)(9EtG)]2+ as discussed in Chapter 4,
that the addition of [Pt(dien)(Gua)]2+ to the intact NC/SL2 complex would result in some
dissociation.
6.3.10 Conclusions
The studies presented in this chapter are complementary to the total work of this disser-
tation. The goal was to develop compounds designed to target HIV1 NCp7 and study the
factors affecting this interaction. 1H NMR and CD studies confirmed the inertness of the
PtN4 coordination sphere. No significant binding occurred between [Pt(dien)(9EtG)]2+ or
[Pt(dien)(1MeCyt)]2+ with N-AcCys or zinc finger proteins. The cytotoxicity profiles ob-
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Figure 6.12: Mass spectrum of the 1:1 reaction of [Pt(dien)(Gua)]2+ with NCp7.
Figure 6.13: Mass Spectrum of the 1:1 reaction of [Pt(dien)(Gua)]2+ with NCp7 followed by
addition of SL2.
tained indicate a lack of cytotoxicity for compounds of the structure [Pt(dien)L]n+. The lack
of DNA binding is also indicative of specificity for these compounds. As a whole, the body
of work presented here suggests that [Pt(dien)L]n+ is a chemotype that specifically targets
NCp7, which as discussed in earlier chapters, is a target of great interest for HIV treatment.
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Chapter 7
Recovery of K2PtCl4 from Laboratory Waste
Samantha D. Tsotsoros, Daniel Lee, and Nicholas P. Farrell
Department of Chemistry, Virginia Commonwealth University, 1001 W. Main Street,
Richmond, VA 23284-2006 USA
7.1 Contribution
S.D.T.’s contribution is equal to Daniel Lee’s. Both were responsible for the complete
recovery process.
7.2 Purpose
Platinum is a precious and expensive metal, therefore it is desirable to recover and reuse
platinum collected in experimental waste. The following procedure was adapted from (1)
and (2).
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7.3 General Schematic
Figure 7.1: General schematic for the recovery of K2PtCl4 from laboratory waste.
7.4 Procedure
**Never leave any of these steps unattended for any extended period of time!
**Perform every step in the hood!
1. In a 3L beaker- liquid Pt waste had pH adjusted to 14 with NaOH and was heated on
a hot plate to evaporate solvent. Increase temperature slowly if highly volatile solvents
are present.
• this step can take multiple weeks depending on the amount of solvent there is
2. The dried Pt waste was transferred to a porcelain dish and heated with a Meker burner
until no smoke was seen.
3. The solid Pt waste was added to the same porcelain dish and heated with a Meker
burner until no smoke was seen.
• stir solid carefully to ensure even burning
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• only add more solid to the dish when it is cool- if added when hot, the dish may
crack
• when finished- no smoke present, solid will be black and charry looking
• if the solid does not appear to burn well, ask Dr. Qu to come take a look- may
need at add NaNO3
4. The ash was washed with hot water until the filtrate was clear.
• initially the filtrate will be very yellow
• this removes salts leftover —very important to rinse well
5. The solid was weighed and treated with aqua regia (30mL/g) and gently heated in
batches. The solution was cooled to RT and filtered through filter paper. This was
completed three times for each batch.
6. KCl (1g:1g ash) was added to the filtrate to precipitate K2PtCl6
• the solvent was reduced by heating to 1/3V
• the solution was cooled and placed in fridge to precipitate bright yellow solid
7. The K2PtCl6 was filtered and washed with cold water and ether and dried at 110oF.
**The calculations for the next steps must be EXACT
8. The K2PtCl6 was suspended in water (40g/400mL) and hydrazine dihydrochloride
(4g/40mL water) was added dropwise with stirring at 60-65oC. After 4 hours, the
solution was heated to 80-90oC for 30 minutes
• the solution turned from yellow to red over time
9. The solution was cooled to room temperature and filtered to remove any K2PtCl6 still
present. The solid was washed with cold water.
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10. The filtrate was concentrated by heating at 50-60oC, cooled to room temperature and
placed in the fridge to precipitate solid.
11. The solid was filtered and the filtrate was concentrated and cooled in the fridge to
collect a second crop. This was repeated until no solid was obtained.
12. Recrystallization of collected K2PtCl4.
• Water was added to dissolve most of the collected solid. The solution was heated
to reduce the volume and was filtered hot to remove any precipitated K2PtCl6.
The filtrate was collected and the volume was reduced by heating. The concen-
trated solution was placed in the fridge and any precipitated solid was collected.
• Recrystallization was performed as many times as necessary to remove all K2PtCl6.
13. Final yield of purified K2PtCl4 : 90g.
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Chapter 8
General Conclusions
Traditionally, platinum has been used as an anti-cancer agent in medicine. Three FDA
approved compounds have not only created a multi-billion dollar industry but improved
patient survival drastically. All three of these compounds have the ligands surrounding
platinum in the cis orientation. Recently, use of trans platinum complexes has opened new
avenues of interesting research.
Due to the rapid deactivation of trans-platinum compounds by sulfur-containing pro-
teins, they do not exhibit cytotoxic properties in vivo. However, these rapid protein reactions
create opportunities to study the interaction of DNA/RNA with proteins and to develop com-
pounds designed to target proteins. Interestingly, one of the first cross-linking experiments
used transplatin to determine the binding site of the HIV1 nucleocapsid protein, NCp7, to
viral RNA.
NCp7 is an attractive drug target due to its intolerance to mutation and important
role in nearly all stages of the viral life cycle. While previous work served as a “proof of
concept” for the use of platinum compounds to target NCp7, the work preseneted within this
dissertation served to improve upon the prototype compound, [Pt(dien)(9EtG)]2+. Chapter
2 and Appendix A explored the chemistry of this prototype compound. Interestingly, the
reaction with sulfur-containing tetrapeptides was enhanced by the presence of a tryptophan.
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This further strengthens the idea of a two-step mechanism in which, recognition by the
nucleobase/tryptophan is followed by covalent modification. The interaction between NCp7
and the viral RNA stemloop, SL2, was disrupted using the PtN4 9EtG complex. The reverse
reaction, where RNA was added to NCp7 followed by addition of platinum complex showed
retardation of the protein-RNA complex. This is an important result as it confirms platinum-
nucleobase compounds as the first inorganic class of drugs designed to inhibit the protein-
RNA complexation.
Though the initial prototype 9EtG compound was successful in affecting the NCp7 in-
teraction with viral RNA, it is important to try to improve the characteristics of the drug.
Chapters 3 and 4 explored the various factors that affect how the platinum drug interacts
with NCp7. By changing the aromatic ligand, the strength of the pi-stacking interaction with
tryptophan, either free or as part of a peptide sequence can be manipulated. The identifi-
cation of two very strong stackers, xanthosine and 4-dimethylaminopyridine, hightlights the
importance of tuning this property. The “carrier” dien ligand also provides room for manipu-
lation in order to affect compound properties. The addition of liphophilic methyl groups was
hypothesized to increase the cell uptake and possibly the octanol-water coefficient. While
this trend did not hold true, the results are still of interest - drug development is a compli-
cated task and requires many trials to obtain optimal results. Cytotoxicity results support
the hypothesis of viral specificity for these complexes as they are not toxic to non-infected
cells.
Another strategy for targeting NCp7 involves the use of covalently-binding platinum
complexes. It has previously been determined that mono-functional platinum complexes
covalently bind to the C-terminal ZF of NCp7 and eject Zn2+. Zinc ejection is one main
strategy used in the design of organic compounds targeting zinc finger proteins. Here, we have
used cis and trans dinuclear platinum complexes to study the reactivity of the C-terminal
ZF of HIV1 NCp7. Due to the fast reaction kinetics when compared to the cis isomer, the
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trans dinuclear complex caused N-terminal specific cleavage of the ZF. The reaction of the
C-terminal ZF of HIV1 NCp7 with the mononuclear cisplatin and transplatin did not result
in peptide cleavage. Transplatin reacted in a significantly faster fashion.
Addtionally, the zinc coordination enviroment was changed to determine its role in zinc
finger reactivity. When evaluted with a monofunctional platinum complex, it was found
that the number of cysteines played an important role in the reactivity of the peptide. As
previous studies have shown, the Cys3His peptide had a greater structural change than the
Cys2His2 peptide. The size of the coordination sphere also affected the degree of strucutural
perturbance. The zinc finger of smaller, and possibly more strained, coordination sphere
showed greater structural changes by circular dichroism than the finger with a slightly larger
coordination sphere.
In total, the work presented here highlights the importance of systematic evaluation of
the PtN4 class of compounds. HIV is a global health concern and development of potent
inhibitors is an important field of work. This goal combined with the tools of bioinorganic
chemistry leads to a field of interesting and important possibilities.
125
Appendices
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The following appendices are included in a format as close to the originally published version
as possible. Contributions are outlined at the beginning of each appendix.
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Appendix A
Platinum-nucleobase PtN4 complexes as chemotypes for selective
peptide reactions with biomolecules
Queite A. dePaulaa, Samantha D. Tsotsorosa, Yun Quab, Craig A. Bayseb, and
Nicholas P. Farrella∗
aDepartment of Chemistry, Virginia Commonwealth University, 1001 W. Main Street,
Richmond, VA 23284-2006 USA
bDepartment of Chemistry and Biochemistry, Old Dominion University, 4541 Hampton
Boulevard, Norfolk, VA 23529-0126 USA Inorg. Chim. Acta, 393 (2012) 222-229
A.1 Contribution
S.D.T.’s contributions were comprised of preparation of [Pt(dien)(9EtG)]2+ following lit-
erature methods and DNA melting and ethidium bromide studies for the compound. Q.dP.’s
contributions were mass spectrometry and NMR studies of the tetrapeptide and amino acid
reactions with the platinum complex. Q.dP. was also responsible for the preparation of the
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written manuscript. Figures were completed by S.D.T. and Q.dP.
A.2 Abstract
The reactions of a subsitution-inert complex [Pt(dien)(9-EtGua)](NO3)2, I, on DNA
and model tetrapeptides were examined. The tetrapeptides Ac-GAXG (gly-ala-x-gly) and
AC-GWXG (gly-trp-x-gly) (X= met or cys) were chosen to compare firstly the relative
reactivity of the thioether versus thiol and secondly to compare the effect of possible stacking
of the platinated nucleobase with tryptophan on subsitution reactions. Characterization of
predicted products was made using [PtCl(dien)]Cl. Melting point and ethidium bromide
inhibition assays confirmed lack of reactivity on DNA. 1H NMR, 195Pt NMR, and ESI-MS
spectroscopy techniques showed that the cysteine-containing peptides reacted significantly
faster than those of methionine. The reactivity differences were confirmed using simple N-
AcMet and N-AcCys. The presence of tryptophan enhanced the rate of reaction slightly for
the methionine-containing peptides. Theoretical calculations on the [Pt(dien)(9-EtGua)]-
GWMG/GAMG interactions show that the GWMG species is roughly 5 kcal/mol more
stable than formation of the GAMG species (-9.3 and -3.9 kcal/mol) due to the additional
pi-stacking interaction. The results show the utility of considering the PtN4 chemotype for
selective reactions with peptides and templates for drug design of specific protein inhibitors.
A.3 Introduction
Zinc finger proteins are involved in many fundamental biological processes including
genetic information storage and transfer [1]. These structural proteins contain four Zn-
bound residues from histidine (His, N-donor) and cysteine (Cys, S-donor). The nature of the
coordination sphere (Cys2His2, Cys3H, Cys4) affects the chemical reactivity of the zinc site
and especially the nucleophilicity of the metal-bound cysteine-ates [2,3]. Zinc finger proteins
are rich templates for metal-ion replacement. Uses and applications of M replacement include
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spectroscopic probes {Co(II), Cd(II)}; understanding of toxic and carcinogenic properties
of inorganic ions {Ni(II), Pb(II), As(III)} and as possible targets for medicinal inorganic
chemistry {Au(I), As(III), Sb(III), and Pt(II)} [4].
We have started examining the interactions of platinum-metal compounds with zinc
fingers and the factors affecting chemical reactivity of this system. The nature of the coor-
dination sphere and central metal ion modulates the reactivity of coordination compounds.
The anti-cancer drug cisplatin (cis-[PtCl2(NH3)2]) has previously been shown to react with
a 30-amino acid synthetic zinc finger with eventual replacement of the zinc ion upon binding
of two cisplatin moieties [5]. A mass spectral survey comparing [MCl(dien)]n+ (M = Pt(II),
Pd(II) and Au(III)) showed the formation of Pt(dien) and Pd(dien) adducts with the C-
terminal (Cys3His) finger of the HIV nucleocapsid NCp7 protein while for Au(III) all ligands
were lost [6]. The analogous [MCl(terpy)]n+ system showed only “metal-scrambling” with for-
mation of [Zn(terpy)2]2+ and no evidence of M(Ligand)-ZF adducts [6]. Interestingly, these
reactions of the platinum compounds can be reproduced using zinc chelate model systems
[7].
A further set of functionalized platinum compounds under study is that based on
platinum-nucleobase compounds of general formula [PtL3(nucleobase)]n+ compounds where
L can be a combination of neutral and anionic ligands and nucleobase is guanine or cytosine-
based [4]. Both trans-[PtCl(9-EtGua)(pyr)2] and (SP-4-2) [PtCl((9-EtGua)(NH3) (quin)]+
eliminate Zn from the C-terminal zinc finger of NCp7 (ZF, see Fig. A.1) and indeed show
incipient anti-viral activity - attributed to inactivation of the biological functions of the pro-
tein [8,9]. Model studies further showed the existence of intermediate Zn-Pt-9-EtGua species
[10]. Targeting the zinc finger motifs of retroviral nucleocapsids is an attractive approach
to designing drugs capable of interfering with specific steps in the viral life cycle of HIV-1
[11-13].
A critical feature in nucleopcapsid-DNA/RNA recognition is the stacking of aromatic
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amino acids (phenylalanine, tryptophan) to purine and pyrimidine bases (guanine, cytosine)
on DNA/RNA[14,15]. Platination and alkylation of purines and pyrimidines enhances pi-pi
stacking with tryptophan over that of the free nucleobase [16,17]. The prototype PtN4 com-
pound [Pt(dien)(9-EtGua)]2+, I, has been shown to interact in a non-covalent manner with
the C-terminal finger of HIVNCp7 containing the tryptophan residue, and this recognition
motif may impart some selectivity to the reaction over other zinc fingers and biomolecules
[8]. Further, in ESI MS-MS studies a small peak corresponding to a Pt(dien)-ZF adduct
is observed, implying potential loss of the nucleobase ligand and covalent binding of the
Pt(dien) moiety [6,8]. This finding implies that in the presence of a “non-covalent” interac-
tion (i.e.”target activation”) a second, bond-forming interaction (“target fixation”) can occur.
Interestingly, the 1H NMR study of ZF with the platinated oligonucleotide 5’-dTACGCC-3’,
(where the Pt(dien) moiety is bound to the N7 of the guanine nucleobase) shows a close
approximation of the methionine S to the platinated nucleobase [18].
To examine these features further, and to ask whether prior “non-covalent” recognition
can be manipulated to enhance reactivity, we have studied the interactions of [Pt(dien)(9-
EtGua)]2+ with a series of small designed tetrapeptides. The analogous pairs of methionine
and cysteine-containing peptides can assess the effect of a tryptophan (W) versus alanine
(A) residue proximal to the putative binding site and also compare the reactivity of methio-
nine versus cysteine-containing residues in otherwise similar sequences, as well as extending
the chemistry of platinum-nucleobase compounds with protein models. These studies may
contribute to understanding of the features required for development of new platinum-metal
based electrophiles capable of selective interactions with proteins. Fig. A.1 shows the struc-
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Figure A.1: Structures of [Pt(dien)(9-EtGua)]2+, I, and the model tetrapeptides studied.
The C-terminal residue of Nucleocapsid Protein NCp7 is shown in the red box.
tures of all compounds studied in this paper.
A.4 Experimental
A.4.1 Materials and Reagents
The complex [Pt(dien)(9-EtGua](NO3)2 (dien= diethylenetriamine) was prepared by
literature methods [8]. Its purity was confirmed by ESI-MS, 1H and 195PtNMR spectroscopy,
and elemental analysis (performed by QTI Laboratory, USA). The peptides N- acetyl-gly-ala-
meth-gly (GAMG), N-acetyl-gly-trp-meth-gly (GWMG), N-acetyl-gly-ala-cys-gly (GACG),
and N-acetyl-cys-trp- gly (GWCG) were purchased from GenScript Corporation. All reagents
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and reactants were used without further purification.
A.4.2 1H and 195Pt NMR spectroscopy
Experiments were conducted on a 300 MHz NMR Varian Spectrometer. The pH of the
solutions were adjusted when necessary using DNO3 and NaOD solutions. The 195Pt chem-
ical shifts are reported relative to PtCl62− (external standard). Reagents were mixed in 1:1
stoichiometric ratio at 25oC (D2O for 1H NMR, D2O/H2O mixtures for 195Pt NMR) and were
mixed immediately before starting the spectral acquisition. For the 195Pt NMR experiments,
two separate fresh solutions were prepared containing (i) the Pt(dien)(9-EtGua)(NO3)2 com-
pound (1.39x10−5 mol) in 0.5 mL of D2O, and (ii) a stoichiometirc equivalent (1.39x10−5
mol) of the peptide dissolved in 1 ml of H2O.
A.4.3 Electrospray ionization time of flight mass spectrometry (ESI-
TOFMS)
Solutions were prepared as per NMR experiments. Experiments were conducted on
a Waters/Micromass QTOF-2 instrument operated in positive ion mode. Solutions were
directly infused in water at a flow rate of 3 µL/min using a source voltage of 2.75-2.95 kV
and a cone voltage of 40 V. The source temperature was maintained at 110oC throughout.
Collision gas was introduced into the hexapole to aid in ion cooling. All spectra were analyzed
using the MassLynx 4.0 software provided from the manufacturer. In the spectra, all peaks
are labeled with the monoisotopic masses for the proposed species; the observed masses
covered the isotopic range expected. pH was adjusted using NH4OH and HCl.
A.4.4 Fluorescence experiments with tetrapeptides
An X-300 spectrofluorometer was used to perform the fluorescence experiments. Several
titrations were performed every 5 min using the GWMG or GWCG peptide (100 µM) in 3
mL of a buffer solution and addition of aliquots of [Pt(dien)(9-EtGua)](NO3)2 (30 µL, 1 mM
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in buffer solution) in the range [peptide]/[Pt quencher] = 10-100. Tris-HCl (50 mM NaCl/10
mM Tris-HCl) buffer at pH 7.4 was used during all experiments, and the data were recorded
at 22oC. The excitation wavelength was maintained at 315 nm while monitoring emission
from 330 to 420 nm.
A.4.5 DNA Binding
Studies were performed as previously [19]. Briefly, DNA melting studies were recorded
on a JASCO V-550 UV/Vis spectrometer with compound to nucleotide ratios (ri) of 0.01,
0.03, 0.05, 0.075, and 0.1 in 10 mM NaClO4 at pH 6. The concentration of calf thymus
(CT) DNA was 100 µM for each experiment. The results were determined from an average
of two trials. Ethidium bromide (EtBr) fluorescence studies were recorded on a Varian Cary
Eclipse fluorometer with a single-cell Peltier accessory. Samples were irradiated with 525
nm light and emission was recorded at 600 nm with a scan rate of 600 nm/min at 25oC.
The experiments were carried out in phosphate buffer at pH 7.4. CT DNA (100 µM) was
incubated with compound for 1 h and titrated with EtBr at ri values from 0.05 to 0.25. The
results were determined from an average of three trials.
A.4.6 Theoretical Methods
Geometries were optimized at the DFT level using the SVWN exchange-correlation
functional and the PQS software package [20]. The SVWN functional was selected as studies
have shown that it provides a reasonable qualitative representation of pi stacking interactions
[21]. Platinum was represented by the Hay-Wadt relativistic effective core potential basis set
commonly designated LANL2DZ [21]. All other atoms were represented by the Dunning split-
double-f basis set with polarization functions on all heavy atoms and hydrogens attached to
nitrogen or oxygen [23]. Reported structures are minima on the potential energy surface.
Relative free energies of the systems were corrected for solvation in water using the COSMO
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method [24].
A.5 Results
To examine the reactivity of a prototypical PtN4 chromophore with the selected tetrapep-
tides, the expected products were characterized using the more substitution-labile [PtCl(dien)]Cl
as “control” and then their reactivity compared. Examination of the interaction of I with
Calf Thymus (CT) DNA by melting point changes and interference with ethidium bromide
(EtBr) intercalation showed essential no reactivity, in contrast to the well-studied chloride
analog, Fig. A.2 [25].
Figure A.2: Reactivity of I towards DNA as determined by competitive inhibition of ethidium
bromide fluorescence.
A.5.1 Reactions of [PtCl(dien)]+ and [Pt(dien)(9-EtGua)]2+ with
N-acetyl-methionine and methionine-containing tetrapeptides
The principal solution characterization of control reactions with [PtCl(dien)]Cl and N-
Ac-methionine and methionine peptides is given in Table A.1. The reactions of [PtCl(dien)]Cl
with N-AcMet gave a 195Pt NMR spectrum with δ(Pt) at -3374 ppm while the 1H S-CH3
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chemical shifts at δ(2.547, S-CH3) and δ(3.94, S-αCH2) are consistent with the literature [26].
The spectral properties of the products using GAMG and GWMG peptides are completely
consistent with formation of [Pt(dien)(GAMG)] and [Pt(dien)(GWMG)] species, respec-
tively, Fig. A.3 and Table A.1.
Figure A.3: 1H NMR characterization of methionine chemical shifts in platinated GAMG
and GWMG.
Table A.1: Characterization of [Pt(dien)]2+ complexed to N-AcMethionine, N-AcCysteine
and methionine tetrapeptides
δ(1H NMR) δ(195Pt NMR) MS Calculated MS Observed
][Pt(dien)(N-AcMet)]2+ 2.57 (S-CH3)(S-αCH2) -3376 489.50 489.00
[Pt(dien)(N-AcCys)]2+ 3.30 (S-CH2) -3192 461.5 459.98
[Pt(dien)(GAMG)]2+ 2.70 (S-CH3) -3374 674.3 673.03
[Pt(dien)(GWMG)]2+ 2.60 (S-CH3) -3380 790.3 788.05
The reaction of [Pt(dien)(9-EtGua)]2+, I, and N-AcMet in a 1:10 molar ratio, pH 7
and 37oC, did not show any formation of [PtN3S] species until after 24 h reaction, when at
that time a small amount of a white precipitate formed (presumably 9-EtGua which is only
sparingly soluble in H2O). After 3 days of reaction a peak at -3376 ppm may be observed in
solution indicating the presence of the [PtN3S] species (data not shown). To investigate the
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formation of [PtN3S] adducts with the tetrapeptides, 1:1 molar ratio reactions of I and the
peptides GAMG and GWMG were followed by 195Pt NMR at 20oC. The first 195Pt NMR
spectrum showed only one peak at -2851 ppm corresponding to the starting material. With
GAMG an additional 195Pt NMR spectrum for the colorless and clear solution was retaken
after 3 days of incubation at 37oC and showed a very small peak at -3380 ppm. A slight
increase in intensity is seen after a prolonged period of incubation (8 days, 37oC), Fig. A.4.
Similar behavior was seen for GWMG, with somewhat increased reactivity and after pro-
longed reaction the solution turned yellow (see below). To attempt comparative integration
between the two peptides the ratio of the Pt-peptide peak was integrated versus the Pt
starting material normalized to 1. This approach showed an approximate two-fold increase
in formation of [Pt(dien)-(GWMG)] over [Pt(dien)-(GAMG)] species. Given the nature of
these reactions and possible alternative products these rate differences should be viewed
as qualitative but nevertheless there does appear to be a preference for the tryptophan-
containing peptide. In both cases small peaks corresponding to free 9-EtGua can be seen in
the 1H NMR spectra recorded at the latest time point.
A.5.2 Reactions with N-acetylcysteine and cysteine-containing tet-
rapeptides
A 1:1 M ratio reaction between the compound [Pt(dien)Cl]Cl and N-AcCysteine (at pH
7.1) was followed at 37oC by 195Pt NMR Spectroscopy. Immediately, the solution turned
yellow and a major new peak appeared at -3192 ppm, which is assigned to the PtN3S species.
With [Pt(dien)(9-EtGua)]2+, after 12 h of reaction the 195Pt NMR spectrum also showed the
peak at -3192 ppm growing in intensity and a small amount of white solid precipitated.
The δ(195Pt) shifts of [Pt(SR)(dien)] where SR = alkanethiolates have been reported in the
-3150 to -3200 ppm range [27]. In the mass spectrum, as well as the peak corresponding to
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Figure A.4: Kinetic Profile of reactivity of [Pt(dien)(9-EtGua)]2+ toward GAMG and
GWMG showing some enhancement of nucleobase substitution in presence of tryptophan.
Comparative integration normalizing for starting material as 1.0 gave a relative ratio of
0.2-0.1 for for platination of GWMG over GAMG peptide (shown on spectra).
[Pt(dien)(N-AcCys)]+ a peak at 755.93 can be assigned to the dimer with bridging thiolate
{[Pt(dien)]-l-N-AcCys-[Pt(dien)]}, (calculated value 759.7 (loss of 4H+). This is consistent
with the pH-dependent interconversion between [Pt(dien)GS)]+ and [(Pt(dien)2l-GS]3+ (GS
= anion of glutathione) [28]. Both monodentate and bridged thiolates give similar d(195Pt)
shifts [27].
For the non-tryptophan-containing peptide (GACG) the reaction after 24h gave clear ev-
idence from 1H, 195Pt and MS spectra for formation of a significant yield of [Pt(dien)(GACG)]
species with concurrent loss of nucleobase, Fig. A.6. The 195Pt NMR spectrum over a number
of days showed an increase in the [PtN3S] species and the mass spectra also showed concomi-
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Figure A.5: Mass spectral characterization of the [Pt(dien)(9-EtGua)]2+ reaction with
GAMG and GWMG showing formation of the platinated peptide upon nucleobase sub-
stitution.
tant increases in product peak intensity. Unfortunately the analogous tryptophan-containing
peptide gave an immediate cloudy yellow solution and spectral analysis was complicated.
The presence of a peak at δ(195Pt) = -3177 ppm confirmed formation of the corresponding
[PtN3S] species within 12h. Again, after 24h mass spectra showed the evidence for product
but as with GWMG a multitude of peaks may indicate peptide cleavage.
A.5.3 Theoretical Studies
The fluorescence quenching of tryptophan residues suggest the occurrence of pi-pi in-
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Figure A.6: 1H NMR, 195Pt NMR and mass spectral evidence for formation of platinated
[Pt(dien)-GACG] by reaction with [Pt(dien)(9-EtGua)]2+.
teractions between I and the GWXG peptides. To examine possible consequences on the
reactivity the system was subjected to theoretical calculations. Structures representing the
potential platinated Gua-GWMG/GAMG interaction were optimized with the SVWN func-
tional. This modeling study assumed that platinated 9-MeGua forms a pi-stacking interaction
with the indole ring of GWMG in a similar conformation as that observed in the solution
structure of NCp7 with a DNA 18-mer (i.e., with the carbonyl group at C6 forming a hy-
drogen bond forms with the W amide proton [15b]). The GWMG and GAMG peptides
were truncated by replacing G by -NH2 on the C-terminal end and -CHO on the N-terminal
end. For the [Pt(dien)(9-MeGua)]2+-GWMG complex, the stacking interaction optimizes to
a conformation with the 6-membered ring of Gua centered over the W indole nitrogen and a
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hydrogen bonding interaction between the central NH of the dien and the W backbone car-
bonyl group, Fig. A.7A. The inter-ring distance ranges from ∼3.0 at the closest point near
C2Gua to ∼3.4 on the C8Gua end due to the positioning of one of the dien protons between
the rings in close contact with C4Ind (2.09 ). In the analogous complex of non-metallated
9-MeGua with the GWMG model (Fig. A.7B), the rings are slightly further apart at the
C2Gua end (∼3.1 ) which may be attributed to weaker donor-acceptor and electrostatic con-
tributions to the stacking interaction. For the [Pt(dien)(9-MeGua)]2+-GAMG model (Fig.
7C), the indole ring of the Pt-GWMG model complex was replaced by a hydrogen to con-
vert W to A. The NH-OC6 and dien NH-OC backbone hydrogen bonding interactions were
maintained in the optimized Pt-GAMG model for an overall similar configuration of the
[Pt(dien)(9- MeGua)]2+ fragment and the peptide backbone. The relative energy of forma-
tion of the Pt-GWMG complex from platinated Gua and model peptide is -9.3 kcal/mol,
roughly 5 kcal/mol more stable than formation of the GAMG species (-3.9 kcal/mol) due to
the additional pi stacking interaction. Although these calculations have not considered a full
conformation search of the interaction of [Pt(dien)(9-MeGua)]2+ with the model peptides,
they do suggest that, given a similar configuration of the Pt complex and the peptide back-
bone, the additional pi interaction enhances the interaction by ∼5kcal/mol. Noting that a
dien proton is somewhat intercalated between the rings, formation of a cation-pi interaction is
an alternate or complementary explanation for the more favorable interaction with GWMG
over GAMG. Stabilization of the “non-covalent” interaction may be reflected in the greater
reactivity of the GWMG over GAMG with respect to nucleobase substitution. However,
more reactive systems giving greater overall nucleobase substitution are required for confir-
mation - as stated the GXCG systems, although faster than GXMG, were not comparable
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Figure A.7: DFT(SVWN)-optimized structures of the interaction of (A) [Pt(dien)(9-
MeGua)]2+ and (B) 9-MeGua with a truncated GWMG model peptide and [Pt(dien)(9-
MeGua)]2+ with a model of GAMG. Hydrogen bonding interactions conserved in the models
are shown.
due to possible side-reactions.
A.6 Discussion
This work set out to examine the reactivity of substitution-inert platinum-nucleobases
with amino acids and model peptides. The results are consistent with a slow displacement
of the guanine nucleobase by cysteine. The reaction is clearly much faster and more favored
than the analogous reactions with methionine. It is of interest that [Pt(dien)(Met)]2+ has
been shown to undergo surprising displacement of the sulfur amino acid by the 5’-guanosine-
monophosphate (5’-GMP) nucleotide, and these results suggested possible pathways to final
DNA adducts of anticancer drugs like cisplatin [26]. The slow displacement of the coor-
dinated nucleobase shown here is consistent with the earlier observations on the “reverse”
reaction. A second point of interest is that thiolate (as NACys) reactivity in these systems
is significantly greater than thioether (as NAcMet). Using sterically hindered dien chelates,
[PtCl(R4(dien)]+ (R = Me, Et) selective binding of the sulfhydryl group in glutathione was
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seen compared to the methionine thioether of the dipeptide N-AcMetHis [29]. Steric bulk in
the dien ligand has also been shown to allow discrimination between 5’-GMP and methion-
ine [30]. Modulation of ligand leaving group is a further approach to selectivity and, unlike
the sterically hindered complexes which still contain the substitution-labile chloride, allows
distinction between DNA and protein binding. Thirdly, the results show that a reasonable
explanation for the presence of the [Pt(dien)-ZF] adduct under ESI MS-MS conditions in
the reaction of [Pt(dien)(9-EtGua)]2+ with ZF is the nucleophilic displacement of the bound
purine by a Zn-cysteinate [8]. Indeed the sequences used here are quite similar to the GCWK
sequence surrounding the tryptophan residue in ZF, see Fig. A.1.
This study is one of the first systematic studies of reactivity using “inert” PtN4 coordi-
nation spheres. While a significant amount of work has been performed on the interactions
of thiols with Pt-Cl complexes, studies on PtN4 systems, especially with a nucleobase, are
scarce. There is some evidence that the Pt-N bond is susceptible to strong nucleophiles.
The [Pt(bipy)(en)]2+ cation reacts slowly with cysteine residues in thioredoxin [31], Matrix-
assisted laser desorption-ionization time of flight mass spectrometry (MALDI-TOF MS)
and UV spectroscopy indicated the formation of Pt(bpy)(Cys-Ala-Pro-Cys)-containing pep-
tide fragments, indicating that the Pt(bpy)2+ unit binds to the active site of thioredoxin.
The thioredoxin-platinum complex has no catalytic activity for the reduction of glutathione
disulfide in the presence of NADPH and thioredoxin reductase, so that the platinum complex
functions as an inhibitor [31]. Conjugation of a cathepsin targeting ligand to the [Pt(dien)]
moiety gave a [Pt(dien)-NH2R)] species which reacted slowly, over 72h, with cysteine giving
two new peaks at δ(195Pt) peaks at -3165 and -3203 ppm indicative of formation of the
[PtN3S] species [32]. Kinetic studies using [Pt(terpy)(guanosine)]2+ showed that L-cysteine
and GSH are efficient nucleophiles with k2 values of 1.84 and 4.72 M−1 s−1, respectively, for
displacement of the guanosine [33].
Much of platinum complex drug development has been based on modulating reactivity of
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Pt-Cl moieties for anti-cancer applications, with the implicit assumption of DNA as the final
target by nucleobase displacement of the relatively substitution-labile chloride. The results
shown here, combined with previous results on steric effects on “carrier” dien ligands [29,30]
suggests that the PtN4 chemophore is capable of systematic modulation for peptide and
protein inhibition. The reactivity will depend on the nature of the PtN4 coordination sphere
- the [Pt(dien)NH2R)] species [32] appears to react slower than the [Pt(dien)(nucleobase)]
chemistry reported here - the chemical differences being a secondary amine N-donor versus
a heterocyclic nitrogen. The non-covalent TriplatinNC does not undergo displacement of its
“dangling” amine moieties even upon extended reaction with GSH [34].
With respect to zinc proteins in general, target selectivity is a major issue for inhibition
using small molecules. In the specific case of zinc fingers, the concept of “weak electrophiles”
from organic chemistry has been suggested as one way to gain selectivity and distinguish
between the cysteine nucleophilicity of the various coordination spheres (Cys2His2, Cys3His,
Cys4) [2,3]. We suggest that the coordination chemistry analogy of a weak electrophile,
especially to target proteins, is substitution-inert or “semi-inert” coordination spheres such
as [Pt(dien)(9-EtGua)]2+ - a PtN4 chromophore is capable of more extensive control than
that of PtN3Cl, containing the substitution-labile Pt-Cl bond. The extra stabilization of
the “non-covalent” pi-pi stacking interaction as shown on the model peptides allows further
avenues for design of specifically targeted inhibitors and further confirms the viability of the
medicinal chemistry dual approach of target recognition (non-covalent) followed by target
fixation (covalent).
Finally, the purpose of this paper was to examine the electrophilicity of I. It is notable
that the mass spectral studies indicated some peptide cleavage for both GWXG peptides.
This aspect was not examined in detail but the use of [Pt(en)]2+ and [Pd(en)]2+ can promote
peptide cleavage next to a tryptophan residue, offering further opportunities for selective
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protein inhibition [35].
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B.1 Contribution
S.D.T.’s contributions were comprised of {1H, 15N} HSQC NMR spectroscopy studies for
1,1-t,t and 1,1-c,c with ZF and preparation of the corresponding figures. I.Z’s contribution
was mass spectrometry experiments and J.B.M.’s contributions were mass spectrometry
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studies and preparation of the written manuscript.
B.2 Abstract
Electrospray ionisation mass spectrometry (ESI-MS) and {1H, 15N HSQC} NMR spec-
troscopy has elucidated the binding of a dinuclear platinum compound to a zinc finger peptide
with induced backbone cleavage. Cleavage is selective on the N-terminal side of the cysteine
residue following incubation at neutral pH, and is further dependent on structure of dinuclear
compound.
B.3 Introduction
Figure B.1: Structures of (A) I
(1,1-t,t) and (B) II (1,1-c,c) dinu-
clear platinum anti-cancer drugs and
(C) the C-terminal finger (ZF) of
HIVNCp7. Numbering as per full
protein.
Zinc finger proteins are involved in DNA recog-
nition, transcription, apoptosis, repair and RNA
packaging.1 The electron-rich nature of the zinc co-
ordination sphere renders the peptides susceptible
to oxidation and nucleophilic attack by alkylating
and metallating agents.2,3 In this communication we
report on the selective peptide cleavage of the C-
terminal nucleocapsid zinc finger of HIVNCp7 (ZF)
by dinuclear platinum complexes [PtCl(NH3)22m-
NH2(CH2)6NH2]2+, Fig. B.1. The cleavage is spe-
cific for the N-terminal side NH3-Lys-Gly-Cys-Trp-
(KGCW) sequence and is also dependent on the ge-
ometry of the dinuclear compound.
The results have implications for zinc finger targeting.
Zinc finger proteins are excellent templates for
metal ion substitution.3 For platinum compounds, the
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nature of the reaction depends on compound struc-
ture. For [PtCl(dien)]+ formation of {ZF-Pt(dien)} by formal substitution of the Pt-Cl
bond by cysteinate is observed, and the conclusion is supported by studies on model zinc
chelates.4,5
Mass spectrometry and model studies also suggest the possibility of a Cl− transfer
from Pt to produce a 5-coordinate Zn.4,5 The reaction of a 31-amino acid ZnCys4 zinc-finger
model with the anti-cancer drug cisplatin (cis-[PtCl2(NH3)2], cDDP) proceeds in a stepwise
fashion with complete deligation of Zn(II) only seen upon coordination of two equivalents
of the Pt complex.6 Studies on the S/N-donor preferences of [PtCl(Nucleobase)(L)(L’)]+ (L
= L’ = pyridine (pyr) or L = NH3, L’ = pyr, quinoline (quin) etc.) suggest the potential
for specific protein rather than nucleic acid reactions.3,7 ESI-MS and CD spectra of trans-
[PtCl(9-EtGua)(pyr)2]+ with ZF confirmed complex formation and subsequent loss of Zn,
again in presence of two [Pt(pyr)2] units.8 Similar behavior is also seen for [SP-4-2]- [PtCl(9-
EtGua)(NH3)(quin)]+ and indeed this specific compound shows incipient and moderately
selective antiviral activity, in contrast to the cytotoxic parent dichloride compound.9
B.4 Results and Discussion
To further analyze the parameters for zinc displacement and the apparent necessity for
two Pt units, we have examined the interaction of the C-terminal zinc finger (ZF) of the HIV
NCp7 nucleocapsid protein with the isomeric pair of dinuclear platinum complexes I and II,
Fig. B.1.10
Using ESI-MS, the earliest product peak observed, immediately after mixing in water at
37oC and pH 7.0, is at 978.6 m/z (3+), corresponding to a 1:1 adduct of I:ZF, Fig. B.3 (ESI).
This could represent a non-covalent I:ZF association or displacement of Cl− with transfer to
Zn. Collision induced dissociation (CID) of this peak at 978.6 (A), showed the presence of
intact ZF
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Figure B.2: ESI-MS/MS of the 978.6 peak (A) from 1,1-t,t (I) and intact ZF (1:1) immedi-
ately upon mixing.
Figure B.3: ESI-MS of the 1:1 com-
plex of I (1,1-t,t) with intact zinc fin-
ger. The non-covalent association of
ZF and Pt compound is shown in the
inset at 978 m/z.
1145.2 m/z (B) and platinum compound 645.5 m/z
(C), indicating the presence of a non-covalent compo-
nent, Fig. B.2. The spectrum also contains a peak
at 1258.7 m/z (D), representing the 2+ ions of the
{ZF + Pt(NH3)2}. A notable feature is the presence
of a peak at 894.1 m/z (3+) (E, species III) corre-
sponding to an adduct of I-2Cl− i.e. [Pt(NH3)22m-
H2N(CH2)6NH2] with a peptide formed by cleav-
age of the N-terminal KG amino acids ZF-KG, (Zn-
CWKCGKEGHQMKDCTER). Isotopic distribution
confirms the presence of a zinc ion in this species.
A companion peak at 871.9 m/z (not shown) is as-
signed to the same species with loss of Zn. There is
also significant fragmentation observed at lower m/z
values of the 1,1/t,t compound itself representing loss
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Figure B.4: Top- incubation of 1,1-t,t with ZF after 4 hours, bottom- spectrum at 0 hours.
Peaks denoted (A and B) represent in this case intact ZF, 3+ and 2+, respectively. Peak
III is peptide with loss of -KG.
of chloro and am(m)ine ligands, as observed previously.11
Fig. B.4 shows spectra at different time points for the I:ZF reaction, with decrease
in intensity of free ZF peaks. Most interesting is the increase in intensity for species III
at 894.1 m/z (3+) again corresponding to loss of the N-terminal KG amino acids (ZF-KG)
in a platinated peptide. Thus, cleavage occurs even in the absence of added CID energy
and III is a major product of the reaction. Species IV centered at 916.13 m/z may be
assigned to the 3+ state of [ZF + Pt(NH3)22] with two {Pt(NH3)2} moieties bound to
the peptide.Sequential ESI-MS/MS of the 894.1 m/z ion reveals mostly peptide cleavages
producing y-type ions from y1 (Arg, R) through y13 (Gly, G) fragments from the C-terminal
arginine. No platinated peptides are observed in these fragments. Importantly, there are
no respective b-type ions from the -CWKC- region, and while free Arg and ArgGlu residues
are readily observed no corresponding Lys or LysGly ions appear. Thus, the identifiable
cleavages for I occur upstream from the zinc-coordinating cysteine on the N-terminal side of
the peptide, NH3-X-Y-Cys-Trp-.
The 1H NMR spectrum of ZF has been fully assigned12 and the reaction with I results
in immediate broadening of most peaks with concomitant decreases in intensity - attributed
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principally to loss of ordered structure. The use of {1H, 15N} HSQC NMR spectroscopy
has helped delineate the mechanism of DNA binding of mononuclear and polynuclear Pt
complexes.13 We have also used this technique to examine the reaction of I and II with the
S-donors glutathione (GSH) and methionine (Met).14−16 The {1H, 15N}HSQC NMR of fully
15N-labeled I, Fig. B.5A, in presence of an equimolar amount of ZF shows the time-dependent
appearance of three new peaks in the Pt-NH3 region at {3.88/-62.2} (i); {3.73/-57.0} (ii), and
{3.53/-59.2} (iii) ppm, shifted from the parent values of I at {3.87/-63.4} ppm.14,15 Peak (ii)
increases in intensity over time with concomitant disappearance of peak (iii). The number
of peaks suggest the presence of more than one species but, importantly, the values are
consistent with displacement of the Pt-Cl bond by an S donor ligand. Peak (i) may represent
a S ligand trans to N in a [PtN3S] coordination sphere.14 The distinct 15N downfield shifts
for (ii) and (iii) are strongly indicative of [PtN2S2] coordination spheres. For example, in
the reaction of tDDP with glutathione (GSH) the products trans-[Pt(NH3)2(GS)2] and the
related GS-bridged species [{trans-Pt(NH3)2(GS)2m-GS]+ occur at {3.52/-62.7} and {3.83/-
59.1} ppm respectively.14 Concomitantly, the peak at {5.022/-46.0} ppm corresponding to
the linked -NH2 simply decreases in intensity and eventually disappears. In summary the
NMR results are consistent with Cys S displacement of the Pt-Cl bond with concomitant
trans-labilization of the linker and match very well the mass spectroscopy results.
Interestingly, the reaction of the 1,1/c,c isomer, II, with ZF yields a different set of
Figure B.5: {1H, 15N} HSQC NMR of 15N-I, A, and I incubated with ZF for 3 hours, B, and
20 hours, C.
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products. The major peak observed after four hours of incubation at 37oC, is at 922 m/z,
assigned to the 3+ ion of the species {{ZF-Zn}-[{Pt(NH3)}2m-H2N(CH2)6NH2]}3+, where II
has lost the chloro ligands and two associated NH3 groups while simultaneously displacing
the zinc ion, Fig. B.6 (ESI). The species is formed by Pt-Cl substitution followed by trans
labilization of the NH3 group in II. No evidence is seen for peptide cleavage even at time
points up to 24 h. The relative intensity of free ZF is also higher than for 1,1/t,t, in agreement
with the slower substitution kinetics of the 1,1/c,c isomer.17
The natural hydrolysis of amide bonds in peptides and proteins is a slow process under
native conditions.18 Pd and Pt salts such as [M(H2O)4]2+ and [M(en)(H2O)2]2+ display pep-
tidase activity in methionine-containing peptides - the thioether residue acts as an “anchor”
through M-S bond formation, directing the adjacent peptide bond cleavage.19 This initial
“anchoring” is followed by either of two possible mechanisms: the metal ion binds a carbonyl
oxygen making the peptide bond susceptible to water attack or attack of the amide bond
by a metal complex with an aqua ligand.20 Cisplatin also mediates peptide hydrolysis down-
stream from a methionine residue, with formation of multidentate peptide chelates inducing
conformational stress and peptide backbone cleavage which occurs at the second amide bond
in the N-terminal direction from the site of the coordinating side chain.21 The strategy in
all these cases requires the presence of labile sites (even on Pd) for rapid M-S and possibly
M-N(histidine) bond formation and conditions are mildly to strongly acidic.
The complex system presented here may be explained by the above discussion and the
known chemistry of dinuclear platinum complexes with sulfur thioether and thiol donors.1416
The pKa and aquation rates of the dinuclear compounds have been measured and equilibrium
favors the chloro forms.22,23 Glutathione binding through the cysteine residue rapidly (hours)
labilizes the diamine linker of I.14 In contrast, the diamine linker remains intact in the 1,1/c,c
isomer and novel GS-bridged (m-thiolato) macrochelates are formed, as a result of the labile
chloride being trans to the more substitution-inert NH3 ligand.16 Similar differences between
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Figure B.6: Incubation of 1,1-c,c, II, with ZF after 4 hours. Peak denoted A represents loss
of Zn and subsequent loss of NH3 and Cl on the platinum compound. B is intact free ZF.
the two geometries are observed with methionine.16 Based on these collected observations a
stepwise mechanism of peptide cleavage may be proposed where Pt-Cl bond substitution in
I by zinc-bound cysteinate results in trans-labilization of the Pt-NH2(diamine) bond which
will produce an available coordination site; further peptide back- bone bonding especially to
a second Pt-Cys(S) bond (consistent with observation of [PtN2S2] species observed by NMR
and {Pt(NH3)2}-ZF species in MS) is then possible with concomitant cleavage of the peptide
bond and eventual zinc ejection:
This scheme also explains the fragmentation (y1 to y13) pattern observed from mass
spectrometry and the isomeric dependence of the reaction - in the 1,1/c,c I the ligand trans
to S is the substitution-inert NH3. Further, the Pt-m-SR(thiolato)-Zn coordination motif
has been confirmed in model systems, suggesting analogies for the nature of the [PtN2S2]
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species.5 It is notable that reaction occurs at biologically relevant pH and the possibility exists
of direct substitution by the highly nucleophilic zinc-cysteinates, as substitution on S can
occur in absence of Pt complex hydrolysis.14 To our knowledge, this is the first demonstration
of metal-assisted peptide cleavage on zinc fingers and is a novel strategy for inactivation of
this important biological target.3 These initial intriguing results merit further study of this
system.
B.5 Experimental
Platinum compounds and zinc finger starting materials were prepared as previously.14,15
B.5.1 Mass Spectrometry
For mass spectrometry experiments, initial 1mM reaction mixtures were made in water
at 37oC and pH 7.0 adjusted using ammonium hydroxide, then H2O/MeOH (6/94) aliquots
of approx. 10 µM used for spraying. Experimental procedure in general followed published
protocol.8 The reaction solution was not adjusted for pH during the reaction.
B.5.2 NMR Spectrometry
NMR experiments also followed published procedure and were conducted at 1 mM con-
centration (1:1) in 5% D2O/95% H2O.8
For HSQC {1H,15N} NMR Spectroscopy the spectra were recorded at 37oC on a Bruker
AVANCE III 600 MHz spectrometer (1H, 600.1 MHz; 15N, 60.8 MHz ) fitted with a pulsed
field gradient module and 5mm inverse quadruple resonance (QXI) probe. The 1H NMR
chemical shifts were internally referenced to TSP, the 15N chemical shifts externally refer-
enced to 15NH4NO3. The two-dimensional [1H,15N] HSQC spectra were recorded in phase
sensitive mode using Echo/Antiecho-TPPI gradient selection. A total of 1024 points were
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acquired in the 1H dimension and 96 complex points in the 15N dimension with 128 tran-
sients. 1 mM platinum complex was allowed to react with 1 equiv. of ZF in 5% D2O/95%
H2O.8, and the reaction was followed by HSQC spectroscopy. 20 two-dimensional spectra
were obtained at hourly intervals, which can determine the half-life of the reaction by the
integration of 15NH3 peaks.
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C.1 Contribution
S.D.T.’s contribution is comprised of the following sections: Introduction, Targeting
of Zinc Fingers by Cobalt Complexes, and Pt Complexes as DNA/Protein Crosslinkers.
S.R.S.’s contributions include the sections: Interaction of platinum molecules with zinc fin-
gers, platinated DNA affects zinc finger conformation and small molecule models for plati-
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nated DNA-zinc finger interactions.
C.2 Synonyms
Anticancer metallodrugs; Antiviral metallodrugs; Cobalt Schiff base; Metallated DNA;
Polynuclear Pt complexes; Pt-DNA adducts; Ternary crosslinks; Transcription factor hijack-
ing; Zinc finger targeting
C.3 Definition
This entry describes the interactions of zinc finger peptides with metallated DNA and
small molecule platinum-metal probes. The interactions have biological consequences from
sequence-specific inhibition of zinc finger function to hijacking of transcription factors by
binding to platinated DNA. Small molecule interactions have chemical consequences because
the formal analogy between alkylation and metallation suggests the possibility of electrophilic
attack of the cysteine and histidine residues with eventual zinc ion ejection and loss of tertiary
structure and consequently biological function. These approaches create new opportunities
to investigate the chemical properties of zinc fingers and may possibly produce new leads for
disease intervention where zinc finger function is implicated.
C.4 Introduction
In biology, zinc serves either a structural or catalytic purpose. When zinc acts in a
catalytic manner, it is bound to a water molecule that is converted to a hydroxyl ligand.
Structural zinc is characterized by coordination to four amino acids, generally histidine
and cysteine. These types of zinc sites include zinc fingers (ZF), which compose 2-3% of
the human genome (Klug 2010). The most common role of zinc fingers in biology is in
the binding of DNA to transcription factors and they are also involved in RNA packag-
ing, transcriptional activation, regulation of apoptosis, and protein folding and assembly.
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Figure C.1: The three main coordination en-
vironments of zinc fingers: C2H2, C3H, and C4
Zinc fingers are defined by the number
and type of amino acids coordinated to the
central zinc atom (Fig. C.1). Analysis of
Cys2His2 zinc finger proteins has allowed for
elucidation of DNA recognition mechanisms
and their role in transcriptional regulation.
The Cys3His motif is involved in RNA and
DNA recognition, cell-cycle control, and cel-
lular signaling
Figure C.2: General schematic of electrophilic
attack on a zinc finger. Platinum agents attack
at cysteine residues, while cobalt agents attack
at histidine residues. X= (Cys)(His) or Cys2
pathways. The third common zinc Cys4 fin-
ger motif is found in human DNA repair en-
zymes and many nuclear localized systems.
Coordination to zinc enhances the nu-
cleophilicity of the Zn-Cys bond, allowing
for attack by small electrophiles. The chem-
ical reactivity is dependent on the nature
of the zinc coordination sphere (Cys2His2;
Cys3His, Cys4) (Quintal et al. 2011). The
interaction of zinc finger proteins with DNA
and RNA can be inhibited upon chemi-
cal modification of the zinc binding ligands.
There is a formal analogy between alkylation and metallation, where in the latter case chem-
ical modification refers to electrophilic attack of the cysteine and histidine residues by Pt
and Co agents, respectively (Fig. C.2).
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In both cases, however, eventual loss of zinc is seen and the proteins lose tertiary
structure and therefore loss of biological function. Tethering of the electrophilic agent to
a sequence-specific DNA may allow for targeting and differentiation between different zinc
fingers and enhancement of selectivity. In this review, the approaches to the use of small
molecule metal-based electrophiles and formation of DNA-protein crosslinks as probes for
zinc finger conformation and reactivity will be discussed. These approaches create new
opportunities to investigate the chemical properties of zinc fingers and may possibly produce
new leads for disease intervention where zinc finger function is implicated.
C.5 Targeting of Zinc Fingers by Cobalt Schiff Base Com-
plexes
Cobalt(III) Schiff-base (Co-sb) complexes may disrupt the structure of a zinc finger
peptide by axial ligation of the Co(III) ion to the nitrogen of the imidazole ring of a histidine
residue. The reaction of Co(III)-sb with histidine is a dissociative ligand exchange process,
with loss of the labile axial NH3 ligands by H2O facilitating histidine binding. The reaction
of Co(III)-sb at the zinc finger site irreversibly inhibits protein activity as a result of zinc
ejection due to the binding of cobalt to histidine (Harney, 2009). Zinc ejection causes loss of
tertiary structure and therefore loss of function.
Initial studies showed that cobalt complexes inhibit binding of the human transcription
factor Sp1, to its consensus sequence. DNA-coupled conjugates of the cobalt complexes
selectively inhibited Sp1 in the presence of several other transcription factors. The Snail
family of Cys2His2 zinc finger transcription factors, Slug, Snail, and Sip1, are emerging as
anticancer drug targets as they are implicated in tumor metastasis through the regulation
of epithelial-to-mesenchymal (EMT) transitions. Slug, Snail, and Sip1 bind to the Ebox
consensus sequence CAGGTG in the promoter region of target genes with high specificity to
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mediate transcriptional repression. To improve specificity for the Snail family of transcription
factors, an oligonucleotide containing the DNA consensus sequence was conjugated to the
Co(III) complex yielding Co(III)-Ebox (Fig. C.3) (Harney et al. 2009).
Figure C.3: Scheme for zinc finger-specific inactivation using Co(III)-sb-DNA conjugates.
Co(III)-Ebox is recognized by the Snail family of transcription factors. Loss of axial ligands
and subsequent binding of histidine results in eventual ejection of Zn2+ and transcription
factor inactivation.
No significant changes in the structure of DNA occurred upon conjugation. Through
addition of the Ebox DNA sequence to the Co(III) metal complex, peptide-binding specificity
was improved 150-fold over Co(III)-sb. Co(III)-Ebox was found to effectively inhibit the
Slug, Snail, and Sip1 zinc finger transcription factors from binding to their DNA targets
with eventual loss of Zn2+ (Harney et al. 2009). Studies demonstrate that neither the oligo
nor the Co(III) Schiff base complex alone is sufficient for transcription factor inactivation at
concentrations where the conjugated complex mediates inhibition.
Subsequently, a Co(III) Schiff base DNA conjugate has been designed to target the Gli
Cys2His2 transcription factors in the Hedgehog (Hh) pathway, which has been implicated in
the formation and development of certain cancers such as medulloblastomas and basal cell
carcinomas (Hurtado et al. 2012). In order to test the specificity and efficacy of Co(III)-
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DNA complex, the authors tested the Ci consensus sequence alone, Co(III)-sb, Co(III)-Ci,
and Co(III)-Mut (one base pair mutation). The complete structure of Co(III)-Ci was found
to be the most effective at inhibiting Gli family ZF transcription factors. The mutation
of one base pair in Co(III)-CiMut inhibited its specific and potent activity. The activity of
Co(III)-Ci was specific, as no other zinc finger transcription factor tested was inhibited by the
addition of the complex (Hurtado et al. 2012). These results show that subtle changes in the
oligomer attached to Co(III) can modulate the specificity and activity of these Co(III)-DNA
conjugates both in vitro and in vivo.
The studies performed using Co(III)-DNA complexes demonstrate the development of a
versatile class of specific and potent complexes that may be used to study zinc finger proteins
and may prove valuable as an experimental tool and as anticancer therapeutics.
C.6 Pt Complexes as DNA/Protein Crosslinkers
The structure and nature of DNA adducts of platinum complexes may be manipulated to
facilitate ternary DNA-Pt-protein crosslinks. Table C.1 summarizes the compounds studied.
One of the first examples is the use of trans-diamminedichloroplatinum(II) (tDDP). In order
to map the section of HIV1 RNA that was recognized by the nucleocapsid (NC) protein,
tDDP was used as a crosslinking agent. After digestion of a crosslinked solution of HIV1
RNA and NC protein, the crosslink was shown to form between positions 315-324 of the
RNA. This suggests the possible recognition site for the NC protein on HIV1 RNA (Darlix
et al. 1990).
Various mononuclear and dinuclear platinum complexes have been analyzed for their
crosslinking abilities to zinc finger containing proteins such as the DNA repair proteins,
UvrA and UvrB, and Sp1. The repair of the DNA adducts of the anticancer agent cis-
diamminedichloroplatinum(II) (cisplatin, cDDP) was examined with the bacterial UvrABC
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Table C.1: Various metal complexes form crosslinks with zinc finger proteins and DNA.
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Figure C.4: The binding of dinuclear platinum complexes to DNA. (1) Initial monofunctional
binding, (2) long-range bifunctional interstrand crosslink formation with second platinum
unit and (3) binding of protein at the third active site.
complex (Lambert et al. 1995). A sterically hindered analog, exo-[N-2-methylamino-2,2,1-
bicyclohepane] dichloroplatinum(II) (Pt-BCH) was compared for its protein crosslinking abil-
ities. UvrAB proteins recognized the mono- and diadducts of Pt-BCH with a higher affinity
than those of cisplatin. Analysis of the crosslinks showed the involvement of UvrB in the
ternary nucleoprotein complexes. In general, UvrB has a greater affinity for the adducts
formed by Pt-BCH over those formed by cisplatin (Lambert et al. 1995).
Dinuclear platinum complexes bind to DNA in a manner that is unique from cisplatin
and other mononuclear complexes, the main adducts being long-range (Pt,Pt) interstrand
crosslinks (Kloster et al. 2004). Dinuclear complexes may be formally bi, tri, or tetrafunc-
tional (depending on number of substitution-labile chlorides present - see Table C.1). Even in
the presence of a cDDP-like cis-[PtCl2(amine)2] coordi- nation sphere the (Pt,Pt)-interstrand
crosslinks form preferentially (Fig. C.4).
Thus, upon bifuntional binding to DNA, the third Cl site can then bind to a protein,
preferentially at Cys, His, or Met residues (Kloster et al. 2004). Platinum complexes are
known to bind in the major groove of DNA and the ability of the dinuclear complexes to
crosslink UvrA and UvrB suggests that the proteins contact the major groove of the DNA
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helix within 4-4.5A (Van Houten et al. 1993). The flexibility of the dinuclear platinum
adducts may be important in their crosslinking of Sp1 due to the DNA bending induced
upon Sp1 binding (Kloster et al. 2004).
The results of these platinum crosslinking studies suggest that the formation of metal-
mediated DNA-protein complexes may play a role in the cytotoxic properties of these com-
pounds due to the irreversible crosslinking, and therefore sequestering, of repair proteins or
transcription factors to DNA. The differences between mononuclear and dinuclear platinum
complexes may also explain the different cytotoxic properties of the two classes of anticancer
drugs. The differences in DNA adduct structure between mononuclear and dinuclear com-
plexes may also be used to probe protein recognition of structurally different DNA crosslinks
(Kloster et al. 2004).
C.7 Interaction of Platinum Molecules with Zinc Fingers
The demonstration of zinc finger crosslink formation by platinated DNA is fundamen-
tally an example of coordination compounds acting as electrophiles toward the peptide cys-
teine residues. Small molecule platinum-metal agents have therefore been explored for their
ability to target the HIV nucleocapsid retroviral protein NCp7. Figure C.5 shows the struc-
tures of the metal complexes studied as well as that of NCp7 nucleocapsid protein.
Again, functionality can be studied by use of structurally distinct compounds such
as cDDP, trans-[PtCl (9-EtGua)(pyr)2]+, [PtCl(terpy)]+, and [PtCl(dien)]+ (Quintal et al.
2012). Further, the reactivity of the central metal ion may be altered by use of the general
structure [MCl(chelate)] (M = Pt(II), Pd(II), or Au(III) and chelate = diethylenetriamine,
dien or 2,2’ ;6’ ,2’ -terpyridine, terpy). Interestingly, both Pt(II) and Pd(II)-dien species
showed evidence of adduct formation on ZF by replacement of the M-Cl bond with zinc-
bound thiolate. Eventual loss of the dien ligand, as well as zinc ejection, was observed. Due
to the strong thiol affinity of gold drugs both Au(III) compounds reacted extremely fast
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producing only “gold fingers”. For all terpy compounds metal exchange occurred producing
the product [Zn(terpy)]2+. These results show that by modifying both the metal and ligand
of the reacting compound, the chemical reactivity of zinc finger proteins can by altered
(Quintal et al. 2011).
Figure C.5: Structures of HIV NCp7 nucleocapsid protein (ZF; C-terminal finger, ZF2 shown
in dashed box) and the platinum-metal complexes studied for molecular recognition and
electrophilic attack.
A major challenge for all small molecule electrophiles is selectivity. To enhance the
selectivity of these druges, it is important to understand the details of the zinc finger-DNA
interaction. The recognition of DNA or RNA by the HIV nucleocapsid protein NCp7 is
dominated primarily by pi-stacking between the purine nucleic acid bases and the planar
aromatic amino acid residues, especially between guanine and tryptophan37 (Quital et al.
2011). Fluorescence quenching studies have shown that metallation of nucleobase com-
pounds significantly enhances the pi-pi stacking interactions with L-tryptophan. Metallation
modifies frontier molecular orbital properties, lowering the pi-acceptor LUMO of the metal-
lated nucleobase, thus improving the overlap toward the pi-donor HOMO of the tryptophan.
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Study of the biologically relevant C-terminal peptide (ZF2) of the HIV-NCp7 zinc knuckle
showed that [Pt(dien)(9EtGua)]2+ (9-EtGua = 9-ethylguanine) and [Pt(dien)(5’-GMP)] (5’-
GMP = guanosine 5’-monophosphate) quench tryptophan fluorescence with Ka, association
constants, of 7.5 x 103 and 12.4 x 103 M−1, respectively. Though there is little difference
between their binding with the simple amino acid tryptophan, the extra phosphate group
on the 5’-GMP causes a significant increase in binding with ZF2 (Anzellotti et al. 2006).
ESI-MS of both [Pt(dien)(9EtGua)]2+ and [Pt(dien)(5’-GMP)] with ZF2 showed formation
of a 1:1 adduct between the peptide and Pt-complex. It is most likely that this adduct
formation is facilitated by the pi-pi stacking interactions between the tryptophan and the
platinated nucleobase. Incubation of cis-[Pt(NH3)2(Guo)2]2+ (Guo = guanosine) with ZF2
showed significantly less formation of the 1:1 adduct, possibly due to steric hinderance from
the mutually cis-oriented purines (Anzellotti et al. 2006).
The monofunctional trans-[PtCl(9-EtGua)(pyr)2]+ (pyr = pyridine) has high reactivity
toward sulfur over nitrogen, and it has also been shown to cause Zn ejection in model chelates
(see below). In the presence of a 1:1 stoichiometric ratio of trans-[PtCl(9-EtGua)(pyr)2]+,
the ESI-MS of ZF2 showed numerous peaks consistent with multiple adduct formation. The
peak corresponding to the adduct ([ZF2(Pt[pyr]2)2]-Zn) shows two [Pt(pyr)]2 units bound
to the protein with resultant loss of Zn. CD experiments revealed changes in the three-
dimensional structure of the protein, consistent with the loss of tertiary structure due to Zn
ejection. Therefore, the proposed mechanism for attack of Pt-nucleobase compounds on zinc
fingers consists of two steps: (1) non-covalent recognition through pi-pi stacking of tryptophan
with platinated nucleobase and (2) covalent interaction with Pt-S bond formation followed
by zinc ejection (Anzellotti et al. 2006).
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C.8 Platinated DNA Affects Zinc Finger Conformation
To expand on the studies of platinum-nucleobase complex - zinc finger interactions,
the interaction of Pt(dien)6-mer (6-mer = d’(5’-TACGCC-3’)) with the C-terminal finger
of the HIV NCp7 zinc finger, ZF2, was studied by NMR Spectroscopy. In this case the
Pt(dien) moiety was bound to the single guanine residue (C.6a). The solution structures of
ZF2, the 6-mer/ZF2, and Pt(dien)6mer/ZF2 adducts were calculated from NOESY-derived
distance constraints. For the 6-mer/ZF2 structure, stacking with tryptophan was observed
as well as showed that there was an interaction between Trp37 and the ribose protons of the
carbohydrate moiety of Gua4, confirming the carbohydrate-aromatic ring interaction as a
key recognition site between NCp7 protein and oligonucleotides. The NMR spectrum of ZF2
in the presence of Pt(dien)6-mer showed weakening of the Trp37-Gua4 contact attributed
by the steric effects caused by platination of Gua4. The aromatic ring of the tryptophan
residue changes orientation (Fig. C.6b), causing the DNA to be in a completely different
position than when platinum is absent.
Figure C.6: (a) superposition of the minimized structures of the 6mer/ZF2 adduct (green)
and Pt(dien)(6mer)/ZF2 adduct (orange) (b) change in conformation of Trp37 upon platina-
tion of Gua4 (c) stabilizing interactions of Cyt6 with the protein residues, Cys49 and Thr50,
in the Pt(dien)(6mer)/ZF2 adduct (hydrogen bonding highlighted in red box)
170
Molecular dynamics calculations of the DNA-protein interactions showed that the pi-
stacking between Trp37 and Gua4 as well as the hydrogen bonding between the pentose
and phosphate oxygen(s) of Cyt5 and Gua4 both help stabilize the interactions between the
6-mer and ZF2. Once platinum is bound, the 6-mer is less flexible and stays in one stable
conformation on the surface of the zinc finger. The Gua4-Trp37 interaction is disrupted,
resulting in hydrogen bonding interactions between Cyt6 and Cys49 and Thr50. Additionally,
the backbone CH group is close to N3 of Cyt6. With the addition of this third hydrogen
bond, the bonding mode imitates the three intermolecular Cyt-Gua base pair hydrogen bonds
(Fig C.6c).
In conclusion, these results show for the first time structural characterization of plati-
nated single-stranded DNA interacting with a zinc finger protein, resulting in conforma-
tional change of the peptide. These results further demonstrate the feasibility of using
DNA-tethered coordination compounds to target specific zinc finger proteins (Quintal et al.
2012).
C.9 Small Molecule Models for Platinated DNA-Zinc Fin-
ger Interactions
To provide a small molecule model for the reactions of platinum complexes with ZFs,
the chelate N,N’-bis (2-mercaptoethyl)-1,4-diazacycloheptanezinc(II), [Zn (bme-dach)]2, was
studied. Structures for model metal/DNA/protein crosslinks and zinc ejection were deduced
from ESI-MS spectra of this [Zn(bme-dach)]2 with trans-[PtCl(9-EtGua)(pyr)2]+, a model
for a monofunctional adduct of platinum on DNA. The schematic of the reaction is shown
in Fig. C.7.
The intermediate species [Zn(bme-dach)-Pt (9-EtGua)(pyr)2]+ was observed and after
20 h was identified as the major species present. This is considered to be the first heterodin-
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Figure C.7: Reaction pathway of [Zn(bme-dach)]2 with trans-[PtCl(9-EtGua)(pyr)2]+ with
formation of monothiolate bridges and metal exchanged species (Almarex et al. 2008)
uclear Pt,Zn monothiolate bridged species to be identified using biologically relevant species.
MS experiments showed the final product to be [Pt(bme-dach)]+, giving proof of Zn ejection
followed by platinum replacement (Liu et al. 2005). Similar experiments were performed
for [Pt(dien)Cl]Cl and [Pt(terpy)Cl]Cl. Results showed formation of mono- and dithiolate
bridged intermediates as well as metal exchange and multimetallic aggregate species (Quintal
et al. 2011). These results represent suitable models for the molecular structure of ternary
DNA-protein complexes involving zinc finger proteins discussed above (Liu et al. 2005).
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